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Calmodulin (CaM) phosphorylated at different serine/threonine and tyrosine 
residues is known to exert differential regulatory effects on diversity CaM-binding 
proteins as compared to non-phosphorylated CaM. In this work we describe the 
preparation and characterization of a series of phospho-(Y)-mimetic CaM mutants in 
which either one or the two tyrosine residues present in CaM (Y99 and Y138) were 
substituted to aspartic acid or glutamic acid. We demonstrated some biological 
properties of these CaM mutants, such as their differential phosphorylation by the 
tyrosine kinase c-Src, and their action as compared to wild type CaM, on the activity of 
two CaM-dependent enzymes: cyclic nucleotide phosphodiesterase 1 (PDE1), and 
endothelial nitric oxide synthase (eNOS), as well as c-Src and the epidermal growth 
factor receptor (EGFR). We demonstrated that CaM directly interacts with c-Src in both 
Ca2+-dependent and Ca2+-independent manners in vitro, and that in living cells the CaM 
antagonist W-7 inhibits this kinase induced by the upstream activation of EGFR, in 
human carcinoma epidermoide A431 cells, and by hydrogen peroxide-induced 
oxidative stress, in both A431 cells and human breast adenocarcinoma SK-BR-3 cells. 
Most relevant and for the first time, we demonstrated that Ca2+-free CaM (apo-CaM) 
exerts a far higher activatory action on Src auto-phosphorylation. We also present 
experimental evidences suggesting that the EGFR from A431 cells is subjected to O-
GlcNAcylation, and that CaM may be involved in the regulation of this process through 
binding to the O-GlcNAc transferase (OGT). We detected a positive O-GlcNAcylation 
signal in immunoprecipitated EGFR using immunoblot and two distinct specific anti-O-
GlcNAc antibodies. Conversely, the presence of EGFR was detected by immunoblot 
among the O-GlcNAcylated proteins immunoprecipitated with an anti-O-GlcNAc 
antibody. These signals were enhanced when a highly specific O-linked   β-N-
acetylglucosaminidase (OGA) inhibitor was present. Most significantly, we detected a 
positive O-GlcNAcylation signal in immunoprecipitated and N-deglycosylated EGFR 
using peptide-N-glycosidase F (PNGase F), and from tunicamycin-treated cells when 
were metabolically labeled with GlcNAz. We also performed O-GlcNAcylation assay in 
vitro using immunoprecipitated EGFR and OGT, which resulted in the enhancement of 
the EGFR O-GlcNAcylation signal. We concluded that the EGFR from A431 tumor cells 
is subjected to O-GlcNAcylation. Furthermore, we present preliminary data using in 
silico studies, combined with binding assays such as Ca2+-dependent CaM 
chromatography and co-immunoprecipitation experiments, showing that OGT is a 
putative CaM-binding protein. 
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La calmodulina (CaM) fosforilada en diferentes residuos de serina/treonina y 
tirosina se sabe que ejerce efectos reguladores diferenciales en una diversidad de 
proteínas de unión a CaM en comparación con CaM no fosforilada. En esta Tesis se 
describe la preparación y caracterización de una serie de mutantes fosfo-(Y)-
miméticos de la CaM en el que uno o los dos residuos de tirosina presentes en la CaM 
(Y99 y Y138) fueron sustituidos por ácido aspártico o ácido glutámico. Hemos 
demostrado algunas propiedades biológicas de estos mutantes de la CaM, tales como 
su fosforilación diferencial por la tirosina quinasa c-Src y su acción, en comparación 
con CaM tipo salvaje, sobre la actividad de varios enzimas CaM-dependientes: la 
fosfodiesterasa de nucleótidos cíclicos 1 (PDE1), la óxido nítrico sintasa endotelial 
(eNOS), c-Src y el receptor del factor de crecimiento epidérmico (EGFR). Hemos 
demostrado que la CaM interactúa directamente con Src de forma dependiente e 
independiente de Ca2+ in vitro, y que en células vivas el antagonista de CaM W-7 
inhibe esta quinasa inducida por la activación aguas arriba del EGFR, en células A431 
de carcinoma epidermoide human, y por estrés oxidativo inducido por peróxido de 
hidrógeno, tanto en células A431 como en células de adenocarcinoma de mama 
humano SK-BR-3. De mayor relevencia y por primera vez, hemos demostrado que la 
CaM libre de Ca2+ (apo-CaM) ejerce una acción activadora mucho mayor que el 
complejo Ca2+/CaM sobre la auto-fosforilación de Src. También presentamos 
evidencias experimentales que sugieren que el EGFR de células A431 está sometido a 
O-GlcNAcylatión, y que la CaM puede estar implicada en la regulación de este proceso 
mediante su unión a la O-GlcNAc transferasa (OGT). Hemos detectado una señal 
positiva de O-GlcNacylatión en la EGFR inmunoprecipitado usando inmunoblot y dos 
anticuerpos específicos anti-O-GlcNAc distintos. Adicionalmente, la presencia de 
EGFR se detectó por inmunoblot entre las proteínas O-GlcNacyladas e 
inmnoprecipitadas con un anticuerpo anti-O-GlcNAc. Estas señales se incrementaron 
cuando un inhibidor altamente específico de la O-ligado   β-N-acetilglucosaminidasa 
(OGA) estuvo presente. Más significativamente, se detectó una señal de O-
GlcNAcylatión positiva en el EGFR inmunoprecipitado y N-deglicosilado usando 
péptido-N-glicosidasa F (PNGasa F), y a partir de células tratadas con tunicamicina 
cuando se marcaron metabólicamente. También se realizaron ensayos de O-
GlcNAcylatión in vitro utilizando EGFR y OGT inmunoprecipitados, lo que resultó en el 
incremento de la señal de O-GlcNAcylation en el EGFR. Llegamos a la conclusión de 
que el EGFR de las células tumorales A431 y A549 están sometidos a O-
GlcNAcylation. Además, se presentan datos preliminares de estudios in silico, así 
como ensayos experimentales de unión, tales como cromatografía de afinidad de CaM 
dependiente de Ca2+ y co-inmunoprecupitación, demostrando que la enzima OGT es 
putativamente una proteína de unión a CaM. 
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ABA: abscisic acid 
AREG: amphiregulin  
Apo-­‐‑CaM: apocalmodulin 
Akt: v-­‐Akt murine thymoma viral oncogene homologue 
BCA: bicinchoninic acid 
BSA: bovine serum albumin 
BTC: betacellulin 
CaM: calmodulin 
CaM-­‐‑BD: CaM-­‐binding domain 
CaM-­‐‑BP: CaM-­‐binding protein 
CaMK: CaM-­‐dependent kinase 
CaM KMT: Calmodulin-lysine N-methyltransferase 
CDK: cyclin-dependent kinase 
CID: collision-­‐induced dissociation 
DTT: dithiothreitol 
ECL: enhanced chemiluminescence 
EDTA: ethylenediaminetetraacetic acid 
EGF: epidermal growth factor 
EGFR: EGF receptor 
EGTA: ethylene glycol-­‐bis(2-­‐aminoethylether)-­‐N,N,N’,N’-­‐tetraacetic acid 
eNOS: endothelial nitric oxide synthase 
EPR: epiregulin 
ErbB: erythroblastic leukemia viral oncogene homologue 
ERK: extracellular signal-­‐regulated kinase 
ESI: electrospray ionization 
ETD: electron-transfer dissociation 
EV: empty vector 
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FBS: fetal bovine serum 
GAPDH: glyceraldehyde-­‐3-­‐phosphate dehydrogenase 
GFP: green fluorescent protein 
Grb7: growth factor receptor-­‐bound protein 7 
HB-EGF: heparin-binding EGF-like growth factor 
HEK: human embryonic kidney 
HEPES: 4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic acid 
HER: human EGFR receptor 
HRGβ1: heregulin  β1 
IGFR: insulin-like growth factor receptor 
IGF-­‐‑1R: insulin-­‐like growth factor 1 receptor 
IRS1: insulin receptor substrate 1 
IRS2: insulin receptor substrate 2 
IgG: immunoglobulin G 
JD: juxtamembrane domain 
JAK: Janus kinase 
MAPK: mitogen-­‐activated protein kinase 
MEK:  mitogen-activated protein kinase kinase 
MLCK: myosin light chain kinase 
MS: mass spectrometry 
NLS: nuclear localization sequence/signal 
NP-­‐‑40: nonidet p-­‐40 
NT: non-­‐transfected 
OGA: O-linked  β-N-acetylglucosaminidase  
OGT: O-linked  β-N-acetylglucosamine transferase 
ORF: open reading frame 
PBS: phosphate buffered saline 
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PDE: phosphodiesterase  
PI3K: phosphatidylinositol 3-­‐kinase 
PLCγ1: phospholipase  Cγ1 
PMSF: phenylmethylsulfonyl fluoride 
PNA: peanut agglutinin 
PTB: phosphotyrosine binding 
PTM: posttranslational modification 
PVDF: polyvinylidene fluoride 
RAF: v-Raf murine sarcoma viral oncogene homologue 
Ras: rat sarcoma viral oncogene homologue  
SDS: sodium dodecyl sulphate 
SDS-­‐‑PAGE: polyacrylamide gel electrophoresis in the presence of SDS 
SH2: Src homology 2 
SH3: Src homology 3 
SHP-­‐‑2: SH2 protein tyrosine-­‐phosphatase 
c-Src: proto-oncogene tyrosine-protein kinase cellular Src 
SRY: sex determining region Y  
STAT: signal transducer and activator of transcription 
TK: tyrosine kinase  
TCA: trichloroacetic acid 
TRIS: tris(hydroxymethyl)aminomethane 
v-Src: tyrosine-protein kinase viral transforming protein Src 
W-­‐‑7: N-­‐(6-­‐aminohexyl)-­‐5-­‐chloro-­‐1-­‐naphthalenesulfonamide 
W-­‐‑12: N-(4-aminobutyl)-2-naphthalenesulfonamide  
W-­‐‑13: N-(4-Aminobutyl)-5-chloro-2-naphthalenesulfonamide hydrochloride 
WGA: wheat germ agglutinin 
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Posttranslational modifications (PTMs) of the side chains of amino acids in 
proteins are playing pivotal roles in cell life. They are orchestrating the protein 
behavior, activity and interactions. Currently over 200 modifications has been 
described in the literature such as phosphorylation, acetylation, methylation, 
glycosylation just to mention a few (Walsh et al., 2005, Jensen, 2006). PTMs exhibit 
high diversity in terms of structure, stoichiometry, size, complexity and cellular 
localization (Garavelli, 2004, Walsh et al., 2005). Among the different PTMs, 
phosphorylation is one of the best characterized and consists of the addition of a 
phosphoryl group at serine, threonine, tyrosine and histidine residues of target proteins 
(Fischer, 2013, Puttick et al., 2008). The fact that 500 proteins encoded by the human 
genome are kinases is highlighting the importance of this PTM (Gomase and Tagore, 
2008). Phosphorylation regulates almost all aspects of cell life; it is the driving force in 
transmitting the extracellular signals to the cell interior, protein degradation, protein 
interactions, and gene expression among many others (Fischer, 2013). Of central 
interest in this Thesis is to study the role of tyrosine (Tyr, Y) phosphorylation of CaM 
and how phosphorylation affects the functions exerted by this protein, and the role of 
CaM regulating c-Src activation. In addition other aspects of this Thesis will be to 
outline the possible O-GlcNAcylation on the EGFR, as it has been proposed to 
potentially occur at its CaM-binding site (Kaleem et al., 2009), and the interaction of 
CaM with OGT, the enzyme catalyzing the O-GlcNAcylation process. 
3.1 Ca2+ as a messenger  
 
Calcium ion (Ca2+) is one of the major messengers in cell signaling playing pivotal 
roles in many cellular functions such as muscle contraction, synaptic transmission, 
gene transcription, cell proliferation, autophagy and apoptosis among many others 
(Clapham, 2007). In basal conditions free Ca2+ is at low concentrations within the 
cytosol (from 20 to 50 nM) and about 1 mM in the extracellular space (Barritt, 1999). 
Upon activating the cell by a variety of stimulus the cytosolic concentration of free Ca2+ 
increases to µM levels and   this   “jump”   in   Ca2+ concentration makes of Ca2+ a very 
powerful secondary messenger. Several transport systems are responsible for this 
regulation increasing or decreasing the cytosolic concentration of free Ca2+ such as 
Na+(H+)/-Ca2+ exchangers, Ca2+ channels, and different Ca2+-ATPases located at the 
plasma membrane, endoplasmic reticulum, mitochondria, and other intracellular 
organelles (Clapham, 2007, Barritt, 1999, Berridge et al., 2003). 
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3.2 The Ca2+ sensor protein CaM 
  
 3.2.1 Historical overview 
In 1967 Cheung reported an activator of brain cyclic nucleotide phosphodiesterase 
(PDE) and that during purification it dissociates from the enzyme (Cheung, 1967). At 
the same time Kakiuchi and Yamazaki reported that a heat-stable protein factor along 
with Ca2+ was necessary for the activation of PDE (Kakiuchi and Yamazaki, 1970). 
Shortly after their discoveries these studies merged and gave birth to a new universe in 
cell signaling: they have found that this protein was responsible for the activation of 
PDE in a Ca2+-dependent manner and in the next few years this crystallized in a few 
papers related to the newly found Ca2+ sensor protein that was named calmodulin (Teo 
and Wang, 1973, Wolff and Brostrom, 1974, Cheung et al., 1975, Cheung, 1980, Klee 
and Vanaman, 1982). Since then CaM has been isolated from many organisms and it 
is present in all eukaryotic cell types (Manalan and Klee, 1984, Smith et al., 1987). 
CaM is also a very conserved protein among different species. For example, there are 
just a few differences between mammalian and Drosophila melanogaster CaM, where 
only three amino acids are substituted at positions 99, 143 and 147 (Smith et al., 
1987). 
 3.2.2 Structure of CaM 
Since the discovery of CaM a large number of structural studies has accumulated. 
CaM is an acidic single polypeptide protein that contains 148 amino acid residues and 
has a molecular mass of 16.7 kDa (Means and Dedman, 1980). Its structure consists of 
two terminal globular domains connected by a flexible central linker. Each globular 
domain has two Ca2+-binding sites known as EF hands (Means and Dedman, 1980, 
Chin and Means, 2000). When Ca2+ binds to apo-CaM (Ca2+- free state) a transition 
occurs to the holo-state (Ca2+/CaM complex), which causes the exposure of large 
hydrophobic patches of the protein (Figures 1A and 1B). The exposure of these 
hydrophobic patches is the critical event that drives CaM to bind its targets, as it is 
shown in Figure 1C representing a CaM-myosin light chain kinase (MLCK) peptide 
complex (Chin and Means, 2000). These hydrophobic patches are rich in methionine 
residues: which stabilize the open conformation of Ca2+-loaded CaM and helps it in 
recognizing many different target proteins with various amino acid side chains 
(Bhattacharya et al., 2004). The different EF-hands have different affinity for its ligand, 
the EF hands at the C-terminal have a high Ca2+ affinity (Kd ~10-6, M), which is 10-fold 
higher than the N-terminal EF hands affinity for Ca2+ (Kd ~10-5, M) (Bhattacharya et al., 
2004). Therefore, a different Ca2+ affinity of the four EF-hands allows CaM to adopt 
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many conformations and to be saturated to various degrees (Chin and Means, 2000, 
Bhattacharya et al., 2004). For example, for the activation of CaMK-II only two Ca2+ 
ions bound to the C-terminal sites are required (Shifman et al., 2006) while four Ca2+ 
are required for the activation of the EGF receptor (Dagher et al., 2011). Thus, the 
degree of saturation is the fundamental property that makes it dynamic and flexible, 
and also allows it to bind to several hundred different partners (Shifman et al., 2006, 
Crivici and Ikura, 1995).  
 
Figure 1: Three-dimensional structures of 
CaM in its different conformations: (A) 
Ca2+-free CaM (pdb code: 1CFD); (B) CaM 
loaded with Ca2+ (pdb code: 1CLL) and (C) 
Ensemble of structures (PDB code: 2K0F) 
representing a CaM-myosin light chain 
kinase (MLCK) peptide complex. The ligand 
is shown in grey. The structures were drawn 
using the Cn3D program. The N-terminal (N) 
and the C-terminal (C) of the protein are also 
shown. 
3.2.3 CaM binding domains 
Based on the location of the hydrophobic groups, which serve as anchor points, 
CaM binding motifs have been classified in the following categories: 1–5–10, 1–8–14, 
1–16, IQ, and the IQ-like motifs (Table 1) (Bhattacharya et al., 2004, Jurado et al., 
1999). The key interaction occurs through hydrophobic residues such as Phe (F), Trp 
(W), Ile (I), Leu (L), or Val (V) and typically the C-terminal of CaM interacts with the first 
amino acids and the N-terminal with the hydrophobic residues at positions 10 and 14. 
In the case of 1-16 motifs the N-terminal of CaM binds the amino acid at first position 
and the C-terminal to the residue in position 16 (Bhattacharya et al., 2004). Although 
Ca2+ binding is necessary for CaM to bind to most of its target proteins, apo-CaM is 
also able to bind and regulate many proteins such as neurogranin, neuromodulin, IRS-
1, myosin, and p68 helicase among others (Jurado et al., 1999, Wang et al., 2013). 
Table 1: CaM-binding domains. The 
different CaM-binding domains (CaM-BD) 
including the IQ and IQ-like motifs sequences 
are shown. 
 
 
CaM-BD Motif sequence 
1-5-10  (FILVW)xxxx(FAILVW)xxxx(FILVW) 
1-8-14 (FILVW)xxxxxx(FAILVW)xxxxx(FILVW) 
1-16 (FILVW)xxxxxxxxxxxxxx(FILVW) 
IQ (FILV)Qxxx(RK)Gxxx(RK)xx(FILVWY) 
IQ-like (FILV)Qxxx(RK)xxxxxxxx 
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CaM: functional implications 
Since CaM is regulating a large number of proteins it is not of surprise that this 
Ca2+ sensor is involved in the regulation of many cellular processes, such as cell 
proliferation, apoptosis, muscle contraction, reproductive processes, cell motility, 
cytoskeleton architecture and function, autophagy, gene expression, osmotic control, 
ions transport, and protein folding among others (Chin and Means, 2000, Jurado et al., 
1999, Berchtold and Villalobo, 2014). 
3.2.4 Posttranslational modifications of CaM 
The primary function of CaM is to transduce Ca2+ signaling in cells by binding 
hundreds of proteins including many kinases, it is not of surprise that CaM also 
undergoes posttranslational modifications. Up today CaM has been found to be 
subjected to acetylation, methylation, phosphorylation and glycation. 
3.2.4.1 Acetylation  
Watterson et al. in 1980 shortly after the discovery of CaM reported that the N-
terminus of CaM undergoes acetylation (Watterson et al., 1980). In a later study it was 
reported that the acetylation of lysines 21 and 75 located in the central helix 
significantly reduces the affinity of CaM for MLCK and the acetylation of lysines 13, 30, 
77, 94, or 148 had only a minor effect (Jackson et al., 1987). In general, not much has 
been done in studying the role of acetylation of CaM and the published data on the 
subject are quite poor. 
3.2.4.2 Methylation  
One of the noteworthy modification on CaM is the trimethylation of Lys115 a 
process driven by S-adenosyl-L-methionine: Calmodulin-lysine N-methyltransferase 
(CaM KMT) (Roberts et al., 1986, Rowe et al., 1986). The dimethylation of Lys13 in 
Paramecium has been described as well (Schaefer et al., 1987).  The role of 
methylated CaM is still unclear, but it seems that the methylated form of the protein has 
differential effects on the activation of different CaM targets compared to the non-
methylated protein. As for example, it has been reported that the replacement of 
Lys115 with alanine impairs its ability to activate plant NAD kinase and that the N-
methylation of CaM prevents its degradation by ubiquitin-ATP-dependent proteolysis 
(Gregori et al., 1985). It was also reported that methylated and non-methylated CaM 
both can activate in the same extent PDE1 (Rowe et al., 1986). Moreover, non-
methylated CaM was found in different mammalian tissues (Rowe et al., 1986), and 
CaM KMT has been found to be subjected to different developmental regulation in 
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plants (Oh et al., 1992). It has been also reported of a transgenic tobacco plant 
expressing the CaM mutant K117R, and this mutant plant had decreased growth, 
pollen viability and seed production (Roberts et al., 1992). In support to that study, 
recently it was demonstrated that the expression of CaM KMT in Arabidopsis thaliana 
was found to be at its highest levels during seed development, especially in tissues 
with active auxin signaling (Magnani et al., 2010). Moreover, this group reported that 
CaM KMT has a role in ABA signaling and auxin response to cold, heat and salt stress, 
and in return the enzyme is regulated by auxin and abiotic stresses. The authors using 
a microarray chip containing Arabidopsis proteins indentified that the methylated and 
non-methylated CaM have different binding partners, and that there are methylation-
sensitive and methylation-insensitive partners of CaM (Magnani et al., 2010). It seems 
that N-methylation of CaM is involved in growth, body and seed development, and 
stress related functions in plants and gives rise to the possibility that it has similar role 
in animal cells. However, a Lys115 mutant CaM does not have a differential effect 
compared to wild type CaM on cell proliferation, and viability (Panina et al., 2012) 
CaM can also undergo carboxyl methylation (Gagnon et al., 1981), the protein 
itself is very good substrate for protein-carboxyl methyltransferase, as it has many 
acidic and basic residues and low isoelectric point (Means and Dedman, 1980). CaM 
was also found to be carboxy methylated in living cells (Gagnon et al., 1981). The role 
of this modification is not clear, but it has been reported that carboxy methylated CaM 
has reduced ability to activate PDE1 in vitro and that this modification does not impair 
the Ca2+ binding, but most likely it affects the conformation of the Ca2+/CaM complex 
(Weiss et al., 1980). 
3.2.4.3 Phosphorylation  
Reversible protein phosphorylation of threonine, serine, tyrosine or histidine 
residues is one of the most well studied posttranslational modifications and it is one of 
the most important in functional terms. Phosphorylation plays crucial roles in regulation 
of many cellular processes such as cell growth, cell cycle, apoptosis, cell metabolism, 
and signal transduction among many others (Fischer, 2013). 
It has been demonstrated that CaM is phosphorylated both in vitro and in vivo 
(Plancke and Lazarides, 1983, Nakajo et al., 1986, Salas et al., 2005, Benaim and 
Villalobo, 2002). There are four serine and twelve threonine residues in CaM that could 
be subjected to phosphorylation by protein-Ser/Thr kinases and only two tyrosine 
residues that could be targeted for phosphorylation by different protein-tyrosine 
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kinases. Figure 2 shows the 3D structure of CaM from Homo sapiens where different 
amino acids known to be phosphorylated are highlighted.  
 
Figure 2: Serine, threonine and 
tyrosine residues in CaM 
phosphorylated by different kinases. 
The figure was prepared using the Cn3D 
4.3.1 program and the amino acids 
phosphorylated by protein-
serine/threonine kinases and protein-
tyrosine kinases are highlighted in yellow. 
The CaM structure (pdb code: 1CFD_A) 
is presented as wire and the side-chains 
of the amino acids are shown with sticks.  
 
Phosphorylation of CaM by protein Ser/Thr kinases 
Four of the threonine residues have been reported to be subject to 
phosphorylation: Thr26, Thr29, Thr79 and Thr117 (Davis et al., 1996). The first two are 
phosphorylated by MLCK, the kinase phosphorylates mainly Thr29, while much lower 
phosphorylation of Thr26 was also detected. Interestingly, the MLCK was able to 
phosphorylate CaM in a Ca2+-independent manner even when its canonical CaM-BD 
was mutated (Davis et al., 1996). Thr79 and Thr117 on the other hand are 
phosphorylated by casein kinase-II (CK-II), and this kinase is also responsible for the 
phosphorylation of Ser81 and Ser101 (Nakajo et al., 1986, Meggio et al., 1987, Nakajo 
et al., 1988, Quadroni et al., 1994). Thr79 and Ser81 are located in the central alpha 
helix of CaM, region with great importance for the binding of CaM-BPs (Figures 1B and 
1C, Figure 2). The phosphorylation of Ser101, which is located in the III Ca2+-binding 
pocket, may not only affect the binding of target proteins but also the binding of Ca2+. 
Therefore, the effect of CK-II phosphorylation was investigated and two controversial 
finding were published (Aiuchi et al., 1991, Quadroni et al., 1998). The first one 
reported that CaM phosphorylated by CK-II has higher affinity for Ca2+ compared to 
non-phosphorylated CaM (Aiuchi et al., 1991). In reverse, the other group using flow 
dialysis reported that CK-II-phosphorylated CaM has lower affinity for Ca2+ (Quadroni et 
al., 1998). In fact Ca2+ at low concentrations stimulates the phosphorylation of CaM by 
CK-II and has inhibitory effect at higher concentration (Meggio et al., 1987, Sacks and 
McDonald, 1992).  
Phosphorylation of CaM by receptor and non-receptor protein tyrosine 
kinases  
 
Unlike Ser/Thr phosphorylation of CaM, where only two kinases are so far known 
to be involved: CK-II and MLCK, Tyr99 and Tyr138 are targeted by at least eight 
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different protein-tyrosine kinases (Figure 3). There are only two protein-tyrosine 
receptor kinases known so far, that are able to phosphorylate CaM: the InsR and the 
EGFR, and about six non-receptor tyrosine kinases, four of the Src family plus Syk and 
Jak2 kinases, that also are able to phosphorylate CaM. 
 
Figure 3: Receptor and non-receptor 
protein tyrosine kinases known to 
phosphorylate CaM. The receptor 
protein-tyrosine kinases EGFR and InsR 
are shown in their active conformation as 
well as the non-receptor tyrosine kinases 
of the Src family (c-Src, v-Src, Fyn and 
Fgr) plus Syk and Jak2. 
 
Phosphorylation of CaM by InsR 
In 1985 the group of McDonald for the first time reported that the InsR from rat 
adipocyte membranes is a CaM-BP, suggesting that Ca2+/CaM has an important role in 
insulin-induced events (Graves et al., 1985). One year later the same group reported 
that CaM is not only binding to the InsR, but also enhances the receptor activity and in 
return the kinase phosphorylates CaM (Graves et al., 1986, Wong et al., 1988, Sacks 
and McDonald, 1988, Laurino et al., 1988, Sacks et al., 1989a). Shortly after this 
discovery a few additional papers were published on the subject, demonstrating that 
CaM is phosphorylated by the InsR in different tissues such as adipose tissues, 
skeletal muscle, liver and placenta (Graves et al., 1986, Wong et al., 1988, Sacks and 
McDonald, 1992, Sacks et al., 1989a). The in vitro phosphorylation of CaM by the InsR 
requires different polycations or basic proteins, such as poly-L-lysine or histones, as co-
factors (Sacks and McDonald, 1988) and it has been suggested that in living cells this 
function could be exerted by the C-terminal of K-Ras. Indeed, a stimulatory effect on 
CaM phosphorylation by the InsR was demonstrated in an in vitro assay using a highly 
basic segment from K-Ras where the in vitro phosphorylation of CaM by InsR was also 
demonstrated (Fujita-Yamaguchi et al., 1989, Sacks et al., 1989b). Another interesting 
points on the subject are that low concentrations of Ca2+ have a highly stimulatory 
effect on the phosphorylation of CaM, while higher concentrations inhibits this process 
(Graves et al., 1986, Sacks and McDonald, 1992, Sacks et al., 1989a, Sacks, 1994), 
and that the InsR increased its potential to phosphorylate CaM that was previously 
phosphorylated by CK-II (Laurino et al., 1988). InsR is able to phosphorylated both 
Tyr99 and Tyr138, nevertheless, there is contradictory information published as some 
reports suggest that only Tyr99 is phosphorylated (Laurino et al., 1988, Saville and 
Houslay, 1993, 1994), while others demonstrate that both tyrosines are targeted by the 
InsR (Wong et al., 1988, Williams et al., 1994). 
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Phosphorylation of CaM by EGFR 
In 1986 the group of Wharton detected phospho-Ser-CaM in EGF-stimulated A431 
cells (Lin et al., 1988). However, this was an indirect effect mediated by an unknown 
Ser/Thr kinase. The direct tyrosine-phosphorylation of CaM by the EGFR was 
discovered and extensively studied by the group of Villalobo (San José et al., 1992, 
Benguría et al., 1994, 1995, De Frutos et al., 1997, Palomo-Jiménez et al., 1999, 
Benaim et al., 1998). It was reported that EGFR purified from rat liver by CaM-affinity 
chromatography was able to phosphorylate CaM at tyrosine (Benguría et al., 1994). 
The addition of poly-L-lysine or histones for the in vitro phosphorylation of CaM by 
EGFR, is an important requirement, as in the case with the InsR (Benguría et al., 
1994). Interestingly, 1 µM of free Ca2+ was sufficient to profoundly inhibit CaM 
phosphorylation by EGFR (Benguría et al., 1994, De Frutos et al., 1997). Speaking of 
Ca2+ concentration and EGFR-CaM interaction it is of note that one of the 
consequences of the EGF-mediated activation of the receptor is the increase of 
cytosolic Ca2+ concentration and the extent of this increase maybe equivalent to a 
gradual decrease in the EGF-dependent phosphorylation of CaM (Villalobo et al., 
2000). EGFR predominantly phosphorylates Tyr99, but it is also capable of 
phosphorylating Tyr138 (Palomo-Jiménez et al., 1999). 
Phosphorylation of CaM by non-receptor tyrosine kinases 
Several members of the Src family (c-Src, v-Src, Fyn and Fgr) have been shown to 
phosphorylate CaM as well as other tyrosine kinases such as Jak2 and Syk. It has 
been reported that CaM is phosphorylated in Rous sarcoma virus (RSV)-transformed 
chicken embryo fibroblasts but not in normal chicken embryo fibroblasts, and purified v-
Src has been shown to phosphorylate CaM in vitro and that this phosphorylation was 
inhibited by Ca2+ (Ki= 30 µM) (Fukami et al., 1986). An interesting observation is that v-
Src phosphorylated CaM had a slower electrophoretic mobility compared to non-
phosphorylated CaM (Fukami et al., 1986). We have successfully phosphorylated CaM 
using recombinant c-Src and the presence of poly-L-lysine or histones strongly 
enhances the process (Salas et al., 2005, Stateva et al., 2015). However, the 
subsequent mutagenesis of Tyr99 and Tyr138 to Phe, Glu or Asp showed that when 
Tyr99 was mutated the efficiency of phosphorylation of Tyr138 was far greater as 
compared to the phosphorylation of Tyr99 when Tyr138 was mutated. This suggests 
that Tyr138 is the one preferred by the kinase (Salas et al., 2005, Stateva et al., 2015). 
Other non-receptor tyrosine kinases from the Src family capable of phosphorylate CaM 
are c-Fyn and c-Fgr, and both phosphorylate Tyr99 and Tyr138 (Corti et al., 1999). 
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The other two non-receptor tyrosine kinases known to phosphorylate CaM are Syk 
and Jak2. Syk kinase from spleen is able to tyrosine phosphorylates CaM at very low 
concentration of polycations (Meggio et al., 1987).  As it is true for the Syk kinase, the 
information available for Jak2 CaM phosphorylation is scarce and there is only one 
report demonstrating that Jak2 is in fact capable of phosphorylate CaM (Mukhin et al., 
2001). 
3.3 CaM-dependent systems  
 
As previously mentioned CaM is a ubiquitously expressed protein that has been 
found in all eukaryotic cells. Its subcellular localization may vary and it can be found in 
the cytoplasm, nucleus, attached to the plasma membrane or within organelles, 
regulating more than 300 different proteins with enzymatic or non-enzymatic functions 
(Crivici and Ikura, 1995, Shifman et al., 2006, Berchtold and Villalobo, 2014).  
 
3.3.1 Cyclic nucleotide phosphodiesterase 1 
 
PDEs form a large group of enzymes that specifically hydrolyze the second 
messengers cAMP and cGMP into the non-cyclic   nucleotides   5’-AMP   and   5’-GMP, 
respectively (Weishaar, 1986, Halpin, 2008, Keravis and Lugnier, 2012). Immediately 
after the discovery of cAMP the cyclic nucleotide PDE activity was described (Butcher 
and Sutherland, 1962). During the next two decades, research into the biochemical 
characterization and functional role of PDEs has grown exponentially and in this period 
around 1300 research articles have been published. More and more different PDE 
were found in different tissues and cell extracts. Interestingly the PDE activity as well 
as the distribution of PDE differed among different tissues and this led to a huge 
confusion in the nomenclature. Finally, the different PDEs were classified in 11 families 
based on the primary amino acid sequence as well as their kinetic and regulatory 
properties (Omori and Kotera, 2007). All of these 11 families of PDEs have a N-
terminal regulatory domain (R-domain) and a C-terminal catalytic domain (C-domain). 
The N-terminal region of the PDEs differs the most among PDEs in size and structure, 
and contains sequences that are target for various regulators, and it also contain the 
binding site for cGMP and CaM, phosphorylation sites, and it is involved in membrane 
association and dimerization events (Lugnier, 2006). 
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CaM regulation of PDE1 
 
The existence of Ca2+-stimulated phosphodiesterase activity and that this is 
mediated by a heat stable protein activator was first demonstrated in   the  early   ’70  of  
the last century (Cheung, 1970, Kakiuchi and Yamazaki, 1970). Since their discovery 
Ca2+/CaM-dependent PDEs have been isolated from many mammalian tissues and the 
richest source of CaM-dependent isoenzyme (PDE1) is the bovine brain, but CaM-
dependent PDEs have been isolated also from other tissues such as lung and heart 
(Sharma and Wang, 1986, Sharma and Kalra, 1994). CaM-dependent PDEs are 
named depending on their tissue distribution: brain (60 and 63 kDa isoforms), lung and 
heart, and these isoenzymes have different affinity for cGMP, cAMP and Ca2+/CaM but 
what is common for all of them is that they have higher affinity for cGMP than for cAMP 
(Sharma and Kalra, 1994). Nevertheless, the Km of the different isoenzymes of CaM-
dependent PDEs for cAMP and cGMP may vary in a big range, for instance the Km for 
cAMP of the enzyme in bovine brain has been shown in deferent studies to be in the 
range from 10 to 200 µM (Sharma and Kalra, 1994, Morrill et al., 1979, Klee et al., 
1979, Tucker et al., 1981, Shenolikar et al., 1985). 
 
The crucial role of Ca2+/CaM in the activation of certain PDE isoenzymes is 
obvious, as  Ca2+/CaM is absolutely necessary for the maximal activation of these 
enzymes (Kakiuchi and Yamazaki, 1970, Sharma and Kalra, 1994), but this is only at 
first sight, since Ca2+/CaM has much more to do in regulating this system. The 
activation of cells upon various stimulus leads to the activation of adenylate cyclase 
(AC), an enzyme able to convert ATP into cAMP, thus increasing the cellular 
concentration of cAMP. At the same time the cytosolic concentration of Ca2+ also rises 
and the increased levels of the Ca2+/CaM complex and cAMP concentration activates 
the PDEs that starts to hydrolase cAMP to AMP. At that point the high levels of cAMP 
activate protein kinase A (PKA), which in turn phosphorylates PDE inactivating this 
enzyme. In fact, the inactivation of PDE by phosphorylation is not only due to PKA, the 
increase of the Ca2+ concentration leads to the activation of CaMKKs, which are also 
able to phosphorylate and inactivate the PDE. During these events the Ca2+ continues 
rising and finally achieves its pick and Ca2+/CaM is now able to activate calcineurin 
(CaN), which is a ubiquitous phosphatase, that is able to dephosphorylate and activate 
PDE (Sharma et al., 2006). Taken all together it makes Ca2+ and the Ca2+/CaM 
complex essential regulators of this processes, providing different mechanism for 
achieving a steady-state equilibrium between activation and inhibition of the main 
players in this signaling cascade. 
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Role of phospho-CaM on the regulation of PDE1  
 
It has been reported that CaM phosphorylated by CK-II has lower affinity for bovine 
brain PDE1 compared to non-phosphorylated CaM, while the affinity of the enzyme for 
Ca2+ and the Vmax remain the same (Sacks et al., 1992, Quadroni et al., 1998,). This 
observation was further proved by testing dansylated phospho-Ser/Thr-CaM with a 
peptide corresponding to the CaM-binding site of the same PDE1, as the 
phosphorylated peptide had lower affinity for PDE1 compared to the non-
phosphorylated one (Leclerc et al., 1999). 
 
The information published about the effect of phospho-Tyr-CaM is not that 
homogeneous, as some authors detected lower affinity of phospho-Tyr99/Tyr138-CaM 
(phosphorylated by the InsR) for PDE1 from bovine brain compared to the non-
phosphorylated one (Williams et al., 1994), while purified phospho-Tyr99-CaM 
presented higher affinity (Corti et al., 1999) and in both cases the Vmax was similar to 
the one presented by non-phosphorylated CaM. On the other hand, CaM 
phosphorylated by the EGFR was incapable of activating PDE1 from bovine heart 
(Palomo-Jiménez et al., 1999), while InsR-phosphorylated CaM has no effect when 
tested toward PDE1 isolated from rat hepatocytes (Saville and Houslay, 1994). The 
role of phospho-Tyr-CaM on PDE1 seems to fluctuate depending on the purity of the 
phospho-Tyr-CaM preparation, and the Tyr residues subject to phosphorylation, as well 
as the isoform of the enzyme.  
 
3.3.2 Nitric oxide synthase   
 
Nitric   oxide   (∙NO)   is a very important free radical second messenger molecule 
controlling process such as the immune response, blood pressure and neuronal activity  
among others (Kerwin et al., 1995, Bogdan, 2015, Das and Kumar, 1995, Luo and Zhu, 
2011).   ∙NO  is  produced  by  the  enzyme  nitric  oxide  synthase  (NOS)  as  product  of   the  
conversion of L-arginine into L-citrulline. For each L-citrulline and ∙NO produced, 2 
molecular oxygens and 1.5 NADPH are consumed (Kerwin et al., 1995). 
 
NOS isoforms 
 
There are three isoforms of mammalian NOS: endothelial (eNOS) expressed 
mainly in endothelial cells, neuronal (nNOS) expressed mainly in neuron cells and 
inducible (iNOS) expressed in macrophages, but can be induced in many other cell 
types (Griffith and Stuehr, 1995). The  ∙NO  produced  by  eNOS  controls  vascular  dilation  
and blood flow (Das and Kumar, 1995), nNOS-produced   ∙NO   is   responsible   for  
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neurotransmission (Luo and Zhu, 2011) and the one produced by iNOS is used in the 
immune system as a defense mechanism (Bogdan, 2015). eNOS and nNOS are 
constitutively expressed and are classified as constitutive NOS (cNOS). Their 
enzymatic activity depends on increasing Ca2+ concentration in the cell, due to the 
Ca2+-dependent binding of CaM to these isoforms (Govers and Rabelink, 2001). iNOS, 
on the other hand, is expressed only when required and as soon as it is transcribed, it 
can bind to CaM in the absence or presence of Ca2+, and CaM is a constitutive subunit 
of the enzyme (Cho et al., 1992). The overall structure of the three isoforms is similar, 
with an oxygenase domain and a reductase domain separated by a CaM-BD. The 
oxygenase domain contains binding sites for tetrahydroxybiopterin (TH4), the catalytic 
heme and the active site, and the reductase domain accommodates the binding sites 
for NADPH, FAD and FMN. The NOS enzymes are found to be homo-dimeric proteins 
(Alderton et al., 2001).  
 
CaM regulation of NOS 
 
CaM is essential for the activation of the NOS isoforms. The binding affinity of CaM 
for each of the isoforms differs, with the highest binding affinity for iNOS, followed by 
nNOS and then eNOS (Aoyagi et al., 2003, Ghosh and Salerno, 2003). CaM binds to 
NOS at a 1-5-8-14 CaM-binding motif with the binding region consisting of residues 
731-752 of nNOS, 491-512 of eNOS, and 501-531 of iNOS. It is believed that iNOS 
binds CaM in a Ca2+-independent manner, however no IQ-motif within the protein has 
been identified so far. It is believed that CaM binds to iNOS in both Ca2+-dependent 
and Ca2+-independent manners (Aoyagi et al., 2003). A conformational change that is 
associated with CaM binding to NOS is required for electron transfer within these 
enzymes (Govers and Rabelink, 2001). The conformational change that CaM induces 
in the reductase domain of NOS allows for the FMN domain to interact with FAD to 
accept electrons and pass the electrons to the heme during catalysis. Exactly how CaM 
is able to initiate this process is still not fully understood. Clearly, these conformational 
changes caused by CaM are important for stimulating efficient electron transfer within 
the NOS enzymes (Daff et al., 2001). 
Role of phospho-CaM on the regulation of NOS enzymes 
Carafoli's group have demonstrated that phospho-(Tyr)-CaM  and phospho-
(Ser/Thr)-CaM both have stimulatory effects on the activation of NOS isolated from 
brain compared to the non-phosphorylated protein (Quadroni et al., 1994, Corti et al., 
1999). Titration assay of dansyled CaM and dansyled phospho-(Ser/Thr)-CaM with a 
INTRODUCTION  
   
37 | P a g e  
 
peptide corresponding to the CaM-BD of NOS exhibited lower affinity for the 
phosphorylated than for the non-phosphorylated form (Leclerc et al., 1999). This 
observation was further confirmed and it was reported that CK-II-phosphorylated CaM 
has lower ability to activate eNOS and has two fold reduced Vmax compared to non-
phosphorylated CaM, while the affinity of the enzyme for CaM and Ca2+ was not 
changed (Greif et al., 2004). 
In terms of phospho-(Tyr)-CaM and its effect on NOS activation not much has 
been done during the last few years. What we know is that in a displacement assay of 
a dansylated peptide corresponding to the CaM-BD of the Ca2+-ATPase, which is 
bound to non-phosphorylated CaM or phospho-(Tyr99)-CaM by a peptide 
corresponding to the CaM-BD of NOS showed that the affinity of phospho-(Tyr99)-CaM 
for the CaM-BD of NOS was higher compared to non-phosphorylated CaM (Corti et al., 
1999). 
 
3.3.3 Tyrosine-protein kinase c-Src 
c-Src kinase belongs to the Src family of non-receptor tyrosine kinases. Src family 
kinases are regulating processes such as cell differentiation, proliferation, motility and 
cell survival, stress response among other processes. It comprises Blk, Fgr, Fyn, Lck, 
Lyn, Hck, Yes, and c-Src itself. Fgr, Blk and Hck are found mainly within blood cells; 
Lyn and Lck in blood cells and brain, while Yes, Fyn and c-Src are ubiquitously 
expressed (Parsons and Parsons, 2004, Yeatman, 2004). The 3D structure of c-Src is 
well studied. c-Src is a 60 kDa modular protein formed by a N-terminal region 
containing a myristoyl-binding sequences, a SH4 domain, an Unique domain (UD), 
SH3 and SH2 domains followed by the protein-tyrosine kinase domain (SH1) and a 
short C-terminal tail (Xu et al., 1997). Src family members are attached to the cellular 
membrane through myristoylation in its N-terminal (Patwardhan and Resh, 2010). c-Src 
and oncoprotein v-Src play prominent roles in tumor progression and metastasis 
(Parsons and Parsons, 2004, Wheeler et al., 2009), thus they have been targeted by 
different inhibitors and strategies in thyroid, pancreas and breast cancers (Wheeler et 
al., 2009).  
The non-receptor tyrosine kinase Src is subjected to complex regulatory 
mechanisms mediated by phosphorylation events that control its activation status 
(Okada and Nakagawa, 1989, Cooper and Howell, 1993, Parsons and Parsons, 2004, 
Irtegun et al., 2013). When inactive, c-Src is phosphorylated at Tyr530 (Tyr527 in 
chicken) by the tyrosine kinases Csk and Chk (Chong et al., 2005). Tyr530 is a highly 
conserved residue among all Src kinase family members and it is located at the C-
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terminal tail of the protein. When Tyr530 is phosphorylated the C-tail interacts with the 
SH2  domain  and  the  kinase   is   in   its  “closed”  and   inactive  conformation   (Ayrapetov et 
al., 2006, Roskoski, 2005). Dephosphorylation of Tyr530 by tyrosine phosphatases 
induce   conformational   changes   and   the   subsequent   autо-phosphorylation of Tyr419 
opens up the kinase and stabilizes the catalytic domain in an active state (Roskoski, 
2005). 
CaM regulation of c-Src 
Hayashi et al. demonstrated that a myristoylated peptide corresponding to the N-
terminal of v-Src interacts with the Ca2+/CaM complex, while the non-myristoylated 
peptide was not able to do so (Hayashi et al., 2004). It has been also proposed that 
upon Ca2+ entry in stimulated cells, CaM residing in lipid rafts interacts in a Ca2+-
dependent manner with c-Src, and in turn c-Src phosphorylates and inhibits PP2A, 
preventing in this manner its inhibitory action on Akt and henceforth promoting 
melanoma tumor growth (Fedida-Metula et al., 2012). The activation of c-Src by 
Ca2+/CaM  was  also  demonstrated  in  transfected  neuroblastoma  cells  overexpressing  α-
synuclein,   a   cytotoxic   protein   abundant   in   Lewy   bodies   in   Parkinson’s   disease,   by   a  
mechanism also implicating PP2A (Yang et al., 2013). The direct interaction of CaM 
with a recombinant GST-Src fusion protein was demonstrated to occur through both 
Ca2+-dependent and Ca2+-independent mechanisms, although mutation of the 
proposed CaM-binding site located at the SH2 domain of c-Src only partially prevented 
CaM binding (Yuan et al., 2011). The most recent evidence of CaM binding to Src 
surprisingly involves the unique domain of the kinase. Pérez et al. using NMR and 
peptides corresponding to the Unique and SH3 domains of Src have demonstrated that 
Ca2+/CaM is able to bind to the Unique domain and thus modulating the binding of the 
kinase to the plasma membrane (Pérez et al., 2013). Additionally, Src was shown to 
co-immunoprecipitate with CaM but not with tyrosine-phosphorylated CaM in 
keratinocytes (Wu et al., 2015). 
Nevertheless, these reports did not fully clarify the actual mechanism by which 
CaM interacts and activates c-Src, or if this process always occurs in the cell in a Ca2+-
dependent manner. This highlights the need for additional work to determine whether 
CaM controls the tyrosine kinase activity of c-Src in both Ca2+-dependent and/or Ca2+-
independent manners. There is no information about the role of the phospho-CaM on 
c-Src functionality so far. 
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3.3.4 Epidermal growth factor receptor 
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein, 
and it belong to the ErbB receptor tyrosine kinase family formed by ErbB1/EGFR/Her1, 
ErbB2/Neu/Her2, ErbB3/Her3 and ErbB4/Her4. Its structure consists of an extracellular 
region which is responsible for the ligand-binding, a single transmembrane segment 
and a cytosolic region that contains a juxtamembrane domain (JD), a tyrosine kinase 
domain (TK) and a C-terminal tail (Figure 4) (Schlessinger, 2014, Olayioye et al., 2000, 
Yarden, 2001). A general accepted mechanism of EGFR activation is that upon binding 
of ligands, including EGF (epidermal growth factor), TGF-α (transforming growth factor-
α), HB-EGF (heparin-binding EGF-like growth factor), BTC (betacellulin),  AREG 
(amphiregulin) and EPR (epiregulin) causes structural changes of the domains, and 
induces dimerization of two receptor monomers (Olayioye et al., 2000, Yarden and 
Sliwkowski, 2001, Ferguson et al., 2003).   EGFR   can   form   homо-dimers   or   heterо-
dimers with other ErbB family members (Olayioye et al., 2000, Gullick, 2001). The 
dimerization leads to activation of the intrinsic  tyrosine  kinase  domain  followed  by  autо-
(trans)-phosphorylation at multiple Tyr residues located in the C-terminal tail: Y992, 
Y1045, Y1068, Y1086, Y1148 and Y1173 (Linggi and Carpenter, 2006).  These  autо-
phosphorylation sites then are docking sites for different cytosolic proteins containing 
SH2 (Src homology 2) and PTB (phosphotyrosine binding) that are adaptors and 
signaling proteins forming transduction complexes to activate signaling pathways such 
as the RAF-RAS-MEK-ERK, the PI3K-Akt, the PLCγ-PKC, and the STATs pathways 
(Figure 4). The activation of these signaling pathways results in cell cycle progression, 
cell proliferation, migration, adhesion, survival, and differentiation (Schlessinger, 2014, 
Yarden, 2001, Wagner et al., 2013).  
Ligand-induced EGFR internalization and degradation have been extensively 
studied (Wiley, et al., 1991, Kirisits et al., 2007, Zwang and Yarden, 2009). Following 
activation EGFR undergoes internalization through endocytosis where the receptor-
ligand complex is sorted either for degradation or recycling back to the plasma 
membrane, or for nuclear translocation (Kirisits et al., 2007, Henriksen et al., 2013). 
After ligand binding, EGFR associates to coat adaptors such as adaptor protein 2 and 
Eps15 followed by endocytosis of the receptor through clathrin-coated pits, caveolae-
mediated endocytosis, or through macropinocytosis (Zwang and Yarden, 2009). EGFR 
is frequently overexpressed, miss-regulated or mutated in many solid tumors 
contributing to cancerogenesis, thus the receptor has became an important target for 
cancer therapy (Yarden, 2001, Schlessinger, 2014, Lemmon et al., 2014, Dancey, 
2004). 
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Figure 4: EGFR signaling pathways. 
Schematic representation of the functional 
domains of EGFR, the tyrosine 
phosphorylation residues induced by ligand 
(yellow triangle) stimulation and some 
downstream signaling cascades.
 
CaM regulation of the EGFR 
 
The direct interaction of CaM with the EGFR was first reported in several studies 
done by our group (San José et al., 1992, Martín-Nieto and Villalobo, 1998, Li et al., 
2004). The first evidence of direct binding between these two proteins was the 
identification of solubilized EGFR from rat liver bound to CaM-Sepharose in the 
presence of Ca2+ (San José et al., 1992). Later on the same was replicated using 
human EGFR, overexpressed in stably transfected murine fibroblasts (Martín-Nieto and 
Villalobo, 1998). In recent years the JM domain has been shown to play an important 
role in the regulation of the receptor and the specificity of its signaling (Hubbard, 2009, 
Red Brewer et al., 2009, Jura et al., 2009). In the JM region was identified a basic 
amphiphilic site comprising amino acids 645RRRHIVRKRTLRRLLQ660 with CaM-binding 
properties (Martín-Nieto and Villalobo, 1998). Experiments using the CaM-BD of EGFR 
tagged with GST, determined that the interaction between CaM and the EGFR JM 
occurred in a Ca2+- dependent manner and the formation of the complex was abolished 
in the presence of the Ca2+-chelating agent EGTA (Martín-Nieto and Villalobo, 1998). In 
a more recent paper published by our group the role of CaM binding on EGFR 
functionality was further supported in living cells (Li et al., 2012). We used a conditional 
CaM-KO cell line in which all alleles of the genes encoding endogenous CaM were 
deleted and a construct encoding CaM from Rattus norvegicus was inserted. The latter 
one bearing a Tet-off cassette allowing the suppression of the expression of rat CaM in 
those cells by the addition of tetracycline (Panina et al., 2012). This cell line was stably 
transfected with the human EGFR and it was demonstrated that after the suppression 
of the expression of CaM the EGF-dependent activation of the receptor was 
significantly reduced highlighting the importance of CaM binding for EGFR functionality 
(Li et al., 2012). 
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Several models for how CaM mediates the regulation of the EGFR have been 
proposed (McLaughlin et al., 2005, Sánchez-González et al., 2010). McLaughlin et al. 
suggested that the basic amino acids that compose the cytosolic JM and the tyrosine 
kinase domain of the receptor is attached to the acidic lipids in the inner leaflet of the 
plasma membrane of the cell through electrostatic interaction and serves as an 
autoinhibitory mechanism of the receptor in the absence of ligand (McLaughlin et al., 
2005). Ligand binding to the receptor leads to a rapid increase in the amount of the 
cytosolic Ca2+, thus inducing the formation of the Ca2+/CaM complex, which binds to 
the CaM-BD of the JM domain of the EGFR and detach it from the membrane. The 
detachment  of   the  JM  domain  now  allows  the  receptor   to  form  an  active  homо-dimer 
(Figure 5) ( McLaughlin et al., 2005, Sato et al., 2006). 
 
Figure 5:  Model for the activation of the 
EGFR by the Ca2+/CaM complex. (A) 
ЕGFR in an inactive state. The cytosolic JM 
is bound to the plasma membrane followed 
by the tyrosine kinase domain (TK) domain, 
which is also close to the negatively 
charged membrane. (B) EGF activated 
EGFR: Ca2+/CaM binds to the CaM-BD in 
the JM and pull it out from the negatively 
charged bilayer. Adapted from (McLaughlin 
et al., 2005, Sato et al., 2006). 
However, more recent NMR studies have suggested that the transmembrane 
domain dimerization is most likely enough to trigger the dissociation of the JM from the 
membrane (Matsushita et al., 2013). However, all of these models are based on the 
possibility that the membrane integrity is necessary to hold the receptor in an 
autоinhibited  state  in  the  absence  of  its  ligand  (Lemmon et al., 2014). 
 
Phospho-CaM regulation of the EGFR 
The effect of phospho-(Y)-CaM and phospho-(Ser/Thr)-CaM on the EGFR 
functionality is still not clear. To our knowledge nothing has been done with the 
phospho-(Ser/Thr)-CaM, while our group have shown that phospho-(Tyr)-CaM in both 
the absence and presence of Ca2+ have an activating role in the EGF-dependent EGFR 
activation of the solubilized receptor in vitro, while non-phosphorylated CaM had an 
inhibitory effect in the presence of EGF in this in vitro assay system (Stateva et al., 
2015, manuscript in preparation).  
 
 
INTRODUCTION  
   
42 | P a g e  
 
3.4 O-GlcNAcylation 
Protein O-GlcNAcylation is a posttranslational modification first identified by Hart 
group in 1984 in lymphocyte proteins (Torres and Hart, 1984). It consists in the 
reversible O-linked   attachment   of   single   β-D-N-acetylglucosamine moieties to 
serine/threonine residues in target proteins, but unlike the other types of glycosylation it 
is not further extended to more complex structures and occurs predominantly in 
intracellular proteins (Holt and Hart, 1986). It was shown that this modification has a 
short half-life and it can respond to different stimuli (ligand binding or different type of 
stress) within minutes (Zachara and Hart, 2004, Kneass and Marchase, 2004). Since 
then O-GlcNAcylation has been indentified in all higher eukaryotes from 
Caenorhabditis elegans to human and found to modify hundreds of different proteins, 
modifying their enzymatic activity, intracellular location, turnover, and/or exerting other 
functional roles (Hart, 2014). Altered O-GlcNAcylation has been proposed to contribute 
to the etiology of many illnesses such type-2 diabetes (Lefebvre et al., 2010, Hart et al., 
2011, Ma and Hart, 2013, Vaidyanathan and Wells, 2014), cardiovascular ailments 
(Lefebvre et al., 2010, Marsh et al., 2014),   neurodegeneration   as   in   Alzheimer’s  
disease (Gong et al., 2006, Zhu et al., 2014) and cancer (Li and Yi, 2014, Jozwiak et 
al., 2014, de Queiroz et al., 2014, Ma and Vosseller, 2014). The enzyme that transfers 
GlcNAc moieties to proteins is O-linked  β-N-acetylglucosamine transferase (OGT) and 
unlike the rest of the enzymes involved in glycosylation is not restricted to the 
endoplasmic reticulum or Golgi (Janetzko and Walker, 2014). Three OGT isoforms are 
present in the cell, a canonical long form localized in the nucleus and cytosol (ncOGT), 
another one a bit shorter localized in the inner mitochondrial membrane (mOGT), and a 
third one, the shortest of them (sOGT), also localized in the nucleus and cytosol. These 
isoforms are basically differentiated by the number of tetratricopeptide (TRP) repeat 
motifs present in its N-terminal end (Janetzko and Walker, 2014). Although there is no 
consensus sequence for O-GlcNAcylation, OGT may modulate its substrate specificity 
through its TRP repeats (Iyer and Hart, 2003). It has been also shown that the TRP-
rich domain of OGT is able to bind at the C-terminal of the transcriptional co-regulator 
host cell factor-1 (HCF-1) and subsequently to catalyze its proteolysis (Capotosti et al., 
2011, Lazarus et al., 2013). In addition to OGT, an atypical EGF-like-repeat domain 
specific OGT (EOGT) was found to be also able to O-GlcNAcylate the side chain of 
Ser/Thr at the extracellular segment of different proteins such as Dumpy in Drosophila 
and the Notch receptor in mouse (Sakaidani et al., 2011, Sakaidani et al., 2012, Ogawa 
et al., 2014). Interestingly, the O-GlcNAcylation of the Notch receptor is followed by the 
addition of galactose, generating an O-LacNAc moiety (Sakaidani et al., 2012).  
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The enzyme that removes the O-GlcNAc from the protein backbone is the O-linked 
β-N-acetylglucosaminidase (OGA) that unlike the classical hexosaminidases that are 
resident in the lysosomes it has been found to be distributed in the nucleus and in the 
cytoplasm (Dong and Hart, 1994, Alonso et al., 2014). OGA shares significant 
sequence similarities with acetyltransferases, and appears to be a bifunctional enzyme. 
In fact in a recent study it has been shown to have acetytransferase activity in vitro 
(Toleman et al., 2004). It has been demonstrated that overexpression of OGA induces 
early mitotic exit and disruption of phosphorylation events during mitosis, while 
inhibiting it induces growth arrest (Slawson et al., 2005). 
Protein O-GlcNAcylation is mainly intracellular, dynamic and it cycles on Ser/Thr 
residues in a manner very similar to protein phosphorylation. Interestingly the scientists 
have found out that there are extensive crosstalks between both PTMs, they either take 
place at the same site, or at distinct adjacent sites, competing or facilitating each other 
(Hart et al., 1995, Mishra et al., 2011, Zeidan and Hart, 2010). This crosstalk has been 
found to be involved in the regulation of multiple pathways implicated in the physiology 
of the cell, such as: metabolic control, stress response, epigenetic modification, gene 
transcription, translation of proteins, protein turnover, differentiation, apoptosis and cell 
cycle control among others (Wang et al., 2008, Zeidan and Hart, 2010, Hart et al., 
2011, Lewis and Hanover, 2014). Interestingly, O-GlcNAcylation of some proteins can 
also affect its Tyr phosphorylation, as it is the case of prohibitin (Ande et al., 2009), a 
pleiotropic protein regulating many cellular functions including:  proliferation, apoptosis, 
senescence, development, gene transcription, mitochondrial protein folding and also 
acting as a cell-surface receptor (Mishra et al., 2010, Theiss and Sitaraman, 2011, 
Whelan et al., 2010). 
In recent years there was significant advancement in the field of O-GlcNAcylation 
and the identification of this process is becoming more available (Hart, 2014). Like for 
example, it was demonstrated using microarrays that a large set of serine/threonine- 
and tyrosine-kinases were good substrates for OGT and 42 of a total of 152 candidate 
kinases were found to be O-GlcNAcylated in vitro (Dias et al., 2012). Advances in the 
methodology of protein labeling and recent improvements in Mass Spectrometry (MS) 
techniques allowed scientists to detect and extensively investigate O-GlcNAcylation in 
many different proteins (Hahne and Kuster, 2011). Sprung et al. using high-throughput 
proteomic analysis and labeling proteins of Drosophila melanogaster with the GlcNAc 
analogue azido-GlcNAc indentified many proteins that are potentially O-GlcNAcylated, 
and interestingly the EGFR type III was among them, suggesting that it was susceptible 
to undergoes O-GlcNAcylation (Sprung et al., 2005). Thereafter, in an in silico study it 
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was proposed that the human EGFR could be subjected to O-GlcNAcylation at Thr654 
and Ser1046/Ser1047 (Kaleem et al., 2009), phosphorylation sites of protein kinase C 
(PKC) (Hunter et al., 1984) and CaM-dependent protein kinase II (Countaway et al., 
1992), respectively (Figure 6).  
 
Figure 6: Potential O-GlcNAcylation 
sites in the EGFR based on in silico 
studies. Potential cross-talk between 
EGFR O-GlcNAcylation, and 
phosphorylation of Thr654 by PKC and 
Ser1046/Ser1047 by CaMK-II, and 
occlusion of Thr654 by CaM binding to the 
receptor at its cytosolic juxtamembrane 
region (Kaleem et al., 2009). 
In fact, both residues Thr654 and Ser1046/1047 are very important control 
elements, regulating the functionality of the receptor. The generally accepted theory 
about the role of the phosphorylation of Thr654 by PKC is that this modification leads to 
the so-called   desensitization   or   “shut-down”   of   the   receptor   followed   by  
compartmentalization, internalization and recycling of the EGFR (Countaway et al., 
1992, Llado et al., 2004). A more recent study, however, showed that c-Cbl-induced 
ubiquitination of EGFR and subsequent transfer of the receptor from the early to the 
late endosomes was inhibited by PKC-mediated phosphorylation and that receptor 
degradation and down-regulation were significantly reduced (Bao et al., 2000). Of note 
is to mention that CaM is not able to bind to the CaM-BD of the EGFR when the 
receptor is phosphorylated at Thr654 (Martin-Nieto and Villalobo, 1998), which let 
Kaleem et al. to speculated that the O-GlcNAcylation of Thr654 permit CaM to bind and 
prevents the PKC-mediated phosphorylation of that residue and thus allowing CaM and 
c-Cbl (multi-adaptor protein with E3-ubiquitin ligase) to guide the receptor degradation 
(Kaleem et al., 2009). Interestingly, the other two sites indentified as putative sites for 
O-GlcNAcylation, Ser1046/1047, and possible interplay with phosphorylation on the 
EGFR, are also under the control of Ca2+/CaM, as they are phosphorylated by CaMK-II 
and this phosphorylation leads to the desensitization of the receptor (Countaway et al., 
1992). Kaleem et al. suggested that the O-GlcNAcylation of these two sites could 
activate the receptor. Moreover, in another study it was demonstrated that the InsR, 
also a transmembrane protein-tyrosine kinase receptor was subjected to O-
GlcNAcylation (Yang et al., 2008), highlighting that this modification is not restricted 
only to nuclear and cytosolic proteins. All taken together comes to show the necessity 
of studying the possible role of O-GlcNAcylation on human EGFR, and to explore the 
possible crosstalk between OGT, PKC, CaM and CaMKs.  
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1. To study the possible differential role of phospho-(Y)-CaM and non-
phosphorylated CaM on different CaM-dependent systems using phospho-(Y)-
mimetic CaM mutants: 
 
 To generate and characterize phospho-(Y)-mimetic CaM mutants and to 
study their physicochemical properties. 
 
 To test the phospho-mimetic properties of these CaM mutants on 
different CaM-dependent systems: PDE1, eNOS, c-Src and EGFR. 
 
2. To investigate the possible role of apo-CaM and Ca2+/CaM on c-Src 
functionality in vitro and in living cells. 
 
3. To study the potential O-GlcNAcylation of the EGFR as it has been suggested 
that it may occur at sites regulated either directly or indirectly by CaM. 
 
4. To study whether O-linked β-N-acetylglucosamine transferase (OGT) is a CaM-
binding protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 48 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 49 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 5. Materials & Methods 
 
 
 
 
 
 
 
 
 
 50 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials&Methods  
 
51 | P a g e  
 
5.1 Antibodies 
Anti-mouse IgG (Fc specific) horseradish peroxidase (HRP)-conjugated secondary 
antibody, mouse monoclonal anti-tubulin- (DM1A) antibody, purified mouse IgG 
(technical grade) and rabbit polyclonal anti-phospho-Src (Y418) (recognizing human 
phospho-Y416) were obtained from Sigma-Aldrich Co. (St. Louis, MO). Mouse 
monoclonal anti-phosphotyrosine antibody (4G10, isotype IgG2b), and rabbit 
monoclonal anti-EGFR (E235) antibody (recognizing the C-terminal domain of EGFR) 
were obtained from Millipore (Billerica, MA). Anti-rabbit IgG horseradish peroxidase-
linked secondary antibody was purchased from Invitrogen (Eugene, OR). Rabbit 
monoclonal anti-Src (human) (clone 36D10, isotype IgG), rabbit polyclonal anti-
phospho-Src family (Y416) and rabbit monoclonal anti-GAPDH (clone 14C10, isotype 
IgG) antibodies were obtained from Cell Signaling Company. Mouse monoclonal anti-
O-GlcNAc monoclonal antibody (CTD110.6) and goat anti-mouse IgM (µ heavy chain) 
HRP-conjugated secondary antibody were obtained from Thermo Scientific-Pierce 
(Rockford, IL). The anti-O-GlcNAc antibody (RL2) was obtained from Novus Biologicals 
(Littleton, USA). Anti-OGT antibody (ab50271) was obtained from Abcam (Cambridge, 
UK). 
5.2 Reagents and Materials 
Phenyl-Sepharose 6 (fast flow), Sepharore 4B, (6R)-5,6,7,8-tetrahydrobiopterin 
dihydrochloride, FMN, FAD, cAMP,  3’,5’-cyclic nucleotide PDE1 (from bovine brain), 5’-
nucleotidase (from Crotalus atrox venom), recombinant GST-tagged human EGFR 
(695-end) expressed in baculovirus infected Sf9 cells, eNOS (bovine recombinant 
baculovirus-expressed in Sf9 cells), histone (type II-A), ATP (sodium salt), 4-amino-5-
(methylphenyl)-7-(t-butyl)pyrazolo-(3,4-d)pyrimidine (PP1), benzyl 2-acetamido-2-
deoxyD-galactopyranoside (BADGP), O-(2-acetamido-2-deoxy-D-
glucopyranosylidene)amino N-phenyl carbamate (PUGNAc), (3aR,5R,6S,7R,7aR)-2-
(ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol 
(Thiamet G), tunicamycin, tetracycline, biotin-labeled WGA and UDP-GlcNAc (sodium 
salt) were obtained from Sigma-Aldrich Co. (St. Louis, MO). The ultrasensitive 
colorimetric assay kit for eNOS was purchased from Oxford Biomedical Research 
(Rochester Hills, MI). The QuickChange® XL site-directed mutagenesis kit was 
acquired from Agilent Technology (Santa Clara, CA), and the QIAprep plasmid 
preparation kit from Quiagen Ltd. (Manchester, UK). The Slide-A-Lyzer dialysis 
cassettes and the Classic Magnetic IP/Co-IP kit were purchased from Thermo 
Scientific-Pierce (Rockford, IL). Competent Escherichia coli BL21(DE3)pLysS was 
purchased from Stratagene (La Jolla, CA), and BugBuster® Ni-NTA   His•Bind® 
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purification kit and purified 6His-tagged recombinant human c-Src expressed by 
baculovirus in Sf21 insect cells were obtained from Merck/Millipore (Darmstadt, 
Germany). The ECL kits were obtained from GE Healthcare-Amersham.The PVDF 
membranes were obtained from Pall Corporation (Dreieich, Germany). Streptavidin 
peroxidase-conjugated tetraacetylated N-azidoacetylglucosamine (GlcNAz) and Click-
iT®-protein reaction buffer kit were obtained from Invitrogen (Eugene, OR). Peptide-N-
glycosidase F (PNGase F) (from Flavobacterium meningosepticum), O-glycosidase 
cloned from Enterococcus faecalis and expressed in Escherichia coli (E. coli) and 
neuraminidase cloned from Clostridium perfringens and overexpressed in E. coli were 
obtained from New England BioLabs (Herts, UK). Other chemicals used in this work 
were of analytical grade. The prokaryotic expression vector encoding full-length human 
OGT was a kind gift of Prof. Suzanne Walker (Harvard Medical School, Boston, MA). 
The pETCM vector encoding calmodulin was kindly provided by Prof. Nobuhiro 
Hayashi from the Institute for Comprehensive Medical Science, Fujita Health 
University, Japan. 
5.3 Generation of calmodulin mutants 
PCR-aided site-directed mutagenesis was performed in the pETCM vector 
containing the coding sequence of Rattus norvegicus CaM gene II (Hayashi et al., 
1998) as template using the QuickChange® XL Site-Directed Mutagenesis kit and the 
following set of complementary oligos (Table 2). 
Mutation Primer Sequence (5’- 3’) 
Y99D 5’-GGCAATGGCGACATCAGTGCAGCA-3;;  5’-TGCTGCACTGATGTCGCCATTGCC-3’ 
Y138D 5’-GGGGATGGTCAGGTAAACGACGAAGAGTTTGTACAAATG-3’ 
5’-CATTTGTACAAACTCTTCGTCGTCGTTTACCTGACCATCCCC-3’ 
Y99E 5’-GGCAATGGCGAGATCAGTGCAG-3’;;  5’-CTGCACTGATCTCGCCATTGCC-3’ 
Y138E 5’-GGGGATGGTCAGGTAAACGAGGAAGAGTTTGTACAAATG-3’ 
5’-CATTTGTACAAACTCTTCCTCGTCGTTTACCTGACCATCCCC-3’ 
Table 2: Primers used in this study 
Sequential mutagenesis was carried out to obtain the double substitutions 
Y99D/Y138D and Y99E/Y138E using the Y99D and Y99E mutated vectors, 
respectively, as template. E. coli DH5 was transformed with the pETCM, 
pETCM(Y99D), pETCM(Y138D), pETCM(Y99D/Y138D), pETCM(Y99E), 
pETCM(Y138E) or pETCM(Y99E/Y138E) vectors for their replication, and purification 
by the alkaline lysis method (Birnboim and Doly, 1979) using the QIAprep plasmid 
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preparation kit. The correctness of the mutagenesis procedures was ascertained by 
sequencing the vectors using an oligo annealing to the T7 promoter (Figure 7). 
 
Figure 7: Sequence analysis of CaM(Y99E/D) and CaM(Y138E/D). The substitution of TAC 
(Tyr) to GAG (Glu) and TAC to GAC (Asp) codons are highlighted and arrows pointing the 
substitution are also shown. The alignment of the sequences was done with the CodonCode 
Aligner program.  
5.4 Expression and purification of recombinant calmodulin mutants 
E. coli BL21(DE3)pLysS was transformed with the vectors indicated above using a 
thermic-shock protocol. Single colonies grown in solid medium in the presence of 100 
g/ml ampicillin were collected and seeded in 5 ml of Luria´s broth containing the same 
concentration of ampicillin. Larger cultures (500 ml) were seeded with the pre-culture 
and grown in the same conditions until they reached an OD600 nm = 0.7 ± 0.1. The 
expression of the recombinant proteins was induced with 0.5 mM IPTG during 4 hours 
at 37 ºC. Control cultures in the absence of IPTG were included. The bacteria were 
collected by centrifugation at 6,000 x g for 20 min and frozen at -70 °C until used. The 
bacteria were lysed using the BugBuster® protein extraction reagent kit, centrifuged at 
11,000 x g during 10 min at 4 °C and the supernatant collected, heated at 95 °C for 5 
min and centrifuged again as above. Heat-resistant CaM present in the new 
supernatant was purified as previously described (Hayashi et al., 1998). Briefly, phenyl-
Sepharose 6 (fast flow) was packed in a column and equilibrated with a buffer 
containing 50 mM Tris-HCl (pH 7.5) and 1 mM CaCl2. The sample was applied to the 
column and washed with four column volumes of a buffer containing 50 mM Tris-HCl 
(pH 7.5), 1 mM CaCl2 and 100 mM NaCl. CaM was eluted with a buffer containing 50 
mM Tris-HCl (pH 7.5) and 2 mM EGTA in fractions of 10 ml. The fractions containing 
CaM were desalted using Slide-A-Lyzer dialysis cassettes with membranes of 3.5 kDa 
CaM wt
CaM Y99E
CaM wt
CaM Y138E
CaM wt
CaM Y99D
CaM wt
CaM Y138D
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cut-off against a buffer containing 10 mM Hepes-NaOH (pH 7.5) or 20 mM Tris-HCl (pH 
7.5) and kept at a concentration of 1-2 mg/ml at -70 °C. Protein concentration was 
determined by the BCA method (Stoscheck, 1990) using bovine serum albumin as 
standard. The purity of the samples was confirmed by SDS-PAGE (Laemmli, 1970) in a 
5-20 % (w/v) polyacrylamide continuous gradient slab gel adding 5 mM EGTA or 1 mM 
CaCl2 in the loading buffer to attain the characteristic Ca2+-induced electrophoretic 
mobility shift of CaM (Burgess et al., 1980), and staining the gel with Coomassie 
Brilliant Blue R-250. 
5.5 Absorption spectra 
The absorption spectra in the range 240-340 nm of the different species of CaM 
(120 M) were measured in 20 mM Tris-HCl (pH 7.5) using a CARY/1E/UV-Visible 
spectrophotometer (Varian) equipped with Cary winUV software. 
5.6 Circular dichroism 
Far-UV (200-260 nm) and near-UV (250-320 nm) circular dichroism spectra of the 
different CaM species were measured at 20 ºC in the presence of either 1 mM EGTA 
or 1 mM CaCl2 in a buffer containing 20 mM Tris-HCl (pH 7.5) and 0.1 mM KCl using a 
JASCO J-810 spectropolarimeter (Cremelia, Italy) equipped with a Peltier type 
temperature control system (Model PTC-423S/L), a bandwidth of 0.2 nm and a 
response time of 4 s. Far-UV spectra were recorded in 0.1 cm path-length quartz cells 
at a protein concentration of 0.2 mg/ml, and near-UV spectra in 1 cm path-length 
cuvettes at a protein concentration of 2 mg/ml as previously described (Sun et al., 
2001). The Spectra Manager software (JASCO, v 1.52.01) was used for data collection 
and analysis. Routinely, the corresponding buffer baseline was subtracted and the 
corrected data were normalized per mole of amino acid. Thermal denaturation 
experiments were carried out in the same system by increasing the temperature from 
20 to 90 °C at a scanning rate of 0.66 °C/min. Variations in ellipticity at 222 nm were 
monitored at steps of 0.2 °C. 
5.7 Tb3+ fluorescence 
The emission fluorescence spectra of Tb3+ in the range 520-580 nm in the different 
species of CaM (10 M) upon excitation of tyrosine (if present) at 280 nm were 
measured in 10 mM Pipes-HCl (pH 6.5), 100 mM KCl, and increasing concentrations of 
TbCl3 (0-200 M) using a Photon Technology International Inc. spectrofluorometer 
system (Birmingham, NJ). The Tb3+ emission fluorescence peak at 543 nm upon 
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tyrosine excitation at 280 nm was quantified as previously described (Wallace et al., 
1982). 
 
5.8 Phosphorylation of calmodulin 
Phosphorylation of CaM was carried out at 37 °C for 30 min in a total volume of 0.1 
ml in a buffer containing 15 mM Hepes-NaOH (pH 7.4), 5 mM MgCl2, 1 mM EGTA, 1 
mM DTT,  1.2  µM  histone,  1.2  µM  CaM  (different  species),  and  0.02  μg  of  recombinant  
c-Src. The reaction was started upon addition of 2 mM ATP and stopped upon addition 
of Laemmli buffer and heating the sample at 100 °C for 5 min. Tyrosine-phosphorylated 
CaM and auto-phosphorylated c-Src were detected by standard Western blot technique 
using the anti-phospho-tyrosine 4G10 antibody. Membrane segments were stripped at 
50 °C for 45 min in a buffer containing 2 % (w/v) SDS, 60 mM Tris-HCl (pH 6.8) and 0.1 
%  (v/v)  β-mercaptoethanol, extensively washed with water, incubated in TBST buffer 
(0.1 % (w/v) Tween-20, 100 mM Tris-HCl (pH 8.8), 500 mM NaCl and 0.25 mM KCl) for 
30 min and reprobed with either anti-Src or anti-CaM antibodies as loading controls. 
Alternatively, when larger amounts of phospho-(Y)-CaM was required to assay its 
action on target proteins, CaM (1 mg) was phosphorylated in a 1 ml reaction mixture 
containing 400 mM NaCl, 50 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 5 mM ATP, 2 mM 
EGTA, 1 mM DTT, 1 mg histone, and 8 µg c-Src at 37 ºC overnight as described (Corti 
et al., 1999). Tyrosine-phosphorylated CaM, free of non-phosphorylated CaM, was 
obtained by affinity-purification using an immobilized anti-phospho-tyrosine antibody as 
previously described (Palomo-Jiménez et al., 1999). 
5.9 Phosphodiesterase assay 
The CaM-dependent cyclic nucleotide PDE1 was assayed as previously described 
(Palomo-Jiménez et al., 1999) at 37 °C for 15 min in 250 l of a medium containing 50 
mM imidazole-HCl (pH 7.5), 10 mM Hepes-NaOH (pH 7.4), 0.2 M NaCl, 0.4 mM -
mercaptoethanol, 5 mM MgCl2, 0.4 mM EGTA, 0.5 mM CaCl2 (0.1 mM free Ca2+), 2.5 
mM  cAMP,   0.01   units   of   cyclic   nucleotide  PDE1,   2   units   of   5’-nucleotidase, and the 
concentrations of the different CaM species indicated in the legend to the figures. One 
unit of cyclic nucleotide PDE1 transforms 1 mol of cAMP to AMP per min at 30 °C and 
pH  7.5.  One  unit  of  5’-nucleotidase releases 1 mol of inorganic phosphate from AMP 
per min at 37 °C and pH 9. The inorganic phosphate released from AMP was 
determined colorimetrically based in a described method (Fiske and Subbarow, 1925). 
5.10 Isothermal titration calorimetry 
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Determination of the kinetics parameters of PDE1 in the absence and presence of 
wild type CaM and CaM(Y99D/Y138D) were done in a VP-ITC instrument (GE-
Healthcare). The reaction cell (1.4619 ml) was filled with degassed protein solutions 
and equilibrated at 37 ºC. Stirring speed was 307 rpm and thermal power was 
registered every 2 seconds with an instrumental reference power of 20 µcal/s. Enzyme 
reaction rates were determined by measuring the change in the instrumental power 
supplied to the sample cell after addition of the substrate (Todd and Gomez, 2001). At 
least three independent measurements were carried out in each experimental 
condition. Serial injections of 4.7 mM cAMP were made every 2 min into the sample 
cell loaded with 0.01-0.04 U of PDE1 in the absence or presence of wild type CaM or 
the Y99D/Y138D mutant (3.8 µM) in the same reaction buffer as described in 5.9. To 
avoid distortions associated with dilution events, the power change associated with 
substrate addition at injection i was averaged over the 30 s immediately before the 
injection i+1. Reaction rates under steady-state conditions were then calculated 
dividing the power change for each injection, (dQ/dt)i, by the cell volume and the 
apparent   reaction   enthalpy   (ΔHapp) using the software provided by the manufacturer 
(Origin ITC 7.0). The complete enthalpy of the reaction was determined in separate 
experiments where 15 µl of 4.7 mM cAMP were injected into the cell filled with a 
solution containing 0.1 units PDE1 and 3.8 M CaM wild type and the hydrolysis was 
monitored until initial baseline was recovered. Integration of the area under the peak 
gave the total heat of hydrolysis that was corrected by the heat of cAMP dilution, 
measured independently by injecting the substrate solution in the sample cell loaded 
with buffer. Very similar values of ΔHapp (-19.9 ± 0.5 kcal/mol) were obtained with 
subsequent injections, indicative of no product inhibition. 
5.11 Nitric oxide synthase assay 
Recombinant eNOS was assayed determining the accumulation of nitrite as by-
product of NO oxidation using a nitrate reductase/colorimetric assay kit (Oxford 
Biomedical Research, UK) exogenously supplemented with 25 µM FAD, 25 µM FMN, 
12 µM tetrahydrobiopterin and the concentrations of the different CaM species 
indicated in the legends to the figures following the recommendation of the supplier. 
One unit of eNOS produces 1 nmol/min of NO from arginine at 37 ºC and pH 7.4. 
5.12 Determination of free Ca2+ concentrations 
The concentrations of free Ca2+ in the PDE1 and eNOS assay systems were 
determined using established algorithms of the Maxchelator program. This program is 
freely available at http://maxchelator.stamford.edu. 
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5.13 Cell culture 
Human epidermoid carcinoma A431 cells, human cervix adenocarcinoma HeLa 
cells, human lung carcinoma A549 cells, human breast adenocarcinoma SK-BR-3 cells 
and mouse EGFR-T17 fibroblasts, a stably transfected cell line overexpressing the 
human EGFR, were grown in DMEM supplemented with 10 % (v/v) fetal bovine serum, 
2 mM L-glutamine  and  40  μg/ml  gentamicin   in  a  humidified  atmosphere  of   5 % (v/v) 
CO2 in air at 37°C. In case of activation of the EGFR or c-Src kinases the cells were 
maintained overnight or four hours in a fetal bovine serum-free medium before 
performing the experiments. DT40wt/EGFR cells clone G5, a chicken pre-B lymphoma 
cell line stably transfected with the human EGFR; and the ET1–55/EGFR clone H8, a  
conditional CaM-KO cell line stably transfected with the human EGFR, where the 
expression of recombinant rat CaM is negatively controlled by a tetracycline response 
element (Tet-Off system) (Panina et al., 2012), were grown in RPMI supplemented with 
1 % (v/v) chicken serum, 10 % (v/v) fetal bovine serum, 2 mM L-glutamine and 40 
μg/ml  gentamicin. When CaM down-regulation was performed, the ET1-55/EGFR clone 
H8 and DT40wt EGFR clone G5 cells (negative control) were treated with 1 μg/ml 
tetracycline for the times indicated in the figure legends. 
5.14 Preparation of cell membrane fraction 
A431 cells were washed with PBS (137 mM NaCl, 2.7 mM KCl, 12 mM Na/K-
phosphate, pH 7.4), gently scraped from the plates, harvested by centrifugation, and 
lysed in 3 ml of an ice-cold hypotonic buffer containing 15 mM Hepes-Na (pH 7.4), 1 
mM EGTA, and a cocktail of protease inhibitors (0.5 mM AEBSF, 0.4 µM aprotinin, 25 
µM bestatin, 7.5 µM E-64, 10 µM leupeptin, 5 µM pepstatin A, and freshly prepared 0.6 
mM PMSF). The lysate was incubated 10 min on ice and centrifuged at 130,000 g for 
30 min at 4 °C. The supernatant was discarded, and the pellet resuspended in the 
same buffer and centrifuged as above. This pellet corresponding to the membrane 
fraction was washed with the same buffer but without EGTA, centrifuged again, and 
resuspended in 3 ml of 25 mM Hepes-Na (pH 7.4) containing the protease inhibitors. 
5.15 Electrophoresis and Western blots 
Proteins were separated by slab SDS-PAGE in 5-20 % (w/v) linear gradient of 
polyacrylamide and 0.1 % (w/v) SDS at pH 8.3 according to a described method 
(Laemmli, 1970) at 6 mA during 16-17 h. After processing by SDS-PAGE, proteins 
were electro-transferred from the gel to a PVDF membrane or nitrocellulose in case we 
were testing for CaM for 2 h at 300 mA in a buffer containing 48 mM Tris-base, 36.6 
mM L-glycine, 0.04 % (w/v) SDS and 20 % (v/v) methanol (TGSM buffer); fixed with 0.8 
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% (v/v) glutaraldehyde in T-TBS buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 0.1 % 
(v/v) Tween-20 for 10 minutes and transiently stained with 0.1 %  Fast Green FCF 
(w/v) FCF, 50 % (v/v) methanol, 10 % (v/v) acetic acid to ascertain the regularity of the 
transfer procedure. The membranes were blocked with 5 % (w/v) bovine serum 
albumin, 3 or 5 % (w/v) fat-free powdered milk, as recommended by the antibodies 
supplier, in T-TBS or T-PBS buffer. This was followed by probing over-night at 4 ºC 
using a 1/2000 dilution of the corresponding primary antibody, and thereafter for 1 h at 
room temperature using a 1/5000 dilution of the appropriate secondary anti-IgG or anti-
IgM antibodies coupled to horseradish peroxidase. The bands were visualized upon 
development with the ECL reagents. The intensity of the bands was quantified with a 
computer-assisted scanning densitometry using the ImageJ (1.47v) program. 
5.16 In vitro EGFR phosphorylation assays 
EGFR was assayed in a reaction mixture containing the detergent-solubilized 
receptor from a membrane fraction of A431 cells, 15 mM Hepes-NaO (pH 7.4), 2 mM 
MgCl2, and 2  mM   EGTA   or   100   μM  CaCl2 were added depending on the condition 
tested,  and  1  μg  of  each  CaM  species.  The  reaction  mixture  was  then  incubated  on  ice  
for 30 min in   the   absence   or   presence   of   1   μM   EGF.   Thereafter,   the   reaction   was  
started upon addition of 2 mM ATP at 37 °C for 5 min and stopped with the addition of 
loading  buffer  in  a  final  volume  of  50  or  100  μl.  The  samples  were  boiled at 100 °C for 
5 min. centrifuged and analyze by SDS-PAGE and Western blot as detailed above. In 
case of using recombinant EGFRcyt for the in vitro phosphorylation of OGT, the reaction 
took place as follows: 250 ng of the recombinant EGFRcyt were assay in a buffer 
containing 15 mM Hepes-NaOH (pH 7.4), 5 mM MgCl2, in the absence or presence of 
500 ng ncOGT and in the absence or presence of 5 mM ATP. The reaction mixture 
was then incubated for 2 hours at 37 °C. The reaction was stopped by the addition of 
loading buffer, boiled for 5 min and processes by SDS-PAGE and Western blot as 
described above. 
5.17 Activation of EGFR in living cells  
Cells were grown to confluence in 6-well culture dishes containing 2 ml of DMEM 
supplemented with 10 % (v/v) FBS overnight, and deprived of FBS for 4 hours as 
mention above. In order to study the phosphorylation of EGFR induced by the EGF the 
following was done: 10 nM EGF was added to cells in 2 ml of serum-free culture 
medium and the incubation was continued for different periods of time (0, 2, 5, 10, 15 
and 30 min). The reaction was arrested upon addition of ice-cold 10 % (w/v) 
trichloroacetic acid (TCA). The cells were scraped from the culture dish and centrifuged 
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at 16,060 g for 10 min. The supernatant was discarded and the proteins were 
resuspended in Laemmli buffer, boiled at 100°C for 10 min and centrifuged again for 1 
min. The tyrosine phosphorylation level of EGFR and proper loading controls were 
determined by SDS-PAGE and Western blot analysis using an anti-phosphotyrosine 
and anti-GAPDH or anti-tubulin-α antibodies, respectively. 
5.18 CaM-affinity chromatography and immobilized-CaM pull-down of Src  
Cell membrane-anchored Src from A431 cells was detached from the membrane 
fraction upon incubation with 1 % (w/v) Triton X-100 and 5 % (w/v) glycerol at 0 °C for 
10 min. The sample was centrifuged at 130,000 g for 30 min and the supernatant was 
used to isolate Src by CaM-affinity chromatography or pull-down using immobilized 
CaM. The isolation of Src by Ca2+-dependent CaM-affinity chromatography was carried 
out loading the solubilized membrane fraction in a small column (1-2 ml bed volume) of 
CaM-Sepharose 4B equilibrated with a buffer containing 25 mM Hepes-NaOH (pH 7.4), 
1 % (w/v) Triton X-100, 5 % (w/v) glycerol, 0.1 mM CaCl2, and the protease inhibitors 
cocktail described above (Ca2+-buffer). The column was washed with 25 volumes of the 
Ca2+-buffer, and Src was eluted using the same buffer but containing 1 mM EGTA 
instead of CaCl2 (EGTA-buffer). Proteins in the eluted fractions (0.6 ml) were 
precipitated with 10 % (w/v) TCA and processed by SDS-PAGE and Western blot for 
Src identification. The pull-down of Src was done using a slurry of CaM-Sepharose 4B 
beads (200 µl) in a buffer containing 25 mM Na-Hepes (pH 7.4), 1 % (w/v) Triton X-100 
and 5 % (w/v) glycerol supplemented either with 0.1 mM CaCl2 or 1 mM EGTA. We 
used naked Sepharose 4B beads as negative binding control. The beads were washed 
10 times with the corresponding Ca2+ or EGTA buffers before processing the samples 
by SDS-PAGE and Western blot for Src identification as described above. 
5.19 Co-immunoprecipitation assays 
Immunoprecipitation of Src, EGFR and OGT from A431 cells (2 mg protein) was 
performed using the PierceTM Classic Magnetic IP/Co-IP kit, and anti-Src, anti-EGFR or 
anti-OGT antibodies and protein-A/G following the manufacture instructions. The 
samples were processed for SDS-PAGE and Western blot using the appropriate 
antibodies as described above. 
5.20 Src phosphorylation assays 
The auto-phosphorylation of recombinant c-Src (0.1 µg) was assayed at 37 ºC in a 
medium containing 15 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM DTT, 1 mM EGTA, 
1.2 mM CaCl2 (when added), and 2.3 µM CaM wild type, or the phospho-mimetic 
CaM(Y99D/Y138D) and CaM(Y99E/Y138E) mutants, when added. The reaction was 
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started upon addition of 2 mM ATP and stopped by the addition of Laemmli buffer and 
boiled for 5 min. The samples were subjected to Western blot and probed with an anti-
phospho-tyrosine antibody (4G10) or an anti-phospho-Y416-Src specific antibody to 
detect active phosphorylated Src, and an anti-Src (total) antibody and/or GAPDH 
antibody as loading controls.  
5.21 Src activation assays in living cells 
In the case of A431 cells, Src was activated either upon ligand-dependent 
activation of the EGFR, as an upstream signaling component of c-Src (Sato et al., 
2001), adding 10 nM EGF during 2 min; and in the case of both A431 and SK-BR-3 
cells, upon induction of oxidative stress by adding 1 mM H2O2 for 15 min, as described 
(Basuroy et al., 2010). The reaction was arrested upon addition of ice-cold 1 % (v/v) 
TCA, and the samples were processed by SDS-PAGE and Western blot. The PVDF 
membranes were probed with anti-phospho-tyrosine (4G10) or anti-phospho-Y416-Src 
specific antibodies to detect active phosphorylated Src, anti-phospho-tyrosine antibody 
to detect activated EGFR, and anti-Src (total), anti-EGFR (total) and/or anti-GAPDH 
antibodies as loading controls. 
5.22 O-GlcNAc detection in EGFR 
EGFR was immunoprecipitated from A431 cells using the Pierce Classic Magnetic 
IP/Co-IP kit following the manufacturer instructions. Briefly, a lysate of A431 cells (1-2 
mg proteins) were incubated with anti-EGFR antibody (1:500 dilution) overnight at 4 ºC. 
The lysate containing the antigen-antibody complex was mixed with the magnetic 
beads and incubated for 1 hour at room temperature. The beads were extensively 
washed and the EGFR was released with the low pH (pH 2) elution buffer, resolved in 
SDS-PAGE and subjected to Western blot using appropriate anti-O-GlcNAc antibodies 
(RL2 or CTD110.6). Conversely, a lysate of A431 cells (1-2 mg proteins) were 
incubated as above with an anti-O-GlcNAc antibody (RL2) and the immunoprecipitated 
O-GlcNAcylated proteins were resolved in SDS-PAGE and subjected to Western blot 
using and anti-EGFR antibody. 
5.23 In vitro EGFR O-GlcNAcylation 
Immunoprecipitated EGFR was used for in vitro O-GlcNAcylation assay using 
immunoprecipitated OGT, both immunoprecipitated from A431 cells. The O-
GlcNAcylation reaction took place in a buffer containing 50 mM Tris-HCl (pH 7.5), 1 
mM DTT, 12.5 mM MgCl2 and 1 mM UDP-GlcNAc, and incubated for 2.5 h at 30 ºC. 
The reaction was stopped by adding Laemmli buffer and boiled for 10 min at 100 ºC, 
Materials&Methods  
 
61 | P a g e  
 
resolved in SDS-PAGE, transferred to a PVDF membrane, and probed with an anti-O-
GlcNAc antibody (RL2). 
 
 
5.24 Metabolic protein labeling with azido-GlcNAc 
A431 cells were seeded in 150 cm2 petri dishes and when ~ 70 % confluence was 
obtained  40  µM  GlcNAz  was  added  and  incubated  for  72  h.  The  cells  were  lysed  in  а  
buffer containing 25 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 % (v/v) NP-
40, 5 % (v/v) glycerol supplemented with 20 µM PUGNAc to prevent deglycosylation 
and a cocktail of protease inhibitors (0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride, 
0.4 µM aprotinin, 25 µM bestatin, 7.5 µM [1-[N-[(L-3-trans-carboxyoxirane-2-carbonyl)-
L-leucyl]amino]-4-guanidinobutane], 10 µM leupeptin, 5 µM pepstatin A, and freshly 
prepared 0.6 mM PMSF). The lysate was centrifuged at 16,000 g for 10 min and the 
supernatant used for EGFR immunoprecipitation. Biotinylation of the GlcNAz-labeled 
proteins was performed using Click-iT®-Protein Reaction Buffer kit following the 
manufacturer’s   instructions,   the   samples  were   subjected   to  SDS-PAGE, the proteins 
transferred to PVDF and overlaid with streptavidin-HRP (1:10,000 dilution). 
5.25 N-deglycosylation of the EGFR 
The immunoprecipitated EGFR was first denatured in a buffer containing 0.5 % 
(w/v) SDS and 40 mM DTT and boiled for 10 min at 100 °C. Thereafter, 10 % (v/v) NP-
40, 50 mM sodium phosphate (pH 7.5) and 1,000 units of PNGase F were added, and 
the mixture was incubated for 2 h at 37 ºC. One unit of PNGase F is defined as the 
amount of enzyme required to remove > 95 % of the carbohydrates from 10 µg of 
denatured RNase B in 1 hour at 37 °C. The reaction was stopped by the addition of 
Laemmli buffer and boiled for 10 min at 100 ºC, resolved in SDS-PAGE, transferred to 
a PVDF membrane and probed with anti-O-GlcNAc antibodies (RL2 or CTD110.6). 
When tunicamycin was used as a deglycosylation agent A431 cells were cultured in 
complete  DMEM  supplemented  with  1  μg/ml   tunicamycin  overnight  where only newly 
synthetized EGFR molecules are expected to be fully N-deglycosylated. Higher 
concentrations of tunicamycin to attain more N-deglycosylated EGFR molecules was 
not possible as more drastic treatments result in extensive cell death. 
5.26 O-deglycosylation of the EGFR 
The immunoprecipitated EGFR was first denatured in a buffer containing 0.5 % 
(w/v) SDS and 40 mM DTT and boiled for 10 min at 100 °C. Thereafter, 10 % (v/v) NP-
40, 50 mM sodium phosphate (pH 7.5) and 200,000 units of O-glycosidase and 100 
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units of neuraminidase were added, and the mixture was incubated for 2 h at 37 ºC. 
One unit of O-glycosidase is defined as the amount of enzyme required to remove 0.68 
nmol of O-linked disaccharide from 5 mg of neuraminidase digested, non-denatured 
fetuin in 1 hour at 37°C in a total reaction volume of 100 µl. The reaction was stopped 
by the addition of Laemmli buffer and boiled for 10 min at 100 ºC, resolved in SDS-
PAGE, transferred to a nitrocellulose membrane and overlaid with the lectins WGA and 
PNA.  
5.27 Effect of OGT and OGA inhibitors on EGFR O-GlcNAcylation  
A431 cells were grown to confluence in 6-well culture dishes containing 2 ml of 
DMEM supplemented with 10 % (v/v) FBS overnight in the absence and presence of 
the OGT inhibitor BADGP (2 mM), or the OGA inhibitor Thiamet G (20 µM). Thereafter, 
the EGFR was immunoprecipitated from a cell lysate using an anti-EGFR antibody and 
the immunocomplex was processed by SDS-PAGE and Western blot using an anti-O-
GlcNAc antibody (RL2). The effect of 2 mM BADGP and increasing concentrations 
(0.5-20 µM) of Thiamet G was also tested on total proteins O-GlcNAcylation level from 
an A431 cell lysate as positive control. 
5.28 Expression and purification of recombinant ncOGT 
His-tagged full-length human OGT (ncOGT) recombinant protein was expressed 
and purified as previously described (Gross et al., 2005). Briefly, the plasmid containing 
the sequence encoding the ncOGT was expressed in E. coli BL21(DE3)pLysS cells. 
Single colonies grown in solid medium in the presence of 100 g/ml kanamycin were 
collected and seeded in 5 ml of Luria´s broth containing the same concentration of 
kanamycin. Larger cultures (500 ml) were seeded with the pre-culture and grown in the 
same conditions until they reached an OD600 nm = 1-1.2. The expression of the 
recombinant protein was induced with 0.1-0.2 mM IPTG overnight at 16 ºC. The 
purification of the His-tagged ncOGT was performed using the BugBuster® Ni-NTA 
His•Bind®  Purification  kit according to the manufacturer instructions. 
5.29 Lectin overlay 
The lectin overlay was performed according to the manufacturer protocol with 
small modifications. Briefly, the detergent-solubilized EGFR was immunoprecipitated 
from A431 cells and treated with PNGase F, O-glycosidase, and Neuraminidase 
separated in 5-20 % polyacrylamide gradient gel and transferred to nitrocellulose 
membranes as described above. The membranes were then washed in PBS (pH 7.5) 
and blocked for two minutes with PBS (pH 7.5) with 0.25 % (v/v) Tween-20 and rinsed 
with PBS (pH 7.5),  0.05 % (v/v) Tween-20, twice. Afterwards the membranes were 
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overlaid with 1 µg/ml biotin-labeled WGA or PNA for two hours at 20 °C in a buffer 
containing PBS (pH 7.5), 0.1 % (v/v) Tween-20, 1 mM CaCl2, 1 mM MnCl2 and 1 mM 
MgCl2. Then the membranes were extensively washed with PBS (pH 7.5) 0.1 % (v/v) 
Tween-20 and incubated with streptavidin-HRP (1:10000) for 45 min in PBS (pH 7.5) 
0.1 % (v/v) Tween-20, extensively washed with PBS with 0.05 % (v/v) Tween-20 and 
revealed with ECL. 
5.30 Artificial wound-healing assays 
Artificial wounds were done with a plastic pipette scratching a monolayer of 
confluent A431. The wounded monolayers were washed twice with fresh media to 
remove non-­‐adherent cells before photographs were taken every hour for 72 hours 
using a Cell Observer system equipped with Zeiss Axiovert 200M Multi-stage 
Automated microscope with a 4x objective to follow the repopulation of the wounds. 
The cells were incubated in DMEM containing 1 % (v/v) FBS, in the absence or the 
presence of 10 nM EGF, 100  μM Thiamet G or 1 mM BADGP. 
 
5.31 Ca2+-dependent CaM-affinity chromatography of OGT 
The isolation of recombinant ncOGT by Ca2+-dependent CaM-affinity 
chromatography was carried out loading the purified recombinant ncOGT in a small 
column (1-2 ml bed volume) of CaM-Sepharose 4B equilibrated with a buffer containing 
25 mM Hepes-NaOH (pH 7.4), 1 % (w/v) Triton X-100, 5 % (w/v) glycerol, 0.1 mM 
CaCl2, and the protease inhibitors cocktail described above (Ca2+-buffer). The column 
was washed with 20 volumes of the Ca2+-buffer, and ncOGT was eluted using the 
same buffer but containing 1 mM EGTA instead of CaCl2 (EGTA-buffer). Proteins in the 
eluted fractions were precipitated with 10 % (w/v) TCA and processed by SDS-PAGE 
and Western blot for OGT identification using an anti-OGT antibody. 
5.32 Statistical analysis 
The  paired  Student’s   t   and   the   two-way ANOVA tests were performed using the 
Microsoft Excel (Microsoft Co., Redmon, WA) and GraphPad Prism (GraphPad 
Software Inc., La Jolla, CA) software programs. Data were expressed as the mean ± 
SEM or SD/range and  differences  were  considered  significant  at  p  ≤  0.05  as  indicated  
in the legends to the figures. 
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As CaM can be phosphorylated (Benaim and Villalobo, 2002), and in order to 
better understand its physiological functions in systems relevant for tumor cell biology, 
we decided to study the functionality of phospho-(Y)-CaM using a set of recombinant 
phospho-(Y)-mimetic CaM mutants by substituting either one or the two tyrosine 
residues to aspartic acid (Asp, D) or glutamic acid (Glu, E). Then we characterized their 
physicochemical properties and tested in vitro their action on the activity of several 
CaM-dependent  enzymes:   the  3’,5’-cyclic nucleotide PDE1 (EC 3.1.4.17), eNOS (EC 
1.14.13.39), c-Src (EC 2.7.10.2) and EGFR (EC 2.7.10.1). 
6.1. Expression and purification of the phospho-(Y)-mimetic CaM mutants 
In order to confirm if the generated mutants preserve the general structural and 
functional properties of wild type CaM and modulate CaM-dependent systems such as 
PDE1, eNOS, EGFR, and c-Src we performed an extensive physicochemical 
characterization of the generated CaM mutant species. The first step was to transform 
E. coli BL21(DE3)pLysS with the vectors containing the sequence of the whole panel of 
mutants: CaM(Y99D), CaM(Y138D), CaM(Y99D/Y138D), CaM(Y99E), CaM(Y138E) 
and CaM(Y99E/Y138E) and purify significant amount of each species. The expression 
of wild type and the different CaM mutants in E.coli BL21(DE3)pLysS was very efficient 
and their purification yielded an average ± SEM (n = 12) 13 ± 2 mg CaM per 500 ml of 
bacterial culture. Figure 8A shows an example of the expression of the mutants 
CaM(Y99E), CaM(Y138E), CaM(Y99E)/Y138E, CaM(Y99D), CaM(Y138D), and 
CaM(Y99D/Y138D) induced by IPTG addition, and the material obtained in the 
supernatant after heating the extracted proteins at 95 ºC for 5 min. It can be seen that 
CaM is the majoritarian heat-resistant protein. After Ca2+-dependent phenyl-Sepharose 
chromatography all purified CaM species were homogeneous in SDS-PAGE (Figure 
8B). The CaM variants presented a single band (~ 18 kDa) when electrophoretically 
separated in the presence of EGTA (absence of Ca2+). In the presence of Ca2+, 
however, wild type CaM and both CaM(Y99D) and CaM(Y99E) mutants presented the 
typical Ca2+-induced electrophoretic mobility shift (Burgess et al., 1980), yielding a 
major band at ~ 15 kDa and a minor one with lower mobility. The electrophoretic 
mobility shift was less apparent in the single mutants CaM(Y138D) and CaM(Y138E), 
and in the double mutants CaM(Y99D/Y138D) and CaM(Y99E/Y138E) (Figure 8B). 
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Figure 8: Expression and purification of the different CaM species. (A) The figure shows 
the pattern of proteins of the bacterial cell extract (CE) and the corresponding heated 
supernatant (HS)  of CaM Y/E mutant species (left panel) and CaM Y/D mutant species (right 
panel) in the absence and presence of 0.5 mM IPTG for 4 h as described in Materials and 
Methods. (B) The different recombinant CaM species (~ 1-2 µg) purified as described in 
Materials and Methods were separated by SDS-PAGE in the presence of 5 mM EGTA or 1 mM 
CaCl2 to observe the Ca2+-induced mobility shift. 
6.1.1 UV absorption spectra of the phospho-(Y)-mimetic CaM mutants 
Since CaM has no tryptophan (W, Trp) to contribute to the UV-spectrum of the 
protein in the range of 280 nm, the tyrosine (Y, Tyr) absorption peak at 276 nm is very 
well defined, thus allowing us to detect the changes taking place in that region due to 
the subsequent removal of one or two Tyr residues. The UV absorption spectra (240-
340 nm) of wild type CaM and the whole panel of Y/D and Y/E mutants are shown in 
Figure 9. As expected wild type CaM showed the characteristic absorption peaks at 
252, 258, 265, 269 and 276 nm (Wolff et al., 1977), and the latest one due to the 
presence of tyrosine residues. As expected, the single Y/D and Y/E CaM mutants 
presented a significant reduction of the 276 nm peak, while this peak totally 
disappeared in the double mutants CaM(Y99D/Y138D) and CaM(Y99E/Y138E). The 
Y99D and Y99E substitutions presented a slightly higher decrease in the 270-285 nm 
region of the absorption spectrum than identical substitutions at Y138, pointing out a 
higher contribution of Y99 to the spectrum of wild type CaM. Moreover, no significant 
spectral differences between the respective Y/D and Y/E CaM mutants were found. 
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Figure 9: Absorption spectra of the different CaM species. The plots show UV-light 
absorption spectra of recombinant wild type (wt) and the indicated Y/D (A) and Y/E (B) CaM 
mutants (2 mg/ml) purified as described in Materials and Methods and dialyzed against 20 mM 
Tris-HCl (pH 7.5). 
6.1.2 Circular dichroism studies of the phospho-(Y)-mimetic CaM mutants 
Circular dichroism (CD) is a very powerful tool to study conformational features of 
proteins in solution (Kelly et al., 2005). In the absence of Ca2+, the far-UV (200-260 nm) 
CD spectra of wild type and the full set of CaM mutants showed the characteristic 
negative maxima at 208 and 222 nm (Figure 10), typical of proteins with a high 
percentage of -helical content. Ca2+ binding induces further deepening of the spectra 
due to an increase in the amount of α-helical structure (Martin & Bayley, 1986). 
However, the ratio of molar ellipticity at 208 and 222 nm, a sensitive indicator of 
possible alterations in interactions between neighboring helices (Sun et al., 2001, 
Fasman, 1996), was slightly higher for the mutants (Table 3), pointing to subtle 
differences in helix packing compared to wild type CaM. For all the samples, there was 
a significant, mutant-specific, deepening of the far-UV signals in the presence of Ca2+ 
that may reflect a differential increase in -helical content and/or reorientation of 
existing -helices (Wang et al., 2011, Protasevich et al., 1997). Also, both 
CaM(Y99D/Y138D) and CaM(Y99E/Y138E) mutants presented a slight blue-shift of the 
208 nm minimum in the absence of Ca2+ as compared to wild type CaM (Figure 10).  
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Figure 10: Ca2+-induced changes in the Far-UV CD spectra of the different CaM species. 
Far-UV CD spectra of wild  type  (wt)  and  the  Y/D  and  Y/E  CaM  mutants  (12  μM)  were  recorded  
at 20 ºC in 20 mM Tris-HCl (pH 7.5), 0.1 M KCl, containing 1 mM EGTA (black lines) or 1 mM 
CaCl2 (red lines).  
As shown in Figure 11A, the ellipticity at 222 nm increased in the presence of Ca2+ 
22 ± 3 % for wild type CaM, while for the Y138D and Y138E mutants the increase was 
of 32-35 %, and for the Y99D, Y99E, and double Y/E mutants it reached values of 50 
% and above, the only exception being the CaM(Y99D/Y138D) mutant where no 
significant change was observed. Interestingly, the magnitude of the increase in 
ellipticity  at  222  nm  is  directly  correlated  to  the  value  of  the  Θ208/Θ222 ratio. On the other 
hand, percentage of Ca2+-induced increases in ellipticity at 208 nm and variations 
among CaM species were noticeably smaller, going from 14 % to 29 % (Figure 11B). 
As  a   result,   no   significant   differences   in   the  Θ208/Θ222 ratio were observed in the 
presence of Ca2+, again with the only exception of the CaM(Y99D/Y138D) mutant 
(Table 1) revealing a similar overall structure of the holo forms. Above all, far-UV data 
clearly show that all the single and double Y/D and Y/E CaM mutants bind Ca2+.  
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Sample                    Θ208/Θ222 Θ208 Ca2+/  Θ208 EGTA  Θ222 Ca2+/  Θ222 EGTA 
 
  EGTA Ca2+   
CaM wt 1.09 ± 0.01 1.01 ± 0.01 1.14 ± 0.05 1.22 ± 0.03 
CaM(Y99D) 1.20 ± 0.01 1.01 ± 0.01 1.29 ± 0.01 1.52 ± 0.03 
CaM(Y99E) 1.17 ± 0.01 1.00 ± 0.01 1.26 ± 0.01 1.48 ± 0.02 
CaM(Y138D) 1.12 ± 0.01 1.01 ± 0.01 1.22 ± 0.02 1.35 ± 0.02 
CaM(Y138E) 1.14 ± 0.02 1.02 ± 0.01 1.19 ± 0.06 1.32 ± 0.05 
CaM(Y99D/Y138D) 1.23 ± 0.03 1.10 ± 0.01 1.15 ± 0.09 1.21 ± 0.05 
CaM(Y99E/Y138E) 1.19 ± 0.02 1.03 ± 0.01 1.26 ± 0.03 1.55 ± 0.08 
  
Table 3:  Θ208/Θ222 ellipticity ratio in the absence and presence of Ca2+ of the different 
CaM species.  
Ca2+-binding also induces noticeable changes in the near-UV circular dichroism 
spectrum of wild type CaM (Sun et al., 2001, Wolff et al., 1977, Martin and Bayley, 
1986), which is sensitive to the environment of the six phenylalanines and the two 
tyrosine residues in the molecule. As shown in Figure 12, in the presence of EGTA the 
spectrum is characterized by two well-defined negative bands at 262 and 269 nm, due 
to the phenylalanine residues, and a broad negative region centered at 280 nm due to 
the tyrosine residues. 
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Figure 11: Percentage increase of 
ellipticity of the different CaM mutants in 
the presence of Ca2+ detected by CD at 
222 and 208 nm. The mean ± SEM (n = 3) 
increase in ellipticity in the far-UV circular 
dichroism signals at 222 nm (A) and 208 nm 
(B) of the different CaM species 1, CaM wild 
type; 2, CaM(Y99D); 3, CaM(Y99E); 4, 
CaM(Y138D); 5, CaM(Y138E); 6, 
CaM(Y99D)/Y138D; and 7, 
CaM(Y99E)/Y138E) is represented as 
percentage taking as 100 % the ellipticity of 
each CaM species in the presence of EGTA. 
Measurements were carried out at 20 ºC in 
20 mM Tris-HCl (pH 7.5), 0.1 M KCl, 
containing 1 mM EGTA or 1 mM CaCl2. The 
concentration  of  CaM  was  12  μM. 
Addition of Ca2+ results in an increase of these ellipticity signals, what has been 
interpreted as a change in the environment of both phenylalanine and tyrosine 
residues. Having confirmed by far-UV CD experiment that all single and double Y/D 
and Y/E mutants bind Ca2+, we also examined the near-UV CD spectra of their apo and 
holo forms. In the absence of Ca2+, the ellipticity around 280 nm of the mutants 
diminished noticeably or even became positive (Figure 12), confirming a predominant 
contribution of the two tyrosine residues to this region. In addition, there was a 
significant decrease in the intensity of the bands at 262 and 269 nm compared to wild 
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type CaM, pointing to a partial contribution of both tyrosine residues to these signals. 
However, addition of Ca2+ induced different changes in the spectra depending on the 
mutant. While the Y99D/E mutants showed a small decrease in positive ellipticity at 
280 nm, for the respective Y138 mutants the ellipticity change becames almost zero 
(Figure 12). Differences related to the 262/269 nm bands were even more apparent.  
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Figure 12: Ca2+-induced changes in the near-UV circular dichroism spectra of the 
different CaM species. Near-UV CD spectra for wild type (wt) and the single and double Y/D 
and  Y/E  CaM  mutants  (118  μM)  were  recorded  at  20  ºC  in  20  mM  Tris-HCl (pH 7.5), 0.1 M KCl, 
containing 1 mM EGTA (black lines) or 1 mM CaCl2 (red lines). Ellipticity values were 
normalized per mole of residue. 
  
There was a clear increase in ellipticity for the Y99D/E mutants upon Ca2+ binding, 
while little or no change was observed for the Y138D/E and double mutants (Figure 
12), clearly revealing that the Ca2+-induced alterations observed for wild type CaM in 
this region are mostly due to changes in the environment of Y138. This conclusion fully 
explains the small effect of Ca2+ on the near-UV CD spectrum of the separate CaM N-
terminal half (residues 1-77) previously reported (Martin and Bayley, 1986), a result 
considered surprising by the authors in view of the similar distribution of phenylalanine 
residues in the N- and C-terminal halves of the protein. Indeed, the spectra with/without 
Ca2+ of the Y138D/E and double CaM mutants (Figure 12) are very similar to those 
published for the N-terminal half of CaM (Martin and Bayley, 1986). 
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It is known that Ca2+ binding induces a remarkable increase in the thermal stability 
of wild type CaM (Wang et al., 2011, Brzeska et al., 1983). In order to test whether the 
same was true for the single and double Y/D and Y/E mutants, we carried out thermal 
denaturation experiments by measuring changes in ellipticity at 222 nm 
(Supplementary Figure 1S) at increasing temperature. Figure 13 shows a quasi-
sigmoidal decrease in ellipticity of wild type and all CaM mutants in the absence of 
Ca2+, indicating the occurrence of at least one intermediate state, as previously 
described for wild type CaM (Sun et al., 2001, Wang et al., 2011). In the case of the 
CaM Y138D/E mutants, the temperature-dependent unfolding was clearly biphasic, 
showing a notable deviation of sigmoidicity at temperatures below 50 ºC.  
Although fitting the data to a two- or three-state model did not yield acceptable 
clear-cut information, it is evident from the denaturation profiles that a major thermal 
unfolding for the different CaM species occurred at ~ 55 ºC, all of them being 
completely unfolded above 70 ºC. In addition, lower temperature transitions and/or 
discontinuities, also reported for wild type CaM (Brzeska et al., 1983, Martin and 
Bayley, 1986, Kilhoffer et al., 1981, Gangola and Pant, 1983) were observed in the ~ 
20-40 ºC region, both in the absence and presence of Ca2+. The binding of Ca2+ had a 
profound impact on the stability of wild type CaM and the mutants above 40 ºC. 
Therefore, the major unfolding transition occurring at ~ 55 ºC in the presence of EGTA 
was not observed when Ca2+ is present, and more than 54 % of the initial ellipticity 
signal was still preserved at 90 ºC (Figure 13), confirming that Ca2+ binding to the single 
and double Y/D and Y/E CaM mutants also causes remarkable thermal stabilization. 
 
 
Figure 13: Thermal 
stability of the different 
CaM mutants in the 
absence and presence of 
Ca2+. The plots present the 
decrease in the CD signal at 
222 nm, expressed as 
percentage of the ellipticity 
at 20 ºC, for wild type (wt) 
and the single and double 
Y/D and Y/E CaM mutants 
(12   μM)   in   20   mM Tris-HCl 
(pH 7.5), 0.1 M KCl, in the 
presence of 1 mM EGTA 
(solid lines) and 1 mM CaCl2 
(dashed lines) as described 
in Materials and Methods. 20 30 40 50 60 70 80 90
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6.1.3 Fluorescence studies of the phospho-(Y)-mimetic CaM mutants 
We also studied the fluorescence energy transfer from excited tyrosine residues to 
Tb3+, a surrogate ion that binds CaM at the Ca2+-binding sites, in wild type CaM and the 
different CaM mutant species by measuring the fluorescence emitted by Tb3+ in the 
535-550 nm region upon exciting at 280 nm the tyrosine residues (when present) 
located at Ca2+-binding sites III and IV of CaM. The spectrum obtained for wild type 
CaM presented a distinctive emission peak at 543 nm upon addition of increasing 
concentrations of Tb3+ to the medium (Figure 14A). Interestingly, the absence of Y99 
induced an almost complete loss of the Tb3+ emission peak at 543 nm, whereas the 
absence of Y138 did not (Figure 14A). A similar behavior was observed for the Y/D and 
Y/E mutants. The Tb3+ titration curves shown in Figures 15B and 15C demonstrated 
that the apparent binding affinity of the Tb3+ ion to wild type CaM was slightly higher 
(K’d ~ 20 M)  than  for  the  CaM(Y138D)  or  CaM(Y138E)  mutants  (K’d ~ 50 and75 M, 
respectively). Only trace fluorescence emission of Tb3+ was detected in the CaM 
Y99D/E mutants, and no significant fluorescence was detected in the double Y/D or 
Y/E mutants. 
Figure 14: Tb3+-induced fluorescence emission spectra of the different CaM species. (A) 
The fluorescence emission spectra (520-580 nm) of wild type (wt) CaM and the indicated CaM 
mutants  (10  μM)  was  recorded   in  a  buffer containing 10 mM Pipes-HCl (pH 6.5) and 100 mM 
KCl in the absence and presence of increasing concentrations of TbCl3 (10-200   μM)   as  
described in Materials an Methods. (B, C) The plots present the emission fluorescence at 543 
nm of wild type (wt)  CaM  and  the  indicated  CaM  mutants  (10  μM)  at  increasing  concentrations 
of TbCl3 in the conditions described in Materials and Methods. 
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6.2 Biological activity of the phospho-(Y)-mimetic CaM mutants 
We first tested the capacity of c-Src to phosphorylate the different CaM species. 
Figure 15 shows that both CaM(Y99D) and CaM(Y99E) were phosphorylated in vitro by 
recombinant c-Src with similar efficiency than wild type CaM. However, the CaM 
Y138D/E mutants were phosphorylated with far lower efficiency than wild type CaM, 
suggesting that Y138 is preferrebly phosphorylated by the kinase. As expected, no 
phosphorylation of the double mutants was detected. 
 
 
Figure 15: Phosphorylation of different CaM 
species by recombinant c-Src. The different 
CaM   species   (2   μg)   were   assayed   for  
phosphorylation by recombinant c-Src as 
described in Materials and Methods. The samples 
were probed with an anti-phospho-tyrosine 
antibody to detect the tyrosine-phosphorylated 
CaM species (P-(Y)-CaM) and auto-
phosphorylated c-Src (p-Src). The membranes 
were striped and reprobed with anti-CaM and anti-
Src antibodies as loading controls. 
 
6.2.1 Effect of the phospho-(Y)-mimetic CaM mutants on PDE1 activity 
We next tested the effect of purified phospho-(Y)-CaM free of non-phosphorylated 
CaM on the CaM-dependent enzyme cyclic nucleotide PDE1. Figure 16A shows the 
slightly lower activatory effect of phospho-(Y)-CaM compared to non-phosphorylated 
CaM.  
 
Figure 16: Effect of phospho-(Y)-CaM and non-phosphorylated CaM on the PDE1 activity. 
(A) The plot presents the average ± SEM PDE1 activity in the presence non-phosphorylated 
CaM or phospho-(Y)-CaM (0.97 µM) in three independent experiments (* p = 0.03 using the 
Student’s   t   test)   as  described   in  Materials  and  Methods.   (B)  The  plot presents the average ± 
range activity of PDE1 assayed in the presence of non-phosphorylated CaM (open symbols) 
and phospho-(Y)-CaM (filled symbols) (0.97 µM) in two independent experiments assayed at 
increasing concentrations of free Ca2+ as described in Materials and Methods. 
In addition, an assay performed at increasing concentrations of free Ca2+ in the 
presence of phospho-(Y)-CaM and non-phosphorylated CaM showed no significant 
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differences in the apparent affinity for free Ca2+ and at saturating concentrations of Ca2+ 
a  small decrease (~ 10 %) of PDE1 activity in the presence of phospho-(Y)-CaM 
compared to non-phosphorylated CaM was observed (Figure 16B). 
We then tested the effect of the full set of mutants on the CaM-dependent 
activation of PDE1. Figure 17 shows that all the Y/D and Y/E CaM mutants were able 
to activate PDE1 in the presence of Ca2+ as it does wild type CaM. However, the CaM-
dependent activity attained with CaM(Y99D/Y138D) was consistently lower (~ 20 %) 
than with the other CaM species, including the CaM(Y99E/Y138E) mutant.  
 
Figure 17: Effect of the different CaM species on the activity of PDE1. The cyclic nucleotide 
PDE1 activity was assayed in the absence (None) and presence of the indicated CaM species 
(1.9 µM) in the presence of 100 µM free Ca2+ as described in Materials and Methods. The plot 
presents the average ± SEM of triplicate samples from three separate experiments (** p = 0.02 
using  the  Student’s  t  test). 
We also performed the PDE1 assay at increasing concentrations of the CaM 
mutant species, as compared to wild type CaM, and in agreement with the previous 
result CaM(Y99D/Y138D) showed no significant differences in the Kact (~ 5-10 nM), but 
a small decrease (~ 20 %) in the Vmax of the enzyme (Figure 18A). The single 
CaM(Y99D) and CaM(Y138D) did not presented any differential effect on the PDE1 
activation and they behaved as CaM wild type. No significant differences in the Kact and 
the Vmax of the enzyme were detected when CaM Y/E mutants were tested in the same 
assay conditions, and all the Y/E mutants behaved as CaM wild type (Figure 18B).  
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Figure 18: Effect of different concentrations of wild type CaM and the different CaM 
mutants on the activity of PDE1. The plots present the PDE1 activity assayed as in Figure 17 
but using increasing concentrations of CaM Y/D (A) and CaM Y/E (B) mutants.  
When the assays were performed at increasing concentrations of free Ca2+ no 
significant changes in the apparent affinity for free Ca2+ (~ 5 µM) between wild type and 
the double Y/D and the double Y/E CaM mutants was noticed (Figure 19). And again a 
decrease (~ 20-30 %) in the CaM-dependent activity of PDE1 at saturating 
concentrations of free Ca2+ was observed with CaM(Y99D/Y138D), unlike with 
CaM(Y99E/Y138E), who presented similar activatory effect as compared to the wild 
type CaM (Figure 19).  
 
Figure 19: Effect of different Ca2+ concentrations on the CaM-dependent PDE1 activity. 
The plot presents the PDE1 activity assayed as in Figure 17 in the presence of the indicated 
CaM species (1.9 µM) at increasing concentrations of free Ca2+ using an EGTA/Ca2+ buffer as 
described in Materials and Methods. 
We also performed PDE1 assays using isothermal titration calorimetry. Serial 
injections of cAMP were made into the sample cell loaded with PDE1, in the absence 
or presence of CaM wild type or the CaM(Y99D/Y138D) mutant (3.8 M). Figure 20A 
shows heat production over time from serial injection of cAMP until the reaction 
reaches the plateau and the system was completely saturated. We determined the 
apparent enthalpy of the reaction ΔHapp to be -19.9 ± 0.5 kcal/moles, indicative of no 
product inhibition in experiments similar to the one shown in Figure 20A, but instead of 
injecting serial dilution we injected saturating conditions of cAMP. Knowing the 
enthalpy of the reaction we then performed the experiment in the absence or presence 
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of wild type CaM and CaM(CaMY99D/Y138D). Figure 20B shows a typical experiment 
where the presence of wild type CaM greatly enhanced PDE1 activity, while 
CaM(Y99D/Y138D) had a lesser effect.  
We were able to determine from the data presented in Figure 20 the kinetic 
parameters of the reaction.  We determined in a series of similar experiments that the 
PDE1 activity increased 2.61 ± 0.22 and 1.94 ± 0.09 (p<0.03) folds upon addition of 
wild type CaM and CaM(Y99D/Y138D), respectively.  
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Figure 20: Effect of different CaM 
species on the kinetics of PDE1 
determined by isothermal titration 
calorimetry. (A) The trace corresponds to 
a typical experiment showing the rate of 
heat produced by PDE1 over time after 
injections of different pulses of cAMP from 
which the activity of the enzyme can be 
derived as described in Materials and 
Methods. This particular trace corresponds 
to an experiment performed in the absence 
of CaM using 0.04 units of PDE1. (B) The 
plot presents the PDE1 activity (normalized 
for 0.04 units of enzyme) at increasing 
concentrations of cAMP in the absence 
(filled triangles) and presence of wild type 
CaM (open circles) or CaM(Y99D/Y138D) 
(filled circles) (3.8 µM) in a buffer containing 
50 mM imidazol-HCl (pH 7.5), 200 mM 
NaCl, 5 mM MgCl2, 0.4 mM EGTA, and 0.5 
mM CaCl2 using ITC as described in 
Materials and Methods setting the micro-
calorimeter chamber 37 ºC.  
Moreover, the Vmax was determined to be 7.4 ± 2.8 and 5.5 ± 2.3* (p<0.05) nmols/s in 
the presence of wild type CaM and CaM(Y99D/Y138D), respectively, while the Km of 
the enzyme for cAMP was the same (221 ± 27 µM) in the presence of both CaM 
species (Table 4). 
 
 
 
Table 4: Kinetic values of PDE1 in the absence and presence of CaM wild type and 
CaM(Y99D/Y138D).  
 
CaM species Vmax,(exp) 
(nmols/sec) 
Km (fit)          
(μM) 
Vmax (fit) 
(nmols/sec) 
None 1.8±1.1 170.3 ±94.5 2.4±1.5 
CaM wt 5.3±2.1 221.6 ±17.6 7.4±2.8 
CaM (Y99D/Y138D) 3.9±1.3 221 ±37.3 5.5±2.3* 
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6.2.2 Effect of the phospho-(Y)-mimetic CaM mutants on eNOS activity  
First we tested the comparative action of non-phosphorylated-CaM and phospho-
(Y)-CaM on the activation of recombinant eNOS. Figure 21A shows that phospho-(Y)-
CaM increased the activity of eNOS more efficiently (~ 30 %) than non-phosphorylated 
CaM, suggesting that phospho-(Y)-CaM have higher capacity to activate eNOS. When 
the assay was performed at increasing concentrations of free Ca2+ no significant 
changes in the apparent affinity for free Ca2+ (~ 4-6 µM) when compared non-
phosphorylated CaM and phospho-(Y)-CaM was observed (Figure 21B).  
 
Figure 21: Effect of phospho-(Y)-CaM and non-phosphorylated CaM on the activity of 
eNOS. (A) The plot presents the average ± range activity of eNOS of two independent 
experiments assayed at increasing concentrations of non-phosphorylated CaM (open symbols) 
or phospho-(Y)-CaM (filled symbols) prepared as described in Materials and Methods. (B) The 
plot presents the activity of eNOS assayed at increasing concentrations of free Ca2+ in the 
presence of non-phosphorylated CaM (open symbols) or phospho-(Y)-CaM (filled symbols) 
prepared as described in Materials and Methods.  
We tested the comparative action of wild type CaM, CaM(Y99D/Y138D) and 
CaM(Y99E/Y138E) on the activation of recombinant eNOS. Figure 22A shows that 
both double Y/D and Y/E  CaM mutants strongly activate eNOS in assays performed in 
the presence of Ca2+, and this activation was slightly more efficient than when wild type 
CaM was used. When eNOS was assayed at increasing concentrations of the different 
CaM species (Figure 22B), no significant differences in the Kact (~ 0.1 µM) were 
observed between wild type and the double Y/E CaM mutant. In contrast, a slight 
increment (~ 30 %) in the Vmax compared to wild type CaM was noticeable with 
CaM(Y99E/Y138E). When we tested the effect of the CaM Y/D and Y/E double 
mutants on eNOS activity at increasing concentrations of free Ca2+ no significant 
changes in the apparent affinity for free Ca2+ (~ 4–6  μM)  compared   to wild type CaM 
was detected (Figure 22C). 
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Figure 22: Effect of different CaM wild type and the double Y/D(E) CaM mutants on the 
activity of eNOS. (A) eNOS was assayed in the absence (None) and presence of the indicated 
CaM   species   (4.7   μM)   in   the   presence   of   1   mM   free   Ca2+ as described in Materials and 
Methods. The plot presents the average ± SEM of triplicate samples from three separate 
experiments (p   ≤   0.05   using   the   Student’s   t   test).   (B) The plot presents the eNOS activity 
assayed as in A but using increasing concentrations of the indicated CaM species. (C) The plot 
presents the eNOS activity assayed as in A in the presence of the indicated CaM species (4.7 
μM)   at   increasing   concentrations   of   free   Ca2+ using an EGTA/Ca2+ buffer as described in 
Materials and Methods.  
 
6.3 CaM regulates c-Src in Ca2+-dependent and Ca2+-independent manners 
 
The proto-oncogene product c-Src and its related oncoprotein v-Src play important 
roles in tumor progression and metastasis (Parsons and Parsons, 2004, Wheeler et al., 
2009). Notable among the upstream receptors activating c-Src mediating strong 
metastatic responses are those coupled to G proteins (GPCR), and RTKs, such as 
EGFR (Parks and Ceresa, 2014) and ErbB2/Her2, as the later promotes the 
expression and stability of c-Src (Tan et al., 2005).  
 
6.3.1 Apo-CaM and Ca2+/CaM both interact with c-Src 
 
We first performed a typical Ca2+-dependent CaM-affinity chromatography using a 
detergent-solubilized membrane fraction from A431 tumor cells in order to determine 
whether Src binds CaM in a Ca2+-dependent manner. Figure 23A shows that actually at 
least a fraction of the c-Src loaded in the column in the presence of Ca2+ can be eluted 
with a buffer containing EGTA.  
As this technique does not show whether part of Src remained bound to CaM-
Sepharose in the absence of Ca2+, we performed pull-down experiments using 
Sepharose with immobilized CaM in the absence and presence of Ca2+. Figure 23B 
shows that Src binds CaM, both in the presence of Ca2+ and its absence, while no 
significant binding of Src was detected using control CaM-free naked Sepharose 
beads. Furthermore, we demonstrated that CaM co-immunoprecipitated with Src 
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solubilized from A431 cells (Figure 23C). Overall, these experiments show most likely a 
direct interaction between CaM and Src and that this interaction occurs by both Ca2+-
dependent and Ca2+-independent mechanisms, in agreement with previous findings 
(Yuan et al., 2011). We also performed CaM overlay and cross-linking experiments 
with biotinylated CaM to test whether CaM binds to a recombinant or membrane 
solubilized Src kinase from A431 cells. We were not able to detect, however, any 
binding neither in the overlay or the cross-linking assays. 
 
Figure 23: CaM interacts with Src in 
the absence and presence Ca2+. (A) 
Ca2+-dependent calmodulin-affinity 
chromatography of Src solubilized from 
A431 cells was performed as described 
in Materials and Methods. The input, the 
last fraction after washing with the Ca2+-
buffer (Ca2+-wash), and the EGTA-
eluted fractions were analyzed by 
Western blot using an anti-Src antibody. 
(B) Pull-down of Src solubilized from a 
membrane fraction of A431 cells was 
performed in the absence and presence 
of Ca2+ using CaM-Sepharose as 
described in Materials and Methods. 
Naked Sepharose 4B beads were used 
as negative binding control. (C) Src was 
solubilized from a membrane fraction of 
A431 cells (2 mg protein) and 
immunoprecipitated (IP) using an anti-
Src antibody as described in Materials 
and Methods. The immunocomplex was 
processed by Western blot using anti-
CaM and anti-Src antibodies. Mock IP 
using rabbit IgG was used as a negative 
control. 
 Significant evidence has been obtained on the activatory action of Ca2+/CaM on 
the tyrosine kinase activity of Src (Fedida-Metula et al., 2012, Yang et al., 2013, Yuan 
et al., 2011). However, it was generally accepted that this process is always preceded 
by the generation of a Ca2+ signal upon cell activation required for the formation of the 
Ca2+/CaM complex. Little is known, however, on the possible action of apo-CaM (Ca2+ 
free state) on the activation of c-Src. To solve this question, we tested the effect of 
CaM on the auto-phosphorylation (activation) of human Src in the absence and 
presence of Ca2+ using a full-length recombinant protein. Figures 24A and 24B show 
that little auto-phosphorylation of c-Src was observed in the absence of CaM and that 
the presence of this Ca2+ sensor strongly enhances c-Src activation in both absence 
and presence of Ca2+. The activation of recombinant c-Src was stronger in the 
absence of Ca2+ than in its presence. And surprisingly, this effect was also observed 
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when the basal activity of c-Src was assayed in the absence of CaM. This may 
suggests a direct inhibitory action of Ca2+ on the Src kinase. 
         
 Figure 24: Apo-CaM and Ca2+/CaM both 
activate recombinant c-Src. (A) The 
auto-phosphorylation assay of recombinant 
c-Src was performed in the absence and 
presence of CaM and in the absence and 
presence of Ca2+ for the indicated times as 
described in Materials and Methods. 
Duplicate samples were probed with an 
anti-Src (total) antibody as loading control. 
(B) The plot presents the mean ± range c-
Src phosphorylation in the absence (None) 
and presence of CaM, and in the absence 
(EGTA) and presence of Ca2+ from two 
independent experiments similar to the one 
shown in A.  
 
6.3.2 Effect of the phospho-(Y)-mimetic CaM mutants on c-Src activity.  
 
As CaM is known to be phosphorylated by different Src family kinases (Benaim 
and Villalobo, 2002), we tested the action of phospho-(Y)-mimetic CaM mutants, on the 
auto-phosphorylation of recombinant c-Src. Figure 25 shows little if any differences in 
the activatory action of wild type CaM compared with the CaM(Y99D/Y138D) mutant 
both in the absence and presence of Ca2+. Moreover, both CaM(Y99D/Y138D) and 
CaM(Y99E/Y138E) had the capacity to activate c-Src more strongly in the absence of 
Ca2+ (presence of EGTA) than in its presence (Figures 25 and 26).  
 
 
Figure 25:  A phospho-(Y)-mimetic CaM 
mutant activates recombinant c-Src. (A) 
Auto-phosphorylation assays of 
recombinant c-Src (0.1 µg) was performed 
in a medium containing 15 mM Tris-HCl (pH 
7.5), 5 mM MgCl2, 1 mM DTT, 1 mM EGTA 
and where indicated 1.2 mM CaCl2 (200 µM 
free Ca2+) in the presence of either wild 
type CaM or CaM(Y99D/Y138D). The 
samples were processed for SDS-PAGE 
and Western blot using anti-phospho-
tyrosine and anti-Src antibodies as 
described in Materials and Methods. (B, C) 
The plots present the mean ± SEM (n = 2) 
c-Src phosphorylation in the presence of 
wild type CaM or CaM(Y99D/Y138D) in the 
absence and presence of free Ca2+ from 
experiments similar to the ones shown in A.   
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These results suggest that phospho-(Y)-CaM may not have a distinct regulatory 
role than non-phosphorylated CaM on c-Src activation.  
 
Figure 26: Phospho-(Y)-mimetic CaM 
mutants activate recombinant c-Src with 
better efficiency in the absence than in 
the presence of Ca2+. (A) Auto-
phosphorylation assays performed in 
conditions described in Figure 25 in the 
absence or presence of either 
CaM(Y99D/Y138D) or CaM(Y99E/Y138E). 
The samples were processed for SDS-
PAGE and Western blot using anti-
phospho-tyrosine and anti-Src antibodies 
as described in Materials and Methods. (B, 
C) The plots present the mean ± range c-
Src phosphorylation in the presence of 
CaM(Y99D/Y138D) (n=1) or 
CaM(Y99E/Y138E) (n=2), and in the 
absence and presence of free Ca2+ from 
experiments similar to the ones shown in A. 
6.3.3 The calmodulin antagonist W-7 inhibits Src activation in living cells.  
 
Ligand-dependent activation of EGFR results in the down-stream activation of Src 
(Parks and Ceresa, 2014). To determine whether CaM is involved in EGFR-mediated 
Src activation in EGFR-overexpressing A431 cells, we performed experiments in the 
presence of the CaM antagonist W-7 and the less potent inhibitor W-12. Figures 27A 
(left and center panels), 27B and 27D show that activation of the EGFR by its ligand 
EGF also results in Src phosphorylation at Y416 as expected, and that increasing 
concentrations of W-7 progressively inhibit both phosphorylation processes. In 
contrast, high concentration (50 µM) of W-12, a chlorine-free analogue of W-7 with far 
lower affinity for CaM (IC50 of 260 µM versus 28 µM, inhibiting Ca2+/CaM-dependent 
phosphodiesterase) (Hidaka et al., 1981, Hidaka and Tanaka, 1983), has a much lower 
inhibitory effects on EGFR activation than on Src activation (Figure 27D). It has been 
previously demonstrated that in living cells the ligand-dependent activation of the 
EGFR was aided by the Ca2+/CaM complex, and that W-7 or W-13 inhibits this process 
(Martin-Nieto and Villalobo, 1998, Sengupta et al., 2007, Li et al., 2004, 2012). 
Nevertheless, as the inhibitory action of W-7 on Src phosphorylation was significantly 
stronger than that observed on ligand-dependent EGFR auto(trans)phosphorylation, 
this suggests a direct activatory effect of CaM on Src activity. Interestingly, W-7 itself 
had an activatory effect on the basal Src kinase activity, effect that may be due to the 
fact that this inhibitor may bind to the phospholipids on the inner leaflet of the plasma 
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membrane and thus change its electrostatic surface potential (Sengupta et al., 2007). 
The latter event may be accompanied of the detachment of a region in the Src 
structure that serves as an autoinhibitory mechanism. Similar effect of W-7/W-13 was 
also observed in EGFR, as treatment of a variety of cells lines expressing EGFR with 
this inhibitor led to the activation of the receptor in the absence of ligand (Sengupta et 
al., 2007). 
 
 
Figure 27: W-7 inhibits EGFR- and H2O2-mediated Src activation in A431 cells. (A) A431 
cells were incubated in the absence and presence of the indicated concentrations of W-12 or W-
7 during 15 min. Thereafter, the cells were stimulated either with 10 nM EGF for 2 min or 1 mM 
H2O2 for 15 min. The reaction was arrested and subjected to Western blot analysis as described 
in Materials and Methods, and probed with anti-phospho-tyrosine (4G10), anti-phospho-Src 
(Y416), and anti-EGFR (total), anti-Src (total) and anti-GAPDH antibodies as loading controls. 
(B, C) The plots present the mean ± SEM EGF-dependent (n = 6) and H2O2-dependent (n = 3) 
activation of Src at increasing concentrations of W-7 from experiments similar to those shown in 
A. (D, E) The plots present the mean ± SEM EGF-dependent (n = 6) and H2O2-dependent (n = 
3) activation of Src in the absence (None) and presence of 50 µM W-12 or 50 µM W-7 from 
experiments similar to those shown in A. Statistically significant differences with p < 0.05 (*), p < 
0.005 (**) and p < 0.0001 (***)  using  the  Student’s  t-test are indicated. 
The results discussed above do not represent a clear-cut evidence for a direct 
action of CaM on Src activation in living cells as EGFR is regulated by CaM (San José 
et al., 1992, Martin-Nieto and Villalobo, 1998, Sengupta et al., 2007, Li et al., 2004, 
2012). Therefore, we searched for another way to activate Src without the involvement 
of EGFR to test the possible inhibitory effect of W-7. Figures 27A (right panel), 27C and 
27E show that hydrogen peroxide, a known activator of Src (Sato et al., 2001, Basuroy 
et al., 2010), strongly enhances Src auto-phosphorylation (activation) in A431 cells as 
expected, and that W-7 indeed significantly inhibits this process in contrast to the lower 
effect of the low-affinity CaM inhibitor W-12 at identical concentrations (Figure 27E).  
 We also tested the inhibitory action of W-7 on H2O2-dependent activation of Src in 
a different cell line. Figure 28A show that H2O2 enhances the phosphorylation 
(activation) of Src in SK-BR-3 cells, and that the CaM antagonist W-7 inhibits the H2O2-
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dependent activation of Src while W-12 does not. As W-7 appears to inhibit CaM in its 
Ca2+-bound form (Okawa et. al, 1998) and may not affect apo-CaM, these results 
clearly suggest that Ca2+/CaM regulates Src activity in living cells, although no 
information can be extracted from these experiments on the potential control that apo-
CaM may exert on Src activation. 
 
 
Figure 28: W-7 inhibits H2O2-mediated Src 
activation in SK-BR-3 cells. (A) SK-BR-3 cells 
were incubated in the absence and presence of 
the indicated concentrations of W-12 or W-7 
during 15 min. Thereafter, the cells were 
stimulated with 1 mM H2O2 for 15 min. The 
reaction was arrested and subjected to Western 
blot analysis as described in Materials and 
Methods, and probed with anti-phospho-Src 
(Y416), and anti-Src (total) and anti-GAPDH 
antibodies as loading controls. (B) The plot 
presents the mean ± SEM (n = 5) H2O2-
dependent activation of Src in the absence 
(None) and presence of either 50 µM W-12 or 
50 µM W-7 from experiments similar to the one 
shown in A. Statistically significant differences 
with p < 0.05 (*)   using   the  Student’s   t-test are 
indicated. 
We tried to test the effect of CaM on the activity of Src family kinases espressed in 
ET1-55/EGFR cells, where the expression of CaM is down-modulated by tetracycline 
(Panina et al., 2012, Li et al., 2012), using as control cell line DT40/EGFR cells. After 
the antibiotic treatment for 48 hours we detected with a surprise an increase in the 
phosphorylation at Tyr416 of some unidentified member of the Src-family, but this was 
not due to the decrease of the expression of CaM, because this increased 
phosphorylation was also detected in the control cell line, suggesting that stress 
induced by tetracycline, but not the drop of CaM expression level, was the reason for 
the activation of the Src family kinase(s) (Supplementary Figure 2S). 
6.4 Effect of CaM and phospho-(Y)-CaM on EGF-dependent EGFR activation 
 
Overexpression, and/or truncated, site-mutated or segment-deleted hyperactive 
forms of EGFR are present in many solid tumors in human. The aberrant receptors 
significantly contribute to the oncogenic process (Kim and Muller, 1999, Roskoski, 
2014). Thus, targeting overexpressed and/or aberrant hyperactive EGFR could be a 
valid therapeutic approach against cancer (Roskoski, 2014). In addition to anti-EGFR 
antibodies targeting the extracellular region of the receptor or small chemicals targeting 
the tyrosine kinase domain of EGFR have been developed. Another target site of 
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interest could be the CaM-BD located at the cytosolic JM region of the receptor 
(Villalobo et al., 2013).  
6.4.1 Effect of CaM down-regulation in CaM-KO cells on EGF-dependent 
EGFR activation. 
 
As CaM is implicated in EGF-dependent EGFR activation we used ET1-55/EGFR 
conditional CaM-KO cells stably transfected with the human EGFR (Panina et al., 
2012, Li et al., 2012). Upon addition of tetracycline the expression level of CaM drops 
after 42-72 h of exposure of the antibiotic and we could barely detect the presence of 
CaM through immunoblot (Figure 29A). The activation of the EGFR was significantly 
reduced by the tetracycline addition in a time-dependent manner and the decrease of 
EGFR auto-phosphorylation follows the time-dependent down-regulation of CaM, 
showing that CaM is essential for EGF-dependent activation of the EGFR (Figures 29A 
and 29) as previously described by us (Panina et al., 2012, Li et al., 2012). Since CaM 
is vital for the cells, we used trypan blue exclusion test to determine the cell viability at 
the different times of tetracycline treatment, and at 72 h only 10 % drop in cell viability 
was observed compared to non-treated cells (Figure 29C).  
 
Figure 29: CaM down-regulation in conditional CaM-KO cells decreases EGF-dependent 
EGFR activation. (A) ET1-55/EGFR cells were incubated with 1 μg/ml tetracycline and 
stimulated with 10 nM EGF for 5 min for the indicated times. The expression of EGFR (t-EGFR), 
phospho-EGFR (p-EGFR) and CaM was determined using an anti-EGFR, anti-phosphotyrosine 
(4G10) and anti-CaM antibodies. GADPH is also shown as a loading control. (B) The plot 
presents the mean ± SEM (n=5 for total EGFR, n=3 for phospho-EGFR, and n=3 for total CaM) 
expression of total EGFR (red squares), non-stimulated EGFR (purple circles), EGF-stimulated 
EGFR (black circles) and total CaM (green triangles) in the presence of tetracycline for the 
indicated times. (C) The plot represents the mean ± SEM (n=3) of the cell viability measured by 
trypan blue exclusion test in the absence and presence of tetracycline for the indicated times. 
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6.4.2 Effect of the phospho-(Y)-mimetic CaM mutants on EGFR activation. 
 
Then we wanted to test whether the double Y/D and Y/E CaM mutants have a 
differential regulatory effect on the EGF-dependent activation of the EGFR as 
compared to CaM wild type. Figure 30 shows the effect of the double Y/E and Y/D 
mutants on the EGF-dependent activation of EGFR solubilized from a membrane 
fraction of A431 cells in vitro. The results show that the receptor in the absence of its 
ligand has very low tyrosine kinase activity, and that upon addition of EGF leads to a 
strong activation of the EGFR. The effect of CaM wild type is in agreement with what 
has been already demonstrated by us, where in the presence of Ca2+/CaM has an 
inhibitory effect on the EGF-dependent activation of EGFR in vitro (San José et al., 
1992). Interestingly, CaM(Y99E/Y138E) and CaM(Y99D/Y138D) mutants had a 
differential effect on the activation of the receptor in the presence of Ca2+. The glutamic 
acid double mutant had similar, if not stronger, inhibitory effect compared to the one 
exerted by wild type CaM. On the other hand, the aspartic acid mutant did not exhibit 
the same extend of inhibition on the EGF-dependent activation of EGFR in the 
presence of Ca2+, compared to both wild type CaM and the double Y/E CaM mutant. In 
the presence of the chelating agent EGTA (Figures 30A and 30B) Y/D CaM mutants 
had a strong activatory effect on the EGF-dependent phosphorylation of EGFR as 
compared to wild type CaM (Figure 30).  
 
 
                            
Figure 30: Effect of different CaM species on the EGF-dependent phosphorylation of the 
EGFR in vitro. (A, B) EGFR solubilized from membrane fraction from serum-starved A431 cells 
was incubated in the absence or presence of different recombinant CaM mutants (1  μg), in the 
absence of Ca2+ (presence of EGTA) or presence of Ca2+, and in the absence or presence of 10 
nM EGF as indicated. The samples were resolved in SDS-PAGE and processed by immunoblot 
using an anti-phosphotyrosine antibody to detect phosphorylated EGFR (p-EGFR). GAPDH is 
shown as a loading control. (C) The plot presents the mean ± SEM (n = 6) for wild type CaM 
and CaM (Y99D/Y138D), and (n=3) for CaM(Y99E/Y138E) of the EGF-dependent 
phosphorylation of EGFR in the absence (presence of EGTA) or in the presence of Ca2+ and the 
different CaM species as indicated.        
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6.5 O-GlcNAcylation in tumor cells 
O-GlcNAcylation   is   the  addition  of  β-D-N-acetylglucosamine moiety(ies) to serine 
or threonine of nuclear, cytoplasmic and mitochondrial proteins (Torres and Hart, 
1984). Since 1984 when O-GlcNAcylation was found for the first time (Torres and Hart, 
1984) significant amount of data revealing the function exerted by this non-typical 
glycosylation has been accumulated, and its involvement in diseases such as cancer 
has crystallized in recent years (Hart, 2014, de Queiroz et al., 2014, Jozwiak et al., 
2014). It was found that EGFR type III in Drosophila is subjected to O-GlcNAcylation 
(Sprung et al., 2005) and it has been proposed based on in silico studies that Th654 
and Ser1046/1047 in the EGFR are O-GlcNAcylated (Kaleem et al., 2009). The 
putative O-GlcNAcylation sites proposed for the EGFR are in fact directly or indirectly 
regulated by CaM as Thr654 is located in the CaM-BD of the receptor, and 
Ser1046/1047 are phosphorylated by CaMK-II. Thus we tried to peer whether the 
EGFR is in fact subjected to this PTM in tumor cells and whether CaM could have any 
role in this process.  
6.5.1 EGFR O-GlcNAcylation in A431 and A549 cells 
We first tested for the presence of O-GlcNAcylated proteins in whole cell lysates of 
A431 tumor cells by immunoblot using two distinct anti-O-GlcNAc specific antibodies 
(CTD110.6 and RL2) (Figure 31A). The presence of multiple strongly labeled bands of 
O-GlcNAcylated proteins in a range of > 250 kDa to < 50 kDa were detected presenting 
a similar distribution pattern when both antibodies were used. When cells were treated 
with Thiamet G, a highly specific inhibitor of O-GlcNAc hydrolase (OGA) to prevent O-
GlcNAc deglycosylation (Goldberg et al., 2011), a significant two-fold increase in 
protein O-GlcNAcylation level was detected as expected (Figures 31B and 31D). 
Moreover, we also tested BADGP, a general O-glycosylation inhibitor not specific for 
O-GlcNAcylation but that also inhibits this process (Filhoulaud et al., 2009, Pantaleon 
et al., 2010, Onodera et al., 2014, Xu et al., 2014), and a small but significant decrease 
in protein O-GlcNAcylation was detected (Figures 31B and 31C). 
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Figure 31: Effects of OGT and OGA inhibitors on protein O-GlcNAcylation. (A) A cell 
extract from A431 cells was processed by SDS-PAGE and Western blots (WB) and probed with 
the anti-O-GlcNAc antibodies CTD110.6 and RL2 as indicated. (B) A431 cells were incubated 
overnight in the absence (None) and presence of 20 µM Thiamet G or 2 mM BADGP as 
indicated and whole cell extracts probed with an anti-O-GlcNAc antibody (RL2). Anti-GAPDH 
antibody was used as loading control. (C) The plot presents the mean ± SEM (n = 4) of total 
protein O-GlcNAcylation. (*) p < 0.05 as determined   by   the   Student’s   t   test.   (D) The plot 
presents the mean ± SEM (n = 3) protein O-GlcNAcylation using different concentrations of 
Thiamet G. 
6.5.2 EGFR O-GlcNAcylation detected by immunoblot  
To determine whether the EGFR from A431 tumor cells undergoes O-
GlcNAcylation we treated the immunoprecipitated receptor in the absence and 
presence of PNGase F to remove N-glycans, and tested for O-GlcNAcylation using the 
same two distinct anti-O-GlcNAc antibodies mentioned above (Figures 32A and 32B). 
The results show that in both instances, not only the 170 kDa native EGFR, but most 
significantly and in greater extent the ~150 kDa N-deglycosylated receptor, yielded 
positive signals. To ascertain the specificity of the CTD110.6 anti-O-GlcNAc antibody, 
we competed its reactivity using an excess (20 mM) of free GlcNAc in the incubation 
medium (Figure 32C). Furthermore, we performed the experiment in reverse: 
immunoprecipitating first O-GlcNAcylated proteins from an A431 cell lysate and 
detecting the presence of EGFR in the immunoprecipitate (Figure 32D). When the cells 
were previously treated with the OGA inhibitor Thiamet G, the EGFR signal was slightly 
increased, and a decrease was detected when cells were treated with the O-
glycosylation inhibitor BADGP, which also inhibits OGT (Figure 32D).  
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Figure 32: Detection of O-GlcNAcylation 
signal in immunoprecipitated EGFR by 
immunoblot. (A, B) The EGFR was 
immunoprecipitated (IP) from A431 cells using 
an anti-EGFR antibody and the 
immunocomplex was incubated in the absence 
and presence of PNGase F. The samples were 
blotted with the anti-O-GlcNAc antibodies 
CTD110.6 (A) and RL2 (B). The membranes 
were reprobed with an anti-EGFR antibody as 
loading controls. Mock IP were performed 
using a non-relevant IgG as negative controls. 
Arrowheads point the native and N-
deglycosylated EGFR. (C) Immunoprecipitated 
(IP) EGFR, a non-relevant IgG fraction and an 
A431 cell extract were immunoblotted using an 
anti-O-GlcNAc antibody (CTD110.6) in the 
absence and presence 20 mM GlcNAc. (D) 
A431 cells were incubated overnight in the 
absence (None) and presence of 20 µM 
Thiamet G or 2 mM BADGP. The samples 
were immunoprecipitated (IP) using an anti-O-
GlcNAc antibody (RL2) and the 
immunocomplex subjected to Western blots 
(WB) and probed with anti-EGFR and anti-O-
GlcNAc antibodies. Mock IP was performed 
using a non-relevant IgG as negative control. 
The light chains of IgG were staining with Fast 
Green as loading control.  
 
In agreement with the previous result, we also demonstrated that when A431 cells 
were treated with the OGA inhibitor Thiamet G the O-GlcNAcylation level of the 
immunoprecipitated native 170 kDa EGFR also increased, although little if any 
increment was detected in the ~150 kDa N-glycans-free EGFR band (Figures 33A and 
33B). 
 
Figure 33: Effects of OGA and OGT 
inhibitors on the EGFR O-GlcNAcylation. 
(A) A431 cells were incubated overnight in 
the absence (None) and presence of 20 µM 
Thiamet G or 2 mM BADGP. The samples 
were processed as described in Materials 
and Methods and probed with an anti-O-
GlcNAc antibody (RL2). The membrane 
was reprobed with an anti-EGFR antibody 
as loading control. Arrowheads point the 
native and N-deglycosylated EGFR. (B) 
The plot presents the mean ± SEM (n = 3) 
EGFR O-GlcNAcylation from a set of 
experiments similar to the one shown in A. 
(*) p <  0.05  as  determined  by  the  Student’s  
t test.  
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We then tested whether EGFR activation with EGF has an effect on the O-
GlcNAcylation of the receptor, and to the O-GlcNAcylation of proteins in A431 cells. 
Figures 34A and 34B show that when EGFR is activated by EGF there is a small, but 
not significant decrease in the O-GlcNAcylation, this may be partially due to the 
internalization and degradation of the receptor induced by its ligand (Wiley et al., 1991, 
Lamaze and Schmid, 1995, Oksvold et al., 2003, Henriksen et al., 2013) (see Figures 
35C and 35B). Figure 34C shows that EGF-stimulated A431 cells have the same 
pattern of O-GlcNAcylated proteins compared to the non-treated ones, suggesting that 
EGFR signaling does not modulate this PTM in other proteins. 
 
Figure 34: The effect of EGF-dependent 
activation on the O-GlcNAcylation of the 
EGFR. (A) Serum-starved A431 cells were 
incubated in the absence and presence of 
10 nM EGF during 30 min. EGFR was 
immunoprecipitated and immunoblotted 
(WB) with the anti-O-GlcNAc antibody 
CTD110.6. (B) The plot presents the mean 
± SEM (n = 3) EGFR O-GlcNAcylation. The 
p-value   as   determined   by   the   Student’s   t  
test is also shown. (C) Cell extracts of 
serum-starved A431 cells were incubated in 
the absence and presence of 10 nM EGF 
for 30 min. The samples were then 
processed as described in Materials and 
Methods and probed with the anti-O-
GlcNAc antibody. 
6.5.3 EGFR O-GlcNAcylation detected by metabolic labeling with azido-
GlcNAc 
We next tried to detect O-GlcNAcylation of the EGFR by metabolically labeling 
cellular glycans from A431 cells with azido-GlcNAc. Figure 35A shows that after 
immunoprecipitation both the native 170 kDa EGFR and its ~150 kDa N-glycans-free 
form, obtained after PNGase F treatment, yielded a positive signal following 
biotinylation and overlay by streptavidin-HRP. The extent of the signal was lower in 
EGF-treated cells but this most likely represents degradation of the receptor after 
ligand-induced internalization, as this process has been well documented (Kirisits et al., 
2007, Henriksen et al., 2013) and we further show this degradation in Figures 35B, 
35C. We also treated A431 cells with tunicamycin to obtain EGFR devoid of N-glycans 
by a different method. Figure 34D shows that the native 170 kDa receptor and its ~150 
kDa N-deglycosylated form both were metabolically labeled with azido-GlcNAc, the 
latter even after further treating the immunoprecipitated EGFR with PNGase F. 
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Figure 35: Detection of O-GlcNAcylation signal in EGFR by azido-GlcNAc labeling. (A) 
Serum-starved A431 cells were labeled with GlcNAz and incubated in the absence and 
presence of 10 nM EGF during 30 min. EGFR was then immunoprecipitated, biotinylated and N-
deglycosylated as described in Materials and Methods. The detection of the biotin-GlcNAc 
complex was done by overlaid with streptavidin-HRP as described in Materials and Methods. 
Immunoprecipitated EGFR from cells non-treated with GlcNAz (No GlcNAz) and a mock IP are 
shown as negative controls. Fast Green staining is shown as loading control. (B) Serum-starved 
A431 cells were treated in the absence (-) and presence (+) of 10 nM EGFR for 30 min. The 
reaction was arrested with 10 % (w/v) TCA, and the samples were processed for SDS-PAGE 
and immunoblot using an anti-phospho-(Y) antibody to detect phosphorylated EGFR (P-EGFR) 
and an anti-EGFR antibody to detect total EGFR. GAPDH is shown as a loading control. (C) 
The plot presents the mean ± SEM (n = 3) of the densitometry of the EGFR/GAPDH signal ratio. 
(**) p < 0.01 as determined  by  the  Student’s  t  test. (D) A431 cells were treated overnight with 1 
µg/ml tunicamycin, the EGFR was immunoprecipitated (IP) and where indicated treated with 
PNGase F. The samples were processed as in A. Duplicate samples were probed with an anti-
EGFR antibody. Immunoprecipitated EGFR from cells non-treated with GlcNAz (No GlcNAz) 
and a mock IP are shown as negative controls. Arrowheads point the native and N-
deglycosylated EGFR. 
We tested different human tumor cell lines, with different levels of EGFR 
expression, and a mouse fibroblast stably transfected and overexpressing the human 
EGFR for O-GlcNAcylation of the receptor. Figure 36 shows a positive signal in human 
carcinoma epidermoid A431 cells, which were used as positive control. Also, a positive 
signal was detected in human lung carcinoma A549 cells. The double band observed in 
A549 cells may represent the presence of an unrelated O-GlcNAcylated protein 
associated to the EGFR and/or another ErbB receptor forming heterodimers with the 
EGFR. However, no O-GlcNAcylation of the EGFR was detected in human cervix 
adenocarcinoma HeLa cells or in the recombinant human EGFR expressed in mouse 
EGFR-T17 fibroblasts. 
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Figure 36: O-GlcNAcylation of EGFR in 
different cell lines. A431, A549, HeLa and 
EGFR-T17 cells were incubated overnight in 
the presence of  the OGA inhibitor 20   μM 
Thiamet. The EGFR was 
immunoprecipitated (IP) using an anti-EGFR 
antibody and the immunocomplexes were 
processed by SDS-PAGE and immunoblot 
(WB) using anti-O-GlcNac (RL2) and anti-
EGFR antibodies as described in Materials 
and Methods. A mock IP was performed 
using a non-relevant IgG as a negative 
control.  
 
6.5.4 In vitro O-GlcNAcylation of EGFR 
 
We first show that EGFR and OGT can be co-immunoprecipitated (Figure 37A), 
suggesting that the two proteins interact in living cells. Our results on the in vitro 
enzymatic assays show a significant increment in the O-GlcNAcylation level of the 
EGFR as detected by Western blot using an anti-O-GlcNAc antibody (RL2) (Figures 
37B and 37C). Given the fact that the immunoprecipitated EGFR was already O-
GlcNAcylated before starting the reaction catalyzed by OGT, this increment only 
reached ~1.8 ± 0.2 fold. This, however, strongly suggests that the EGFR undergoes 
this PTM. 
 
 
Figure 37: Enhanced O-GlcNAcylation of 
EGFR upon in vitro reaction catalyzed by 
OGT. (A) OGT and EGFR were 
immunoprecipitated from A431 cells and the 
samples were processed by immunoblot (WB) 
using anti-OGT and anti-EGFR antibodies to 
test for co-immunoprecipitation of both 
proteins. Mock IP were performed using a 
non-relevant IgG as negative controls. (B) 
OGT and EGFR were independently 
immunoprecipitated from A431 cells. 
Thereafter, the immunoprecipitated EGFR 
was incubated in the absence and presence 
of immunoprecipitated OGT and the O-
GlcNAcylation was performed upon addition 
of UDP-GlcNAc as described in Materials and 
Methods. The samples were immunoblotted 
as indicated. OGT and EGFR were detected 
by WB using anti-OGT and anti-EGFR 
antibodies, respectively. (C) The plot presents 
the mean ± SEM EGFR O-GlcNAcylation in 
the absence (None) and presence of OGT 
from 3 independent experiments similar to the 
one shown in B measuring the densitometry 
of the O-GlcNAcylated EGFR band corrected 
by loading as determined by protein staining 
with Fast Green. (*) p < 0.05 as determined by 
the  Student’s  t  test. 
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6.5.5 Effect of OGA and OGT inhibitors on EGFR activation 
We tested OGA and OGT inhibitors on the EGF-dependent activation of the 
EGFR in A431 tumor cells. Figure 38A shows that the presence of Thiamet G and 
BADGP, did not significantly change the time-dependent activation profile of the 
EGFR. The maximum EGFR phosphorylation was around 2 minutes of EGF 
stimulation followed by a subsequent decrease of the receptor auto-
phosphorylation due to dephosphorylation (Figure 38B).  
 
Figure 38: Effect of OGA and OGT 
inhibitors on the EGF-dependent 
activation of EGFR. (A) A431 cells were 
incubated in the absence (None) and 
presence   of   20   μM   Thiamet G or 2 mM 
BADGP overnight. Thereafter, the cells 
were stimulated with 10 nM EGF for the 
indicated times. The reaction was 
arrested and subjected to Western blot 
analysis as described in Materials and 
Methods, and probed with anti-
phosphotyrosine antibody (p-EGFR), and 
anti-GAPDH antibody as a loading 
control. (B) The plot present the mean ± 
SEM (n=3) EGF-dependent  activation of 
EGFR for the indicated times from 
experiments similar to those shown in A. 
 
6.5.6 Possible role of CaM in protein O-GlcNAcylation 
According to Kaleem et al. (2009) CaM could have a central role into the proposed 
interplay between O-GlcNAcylation and phosphorylation of the EGFR. We tried to 
study the possible role of CaM on OGT functionality in order to address this issue and 
clarify whether this Ca2+ modulator has anything to do with the O-GlcNAc modification. 
Figure 39 shows an in silico study proposing that OGT could be a CaM-BP. Using a 
CaM database in silico tool freely available at: 
http://calcium.uhnres.utoronto.ca/ctdb/ctdb/home.html we were able to find a sequence 
located in the C-terminal of the transferase that has great potential of being a CaM-BD 
(Figure 39A). Since we know that CaM-BD regions of a given protein are usually 
conserved among different species we tested whether the putative CaM-BD of OGT is 
also conserved, and the result of the alignment of this region is shown in Figure 39B. It 
is clear that this region is quite conserve is there is only one amino acid substitution, a 
valine at position 993 changed to isoleucine, both hydrophobic amino acids (Figure 
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39B). On the other hand, the putative CaM-binding site was identified as a canonical 1-
5-10 class motif (see Table 1). 
 
Figure 39: Putative CaM-binding domain in human ncOGT. (A) Presents the result from the 
in silico searching tool showing the amino acid sequence in the human ncOGT that have the 
highest potential to present CaM binding capacity (from 0 to 9). (B) Alignment of the selected 
region in different species. (C) The scheme represents the position of the conserved amino 
acids critical for CaM binding and several segments fitting to a CaM-binding domain of type 1-5-
10. 
We performed Ca2+-dependent CaM-affinity chromatography using recombinant 
ncOGT in order to determine whether this enzyme binds CaM in a Ca2+-dependent 
manner. Figure 40A shows that part of the OGT loaded in the column in the presence 
of Ca2+ can be eluted with a buffer containing EGTA. Furthermore, we demonstrated 
that CaM co-immunoprecipitated with OGT from A431 cells (Figure 40B). Overall, 
these experiments show possible direct interaction between CaM and OGT and that 
this interaction occurs by a Ca2+-dependent mechanism. 
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Figure 40: Calmodulin interacts with OGT. (A) Ca2+-dependent CaM-affinity chromatography of 
recombinant ncOGT performed as described in Materials and Methods. The input, the last fraction 
after washing with the Ca2+-buffer (Ca2+-wash), and the EGTA-eluted fractions were analyzed by 
Western blot using an anti-OGT antibody. (B) OGT was immunoprecipitated (IP) from A431 cells 
using an anti-OGT antibody as described in Materials and Methods. The immunocomplex was 
processed by Western blot using anti-CaM and anti-OGT antibodies. A mock IP was used as a 
negative control. 
We finally tested the effect of CaM inhibition and CaM down-regulation on the O-
GlcNAcylation pattern of A431 cells and ET1-55/EGFR cells, respectively. Figures 41A 
and 41B show that neither the inhibition of CaM with W-7 in A431 cells nor the down-
regulation of CaM in the conditional CaM-KO chicken lymphoma cell line has any effect 
on the general pattern of protein O-GlcNAcylation, suggesting that CaM may not 
regulate the enzymatic activity of OGT. 
 
 
 
 
Figure 41: Effect of inhibition or down-
regulation of CaM on the O-GlcNAcylation 
pattern. (A) A431 cells were treated in the 
absence   or   presence   of   15   μM  W-7 for 30 
min. Total cell extracts samples were 
processed by SDS-PAGE and Western blot 
as described in Material and Methods, and 
the membrane was probed with anti-O-
GlcNAc (CTD110.6) antibody. Protein stained 
with Fast Green is shown as a loading 
control. (B) ET1-55/EGFR cells were treated 
with   tetracycline   (1   μg/ml)   for   the   indicated  
times. Total cell extracts were processed by 
SDS-PAGE and Western Blot as described in 
Material and Methods and the membranes 
probed with anti-O-GlcNAc antibody 
(CTD110.6), anti-CaM, anti-EGFR 
antibodies. Protein stained with Fast Green is 
shown as a loading control. 
DISCUSSION  
 
97 | P a g e  
 
            7. DISCUSSION 
 
 
 
 
 
 
 
 
 
 
DISCUSSION  
 
98 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION  
 
99 | P a g e  
 
CaM is a modulator in eukaryotic cells transducing the Ca2+ signal generated upon 
activation by a variety of effectors, and regulates many cellular processes including: 
cell proliferation, apoptosis and autophagy, all of them playing a fundamental role in 
tumorigenesis and tumor progression (Chin and Means, 2000, Jurado et al., 1999, 
Berchtold and Villalobo, 2014). Understanding the different mechanisms by which CaM 
exerts its functions, regulating hundreds of proteins including PDE1, NOS, EGFR and 
c-Src, that also have been identified as important element of signaling pathways that 
control the invasive and metastatic capacities of various tumors (Kim and Muller, 1999, 
Roskoski, 2014, Tan et al.,2005) is of a highest interest. In this Thesis we focus on 
studing the effect of CaM on the functionality on systems important in tumorogenesis, 
particularly the EGFR and c-Src. 
A broad range of Ser/Thr- and Tyr-protein kinases have been shown to 
phosphorylate CaM in vitro and in living cells and the different phospho-CaM species 
have different regulatory role on the activity of many target proteins as compared to 
non-phosphorylated CaM (Benaim and Villalobo, 2002). This suggests that this PTM in 
addition to Ca2+ binding could modulate the activity of CaM. The non-receptor tyrosine 
kinase Src (Fukami et al., 1986), the insulin receptor (Graves et al., 1986), and the 
EGFR (Benguría et al., 1994), are kinases implicated in the phosphorylation of CaM at 
both Y99 and Y138. The dynamic nature of this PTM and the distinct phosphorylated 
forms of CaM at a given time acting on specific target proteins could be difficult to 
observe in living cells due to the short half-life of phospho-(Y)-CaM. In this Thesis we 
show an alternative to explore these events by generation and characterization of 
recombinant phospho-(Y)-mimetic CaM mutants, where one or two of the two only Tyr 
present in CaM were substituted by glutamic acid (E) or aspartic acid (D), as this is a 
common approach used to mimic tyrosine phosphorylation (Potter et al., 2005, Lie et 
al., 2012, Fisslthaler et al., 2008). We generated and extensively characterized these 
phospho-mimetic potential of these CaM mutants. 
7.1 The phospho-(Y)-mimetic CaM mutants binds Ca2+ 
Our data showed, that in contrast to the homogeneous electrophoretic migration (~ 
18 kDa) of the single or double Y/D and Y/E CaM mutants in the absence of Ca2+ 
(presence of EGTA), and the near absence of Ca2+-induced electrophoretic mobility 
shift of the single or double CaM mutants where Y138 was substituted by acidic 
residues (D or E) described in this Thesis, the non-phosphorylatable Y/F CaM mutants 
previously described presented a different behavior (Salas et al., 2005). For instance, 
the CaM(Y138F) and CaM(Y99F/Y138F) mutants presented in the absence of Ca2+ 
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higher electrophoretic mobility than wild type CaM and CaM(Y99F), and even higher 
Ca2+-induced mobility shift (Salas et al., 2005). This suggests that the substitution of 
Y138 by an acidic or a hydrophobic residue exerts distinct effects on the conformation 
of CaM and most likely have a great impact on the conformation of the protein. Our 
results are in agreement with previous findings in which a differential behavior was 
observed when Y138 or Y99 were substituted by diverse amino acids, suggesting that 
mutation of Y138 disrupts the structural coupling between the N and C globular halves 
of CaM potentially mimicking the collapse that CaM undergoes when binding to target 
proteins (Sun et al., 1999, Sun et al., 2001). The central position of Y138 in the Ca2+-
induced conformational change of CaM is also evidenced by the modification of the 
chiroptical properties of this residue, here revealed to be the culprit for the well-known 
changes in the near-UV CD spectrum of CaM. Of note, the spectrum of Ca2+-bound rat 
CaM is very similar to that of Drosophila melanogaster CaM (Maune et al., 1992), 
which only contains the Y138 residue but not that at position 99, further substantiating 
this conclusion. 
The far-UV CD spectra of the different phospho-mimetic CaM species as 
compared to the wild type in the absence or presence of Ca2+ suggest that the 
substitution of one or the two Tyr residues does not disrupt Ca2+ binding. Ca2+ binding 
induced similar conformational changes in the molecules of the whole panel of 
mutants. Nevertheless, the ratio of molar ellipticity at 208 and 222 nm, a sensitive 
criterion of possible alterations in interactions between neighboring helices (Sun et al., 
2001, Fasman, 1996), was slightly higher for the mutants as compared to the wild type, 
pointing to slight differences in the helix packing of the mutants. Of note, the mutant-
specific deepening of the signals in the presence of Ca2+ may be due to a differential 
increase in -helical content and/or reorientation of existing -helices (Wang et al., 
2011, Protasevich et al., 1997). Interestingly, all CaM mutant species presented a slight 
blue-shift of the 208 nm minimum in the absence of Ca2+ as compared to wild type 
CaM. We could not differentiate if this blue-shift was due to a solvent-effect or because 
of a mechanism including the involvement of aromatic-side chains. However, the fact 
that the blue-shift was more noticeable in the spectra of the two double CaM mutants 
suggests that most likely this shift of 2-3 nm is due to a reorganization of the molecule, 
because of the lack of the two tyrosines. 
On the other hand, the near-UV spectra of wild type CaM showed similar spectra 
as to what has been published so far (Sun et al., 2001, Wolff et al., 1977, Martin and 
Bayley, 1986). The spectrum consisted of two well-defined negative bands at 262 and 
269 nm, attributed to the six phenylalanine residues presented in CaM, and a region 
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around 280 nm arising from the two Tyr residues. All the latter picks reacted to Ca2+ 
binding and presented the typical spectra deepening. Unlike the mutants, which 
presented the expected change in the region of 280 nm, the spectra in this region 
became in the case of Y99 mutants even positive, and in the case of Y138 mutants the 
ellipticity became almost zero. Our results clearly show that Ca2+-induced alterations 
observed for wild type CaM in this region are mostly due to changes in the environment 
of Y138. Interestingly, this conclusion fully explains the small effect of Ca2+ on the near-
UV CD spectrum of the separate N-terminal half (residues 1-77) of CaM reported by 
others (Martin and Bayley, 1986). They considered their result as a surprise, because 
of the equal distribution of the phenylalanine residues in the C- and N-terminal halves 
of the protein. Actually, the spectra with/without Ca2+ of the Y138 and double CaM 
mutants (Figure 19) are very similar to those published for the N-terminal half by the 
same group (Martin and Bayley, 1986). 
In agreement with the previous reports showing that Ca2+ binding induces a 
notable increase in the thermal stability of wild type CaM (Wang et al., 2011, Brzeska 
et al., 1983), our results clearly showed that the full panel of mutants preserve this 
spectacular quality. All the CaM species showed quasisigmoidal decrease in ellipticity 
in the absence of Ca2+, clearly indicating the occurrence of at least one intermediate 
state, as previously described for wild type CaM (Sun et al., 2001, Wang et al., 2011). 
In the case of the CaM Y138 mutants, the temperature-dependent unfolding was 
clearly biphasic, showing a notable deviation of sigmoidicity at temperatures below 50 
ºC. The behavior of the Y138 mutant is remarkably similar to that reported for a CaM 
Y138Q mutant (Sun et al., 2001). Although, fitting the data to a two- or three-state 
model did not yield acceptable quality, it is clear from the denaturation profiles that a 
major thermal unfolding for the different CaM species occurred at ~ 55 ºC, and all of 
them were completely unfolded above 70 ºC. In addition, lower temperature transitions 
and/or discontinuities, also reported for wild type CaM (Brzeska et al., 1983, Martin and 
Bayley, 1986, Kilhoffer et al., 1981, Gangola and Pant, 1983), were observed in the 
lower temperature region (20-40 ºC), both in the absence and presence of Ca2+. Most 
importantly, the binding of Ca2+ had a profound impact on the stability of wild type CaM 
and all of the mutants, they exhibited remarkably thermal stability in the presence of 
Ca2+, showing that ion binding has a similar stabilizing effect on wild the type and the 
mutants. This conclusion, together with the far-UV CD spectrum is also supported by 
the fact that the full panel of CaM mutants required Ca2+ to stimulate the activities of 
PDE1 and eNOS, as it was the case for wild type CaM. Therefore, the absence of a 
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significant Ca2+-induced electrophoretic mobility shift in the Y138D and Y138E CaM 
mutants is not a valid criterion to propose absence of Ca2+-binding capability. 
It has been previously reported that terbium ion binds to the four Ca2+-binding 
pockets of CaM and that it can be excitated indirectly by excitation of the tyrosine 
residues at 280 nm. The amount of energy transferred from the excited tyrosine to the 
terbium ion depends on how close the tyrosine and Tb3+ are. Thus, this indirect 
excitation of Tb3+ could be monitored at 545 nm (Wallace et al., 1982). This fact 
allowed us to study the binding and excitation of Tb3+ bound to the different CaM 
mutant species. The near loss of fluorescence emission by Tb3+ upon tyrosine 
excitation in the single mutant lacking Y99, but not the single mutant lacking Y138, 
suggests that Tb3+ is closer to tyrosine 99 located at the III Ca2+-binding site of CaM, 
than to tyrosine 138 located at its IV Ca2+-binding site. This is in full agreement with the 
crystallographic structure of CaM, where the carbonyl group of Y99 participates in the 
coordination of Ca2+, while Y138 has a rather outward projecting conformation unable 
to coordinate Ca2+ (Strynadka and James, 1989). 
In agreement with the distinct spatial projection and accessibility to kinases of the 
two tyrosine-residues of CaM, our c-Src phosphorylation experiments show that Y99 
was phosphorylated with lower efficiency than Y138 by this kinase. The inward 
projection of Y99 within the III Ca2+-binding pocket as compared to a more outward 
projection of Y138 within the IV Ca2+-binding pocket (Strynadka and James, 1989) may 
explain these results. Although both tyrosine residues in CaM are phosphorylated by 
both c-Src and EGFR, as demonstrated using Y99F and Y138F CaM mutants (Salas et 
al., 2005), the substitution of the tyrosine residue at position 138 by a non-
phosphorylatable amino acid somehow disturbs in part the accessibility of these 
kinases to Y99. This is remarkable as it was previously suggested that phosphorylation 
of Y99 by several tyrosine kinases was more efficient than the phosphorylation of Y138 
(Benaim and Villalobo, 2002). Thus, the phosphorylation of single-tyrosine CaM 
mutants may not reflect the comparative efficiency of phosphorylation of both tyrosine 
residues of CaM in living cells. This may be related to the fact that substituting Y138 by 
other amino acids disrupts the structural coupling between the N- and C-globular 
domains of CaM (Sun et al., 2001), as previously mentioned. 
7.2 All phospho-(Y)-mimetic CaM mutants are biologically active 
Our results also show that the single and double Y/D and Y/E CaM mutants all 
retain biological activity, as they were able to activate distinct CaM-binding systems 
including PDE1, eNOS, EGFR, and c-Src. Moreover, we have shown a differential 
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action of wild type CaM and some of the phospho-(Y)-mimetic CaM mutants under 
study on the activity of PDE1, eNOS and EGFR. 
The double mutant CaM(Y99D/Y138D), but not CaM(Y99E/Y138E), exerts a lower 
activatory effect on the Vmax of the CaM-dependent cyclic nucleotide PDE1 isolated 
from bovine brain, as compared to wild type CaM. However, the aspartic acid mutant 
does not significantly change the apparent affinity for Ca2+ or the activation constant 
(Kact) of CaM for the enzyme. Of note is that other studies on the effect of phospho-(Y)-
CaM versus non-phosphorylated CaM on the cyclic nucleotide phosphodiesterase of 
different origin yielded divergent results. Thus, both an increase (Williams et al., 1994) 
and a decrease (Corti et al., 1999) in the Kact, without affecting the Vmax, has been 
reported for phospho-(Y)-CaM phosphorylated by the InsR and a phospho-(Y99)-CaM 
species, respectively, on the PDE1 from bovine brain in comparison to non-
phosphorylated CaM. In contrast, InsR-phosphorylated CaM presented similar Kact and 
Vmax than with non-phosphorylated CaM when assayed on the PDE1 from rat 
hepatocytes, although the phosphorylated form increased the IC50 of CaM antagonists 
inhibiting the PDE1 activity (Saville and Houslay, 1994). In radical contrast, phospho-
(Y)-CaM phosphorylated by the EGFR inhibited by 90 % the activity of the PDE1 from 
bovine heart (Palomo-Jiménez et al., 1999). These conflicting data may be due to the 
fact that at least eleven families of distinct cyclic nucleotide PDEs, including different 
isoforms of the CaM-dependent PDE1 with distinct affinities for cAMP and/or cGMP 
and diverse regulatory properties may coexist and/or being differentially expressed at 
distinct ratios in various tissues and/or cell types in diverse organisms (Francis et al., 
2011). Alternatively, distinct phospho-Y99/phospho-Y138 ratios in the sample of 
phospho-(Y)-CaM used may account for the observed discrepancies. Nevertheless, it 
is likely that the negative charges of the extra aspartic acids present in 
CaM(Y99D/Y138D) may exert a similar action that phospho-CaM in some PDE1 
isoform(s). Furthermore, the absence of effect of the single Y/D mutants suggests that 
the phosphorylation of both tyrosine residues may be necessary for the lower activatory 
action of phospho-(Y)-CaM on PDE1. The absence of significant effect of the 
CaM(Y99E/Y138E) mutant also suggests that the length of the side chain of glutamic 
acid, longer than the one of aspartic acid (3.39 Å and 2.56 Å, respectively, from the 
carboxylic to the C-(Allen, 2002), may be unfitted to interact with the PDE1 site 
where phospho-(Y)-CaM exerts its regulatory action on the enzyme. 
We show that the mutant CaM(Y99D/Y138D), and most prominently 
CaM(Y99E/Y138E), slightly increase (~ 20-30 %) the Vmax of eNOS as compared to 
wild type CaM. Other studies, however, have shown that the single mutant CaM(Y99E) 
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slightly increase (16 %) the activity of recombinant iNOS, has no significant effect on 
nNOS, and significantly inhibited (40 %) the activity of eNOS (Piazza et al., 2012). This 
suggests that the different NOS isoforms may be regulated differently and that the 
phosphorylation of either one or the two tyrosine residues of CaM may exert significant 
differential effects on its activity. Nevertheless, our results are qualitatively, but not 
quantitatively, in agreement with the stimulatory action that phospho-(Y99)-CaM exerts 
on the Vmax of nNOS, where a 3.4-fold higher Vmax than with non-phosphorylated CaM 
was reported (Corti et al., 1999). These authors also reported a two-fold higher Kact of 
phospho-(Y99)-CaM with respect to non-phosphorylated CaM, and a 4-fold lower Kd for 
a peptide corresponding to the CaM-binding domain of nNOS (Corti et al., 1999). The 
different NOS isoforms used in these studies could explain the discrepancy with the 
lower phospho-mimetic capacity of CaM(Y99D/Y138D) and CaM(Y99E/Y138E) when 
compared to tyrosine-phosphorylated CaM observed by us. 
We also tested the effect of CaM(Y99E/Y138E) on the eNOS activity determined 
by ITC technique using increasing concentration of L-arginine. However, we 
encountered huge difficulties with eNOS that made the result obtained uncertain. First 
of all, the calculated enthalpy of the reaction was very low (-1.4 ± 0.1 kcal/mol) and 
only a minute quantity of the heat produced during the reaction was detected. 
Secondly, the critical step of base-line stabilization was prolonged and took about ~1-2 
hours for the base-line to stabilize, time that most likely had a negative impact on the 
enzyme activity. Moreover, during this stabilization period the enzyme was incubated in 
a complex medium containing a variety of cofactors; notably NADPH, as electron 
donor, and FAD/FMN that are essential cofactors and also electron acceptors, short-
circuiting the electron flow due to the diaphorase activity of eNOS before L-arginine 
was added (Grozdanovic and Gossrau, 1995). 
Our results with the phospho-mimetic CaM(Y99D/Y138D) and CaM(Y99E/Y138E) 
mutants suggest that phospho-(Y)-CaM may not have a differential action on c-Src 
activation as compared to non-phosphorylated CaM. Intriguingly, is has been shown in 
keratinocytes that phospho-(Y138)-CaM does not co-immunoprecipitate with Src, while 
non-phosphorylated CaM does (Wu et al., 2015). In contrast, our results using 
CaM(Y99D/Y138D) and CaM(Y99E/Y138E) suggest that CaM phosphorylated at both 
tyrosines may be able to interact with Src because increases its auto-phoshorylation, in 
contrast to what it was reported with CaM phosphorylated at Y138 (Wu et al., 2015). 
No information, however, is available on the possible action of CaM phosphorylated at 
Y99 on Src activity. This underscores, nevertheless, the potential importance of distinct 
phosphorylated tyrosine residues and/or variable phosphorylation stoichiometry in the 
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regulation of CaM-binding proteins, as it becomes apparent in other systems (Benaim 
and Villalobo, 2002). 
It has been shown previously that the cytosolic JM region of the EGFR is essential 
for its activation (Hubbard, 2009, Red Brewer et al., 2009, Jura et al., 2009). In the 
generally accepted theory the JM domain as it contains many positively charged amino 
acids, serves as an auto-inhibitory mechanism by attaching this part of the protein to 
the negatively charged inner leaflet of the plasma membrane (McLaughlin et al., 2005). 
Our group has discovered that within the cytosolic juxtamembrane domain of the EGFR 
lays a region rich in basic amino acids that in fact are forming a CaM-BD (Martin-Nieto 
and Villalobo, 1998). Previous reports have demonstrated that when CaM binds to the 
CaM-BD of the EGFR in vitro it inhibits its tyrosine kinase activity in a Ca2+-dependent 
manner as it mimics the negative charged acidic phospholipids in the plasma 
membrane (San José et al., 1992). In contrast to this, CaM has an activating role in the 
EGF-dependent activation of the EGFR in living cells (Li et al., 2004, 2012), as it helps 
to detach the JM from the plasma membrane (McLaughlin et al., 2005, Sato et al., 
2006, Sengupta et al., 2007) 
Our in vitro assays confirmed previous results showing that wild type CaM inhibits 
the EGF-dependent tyrosine activity of the EGFR in a detergent-solubilized preparation 
in a Ca2+-dependent manner (San José et al., 1992). When no Ca2+ was present in the 
sample, CaM cannot bind to the receptor to inactivate it, thus we observed higher 
ligand-dependent activation of the receptor. Interestingly, as in the case of PDE1 and 
eNOS, here we also observed a differential role of the CaM mutants. 
CaM(Y99E/Y138E) behaved exactly as the wild type CaM inhibiting the EGF-
dependent activation of the EGFR in the presence of Ca2+, while CaM(Y99D/Y138D) 
exhibited far lower potential inhibiting the auto-phosphorylation of EGFR in vitro. The 
latter results, together with some yet unpublished results generated in our lab show 
that phospho-(Y)-CaM free of non-phosphorylated CaM has the ability to activate the 
EGFR instead of inhibiting it in vitro, similar to the one exerted by the 
CaM(Y99D/Y138D) mutant (Stateva et al., 2015, in preparation). All taken together 
comes to show that phospho-(Y)-CaM may have even more potential than non-
phosphorylated CaM in activating the receptor in living cells.  
It is intriguing that CaM(Y99D/Y138D), but not CaM(Y99E/Y138E), exerts a 
differential action on PDE1 and EGFR, as compared to wild type CaM; while in the 
case of eNOS both CaM(Y99D/Y138D) and CaM(Y99E/Y138E) exert similar effect, 
albeit the latter with better efficiency. This could be related to the different length of the 
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side chain of glutamic acid and aspartic acid as mentioned above. Thus, although the 
actual reason for these distinct effects is unknown, we could speculate that each 
enzyme or tyrosine kinase used in this study may have pockets or clefts of distinct 
depths where the negative charge of the carboxyl group of the acidic amino acid must 
adapt in a proper conformation in order to exert its differential action, and that this 
pocket/cleft may be deeper in PDE1 than in eNOS. Although the phospho-(Y)-mimetic 
CaM mutants described in this work exert small differential effects with respect to wild 
type CaM on the two CaM-binding enzymes tested, the observed effects are qualitative 
consistent with those exerted by phospho-(Y)-CaM. Therefore, these mutants might be 
useful tools to study the differential regulation exerted by phospho-(Y)-CaM in a wide 
variety of CaM-binding proteins with and without enzymatic activity in living cells. This 
could be achieved by the stable expression of these phospho-(Y)-mimetic CaM 
mutants in a conditional CaM knockout DT40 cell line recently describe (Panina et al., 
2012), after the down-regulation of endogenous CaM by tetracycline, where the action 
of distinct Ca2+-null and other CaM mutants on the viability and proliferation capacity of 
these cells was tested (Panina et al., 2012). 
7.3 CaM interacts with and activates c-Src  
In this work we also show that c-Src not only binds CaM in the absence and 
presence of Ca2+, as others have previously demonstrated (Yuan et al., 2011, Fedida-
Metula et al., 2012, Pérez et al., 2013), but that the Ca2+/CaM complex, and more 
efficiently apo-CaM, both activate c-Src (Stateva et al., 2015 in press). Although the 
activation of Src by different signals appears to require Ca2+, as demonstrated by the 
attenuation of Src activation in cells loaded with the Ca2+-chelator BAPTA-AM (Bobe et 
al., 2003, Samak et al., 2011), the Ca2+-independent action of CaM on Src activation 
advises for a partial revision of previous findings on the necessary involvement of an 
executor Ca2+ signal preceding the binding of CaM to Src (Fedida-Metula et al., 2012, 
Yang et al., 2013, Bobe et al., 2003, Samak et al., 2011, Pérez et al., 2013). The 
drastic reduction of the cytosolic concentration of free Ca2+ imposed in BAPTA-loaded 
cells may also affect other Ca2+/CaM-dependent systems upstream of Src, as for 
example the EGFR (Martín-Nieto and Villalobo, 1998, Li et al., 2004, 2012), and not 
exclusively Src activation. Therefore, a transient Ca2+ rise may not be an obligatory 
step to attain activation of Src since apo-CaM exerts this role even more effectively 
than Ca2+/CaM. One possibility, however, could be that oscillations in the cytosolic 
concentration of free Ca2+ indeed could act as a rate modulator of the activity of the 
Src/CaM complex, where CaM could be already tethered to Src, as it occurs in other 
CaM-binding proteins such as distinct Ca2+-channels (Saucerman and Bers, 2012). 
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Thus, the kinase activity in the Src/CaM complex could decrease when the 
concentration of Ca2+ rises, by occupying the Ca2+-binding sites of tethered CaM, and 
conversely increases when the concentration of Ca2+ falls and the cation is released 
from CaM. These events may not necessarily be a simple two-steps cycle (Ca2+-free 
and Ca2+-bound), as CaM has two high-affinity and two low-affinity Ca2+-binding sites 
(Chin and Means, 2000). Thus, this process may occur as a multi-stage cycle where a 
variable number of Ca2+-binding sites are free or occupied at a given time, what may 
result in a variable rate of Src activity and a more fine-tuned regulation of the kinase. 
An alternative possibility is that distinct Ca2+-dependent and Ca2+-independent 
CaM-binding sites could exist in Src. Yuan and collaborators (Yuan et al., 2011) 
proposed as the CaM-binding site of human Src the sequence 199KHYKIRKLDSGGF213, 
located in the terminal part of the SH2 domain. However, mutation of this site 
substituting the sequence KHYKIRKLDS by alanine residues only partially prevented 
CaM binding (Yuan et al., 2011). This suggests the existence of additional CaM-binding 
sites in Src. We identified in silico in human Src two additional potential CaM-binding 
sites, that we denote atypical IQ-like motifs, corresponding to the sequences: 
146IQAEEWYFGK155, located in the proximal region of the SH2 domain, and 
311LQEAQVMKKLRH322, located in the proximal region of the tyrosine kinase domain 
(Figure 42). Of note, is to mention that the last sequence located at the proximal region 
of the kinase has a great potential to be a canonical CaM-BD as well (Figure 42). 
These sites may contribute to the binding of apo-CaM, as many IQ- and related IQ-like 
motifs are known to be receptor sites for Ca2+-free CaM in different target proteins 
(Jurado et al., 1999, Rhoads and Friedberg, 1997). 
 
Figure 42: Putative CaM-binding 
domains in c-Src. The overall structure of 
Src family kinases is shown, as well as the 
two putative CaM-binding domains 
including the potential IQ-like motif. The 
alpha helical wheel projection of the 
311LQEAQVMKKLRH322 sequence is 
shown. 
The non-receptor tyrosine kinase Src is subjected to a complex regulatory 
mechanisms mediated by phosphorylation events which control its activation status 
(Okada and Nakagawa, 1989, Cooper and Howell, 1993, Parsons and Parsons, 2004, 
Irtegun et al., 2013). The stabilization of its activation loop induced by auto-
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phosphorylation of Y416 maintains the kinase in an open conformation, allowing 
substrate binding and hence subsequent signal transmission by the resulting 
phosphorylated substrates (Cooper and Howell, 1993). On the other hand, the specific 
phosphorylation of its C-terminal tail at Y527 by Csk or Chk, maintains Src in a closed 
conformation repressing its activity (Okada and Nakagawa, 1989). 
The identification of Src as a CaM-binding protein, and the proposed location of 
the CaM-binding site(s) at the SH2 and/or tyrosine kinase domains, suggests that CaM 
may mediate its action maintaining Src in its open activate conformation. We also 
observed that Ca2+ per se (absence of CaM) has a direct inhibitory action on Src auto-
phosphorylation. This is unlikely to be mediated by an exogenous Ca2+-dependent 
system, as for example PKC, because we used a purified preparation of recombinant 
Src and the assay was devoid of cofactors required for PKC activation. Although 
speculative, an interesting possibility is to search for potential EF-hand Ca2+-binding 
pocket(s) in Src. 
Another point of interest is the fact that the two partners in the well-known 
bidirectional activatory trans-phosphorylation between EGFR and Src, where Src 
phosphorylates the EGFR (Anderson et al., 1990, Lombardo et al., 1995, Sato et al., 
1995, Biscardi et al., 1998, Gao et al., 2001), and the EGFR phosphorylates Src (Parks 
and Ceresa, 2014), are regulated by CaM, albeit in different manners. The regulation of 
EGFR by CaM is a Ca2+-dependent process (Martín-Nieto and Villalobo, 1998, Li et al., 
2004, 2012), while the regulation of Src by CaM appears to be a two-faced process, 
Ca2+-dependent and Ca2+-independent. This opens the door to explore in future work 
how physiological oscillations in the cytosolic concentration of free Ca2+, upon cell 
stimulation by mitogenic and/or other factors, modifies this mechanism by affecting in 
different manner both interconnected partners, the EGFR and Src, and hence the 
proliferative response. 
7.4 EGFR is subjected to O-GlcNAcylation in tumor cells 
Overall our results show for the first time that human EGFR could be subjected to 
O-GlcNAcylation, as it is the case for the insulin receptor (Yang et al., 2008). We 
detected EGFR O-GlcNacylation in two distinct human tumor cell lines, A431 and A549 
cells. A431 cells, derived from a tumor of epidermic origin, and A549 cells derived from 
a lung epithelial tumor. In contrast, no signal was detected in HeLa cells that are 
derived from a virus-induced cervical adenocarcinoma. This demonstrates that EGFR 
O-GlcNacylation may not occur in all tumor cells as this process could depend of its 
tissular and/or organ origin. Moreover, the absence of EGFR O-GlcNacylation signal in 
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EGFR-T17 mouse fibroblasts suggests that this post-translational modification may not 
be working in a non-physiological setting where a recombinant human EGFR is 
artificially expressed in cells of other species.  
O-GlcNacylation normally is expected to take place in the cytosolic region of the 
EGFR. Nevertheless, it is noticeable that when the immunoprecipitated EGFR was 
treated with PNGase F the immunoreactivity of the ~150 kDa N-deglycosylated 
receptor to the two anti-O-GlcNAc antibodies used increased as compared with the 
native 170 kDa EGFR. This suggests that removal of N-glycans from the extracellular 
region of the EGFR could facilitate the exposure of occluded GlcNAc moieties linked to 
complex O-glycans, not related with O-GlcNAcylation events that could be non-
specifically recognized by the two anti-O-GlcNAc antibodies used in this study. In fact, 
the presence of O-glycans in the extracellular region of the EGFR has been described 
(Wu et al., 2011). Other possibility could be that the removal of sialic acids distributed 
in the N-glycans by the PNGase F enzyme is the reason for both antibodies to have an 
increased reactivity with the deglycosylated receptor, as it has been already shown that 
desialation leads to a better binding of certain antibodies (Bolmstedt et al., 1992, 
Nguyen et al., 2006). Alternatively, the increased immunoreactivity of the anti-O-
GlcNAc antibodies after the removal of the N-glycans by PNGase F, could be also 
related to the extracellular O-GlcNAcylation of the receptor, modification driven by 
EOGT (Sakaidani et al., 2011, Sakaidani et al., 2012, Ogawa et al., 2014). We were 
able to find in the extracellular region of the EGFR three sites (215CAQQCSGRC223, 
236CAAGCTGPRE245 and 506CHALCSPEGC515) that contain key amino acids (cysteine, 
glycine and serine/threonine) that are also present in the EGF-like domain consensus 
sequence CXXGXS/TGXXC recognized by EOGT (Alfaro et al., 2012), particularly the 
second one. These sites are in the S1 and S2 cysteine-rich regions of the receptor, and 
the cysteine residues located in the proposed sequences are involved in the formation 
of disulfide bridges (Abe et al., 1998). Moreover, the strict specificity of some of the 
anti-O-GlcNAc antibodies has been questioned, as for example the CTD110.6 antibody 
that also recognizes terminal -GlcNac in complex N-glycans (Tashima and Stanley, 
2014).  
PNGase F is extensively used to remove N-glycans from glycoproteins (Maley et 
al., 1989), but this endoglycosidase is unable to work if a 1-3 bond links fucose to the 
innermost GlcNAc attached to asparagine (Tretter et al., 1991). Although 1-3-linked 
fucose to the innermost GlcNAc residues attached to asparagine is common in plant 
and insect glycoproteins, it appears to be absent in mammalian cells, where 1-6-
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linked fucosylation of core GlcNAc catalyzed by fucosyl transferase 8 (FUT8) appears 
to be the norm (Ma et al., 2006). Nevertheless, to bypass the possible existence of an 
unrecognized aberrant 1-3-linked fucosylation of the innermost GlcNAc attached to 
asparagine in tumor cells we used tunicamycin treatment. Our results with tunicamycin 
also supports absence of 1-3-linked fucosylation of core O-GlcNAc in the EGFR from 
A431 cells, as GlcNAz labeling was clearly detected in the  ~150 kDa N-deglycosylated 
EGFR. 
The apparent lower level of O-GlcNAcylation on the EGFR when the receptor was 
exposed to EGF stimulation could be explained by the EGF-driven internalization and 
degradation of the receptor, as this is one of the major consequences of the ligand-
dependent activation of the EGFR (Kirisits et al., 2007, Henriksen et al., 2013). In fact, 
we could not detect any difference in the pattern of the O-GlcNacylation in the whole 
cell protein extract of A431 cells stimulated with EGF. It seems that EGF-induced 
activation of the EGFR of these cells does not involve changes in the O-GlcNAcylation 
status of other proteins. The lack of effect of EGF-activated A431 cells on protein O-
GlcNAcylation supports the idea that EGFR signaling is not modulating the O-GlcNAc 
machinery.  Moreover, we expected that EGFR may be able to phosphorylate OGT as 
proposed by others (Kaleem et al., 2009). However, by the in vitro phosphorylation 
assay that we performed gave negative results and most likely OGT is not a substrate 
for EGFR (Supplementary figure 3S). 
Besides the fact that lectins have limited binding affinity and specificity they have 
been extensively used in studying protein glycosylation (Yang and Hancock, 2005, 
Etxebarria et al., 2012, Rosenfeld et al., 2007, Fry et al., 2012). WGA is a lectin 
recognizing GlcNAc moieties located at any glycan structure (De Hoff et al., 2009, 
Gallagher et al., 1985), we tried to address the question on whether WGA may be able 
to bind to PNGase F-deglycosylated EGFR (Supplementary figure 4SA). The lectin was 
able to bind to the N-deglycosylated receptor, suggesting that GlcNAc moiety(ies) 
recognized by the WGA could be located at Ser/Thr residue (Supplementary figure 
4SA). Moreover, in order to find out whether EGFR has more complex O-glycan 
structures in its extracellular part as suggested previously, that may be recognized by 
the anti-O-GlcNAc antibodies we have used in our study (CTD110.6 and RL2) or with 
WGA and thus giving false positive for EGFR O-GlcNAcylation, we probed the 
immunoprecipitated receptor with PNA, a lectin that has preferences in binding to 
Ser/Thr attached mucin type O-glycans (Tajima et al., 2005) (Supplementary figure 
4SB). These glycans were found to be present in EGFR expressed in hepatocellular 
carcinoma cell (HCC) line (Wu et al., 2011). In fact, it has been shown that by 
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knocking-down the enzyme responsible for the transfer of this mucin type O-glycans on 
target proteins, GALNT2, the malignancy of HCC cells was significantly reduced 
through mechanism involving EGFR. However, the fact that PNA was not able to bind 
to the receptor immunoprecipitated from A431 cells (Supplementary figure 4S), strongly 
suggests that this mucin type O-glycosylation is not taking place in these cells. 
Therefore, we can exclude the possibility of cross-reaction of the two antibodies or 
WGA with any mucin type O-glycans of the receptor expressed in A431 tumor cells. 
The suggestion that the EGFR could be subjected to O-GlcNAcylation at Thr654 
and Ser1046/Ser1047 based on in silico modeling as proposed before (Kaleem et al., 
2009) is pending experimental confirmation, as many predicting software programs are 
prone to both false-positive and false-negative predictions (Jochmann et al., 2014). We 
attempted some experiments using mass spectrometry (MS) to detect EGFR O-
GlcNAcylation. However, the lack of peptides corresponding to the cytosolic 
juxtamembrane region of the EGFR, where Thr654 is located, prevents us attaining 
meaningful results. Nevertheless, we accumulated significant amount of data 
suggesting that the receptor is subjected to this PTM (Stateva et al., 2015 submitted). 
We believe that the identification in human EGFR of O-linked GlcNAc moiety/ies and 
the specific Ser and/or Thr residue(s) where it may be attached using a suitable MS 
method or another technology could be, if positive, the ultimate proof of EGFR O-
GlcNAcylation. If Thr654 were to be confirmed as an O-GlcNAcylation site in EGFR, an 
interesting subject to study would be to elucidate the possible tripartite crosstalk that 
may be established between the phosphorylation of this site by PKC (Hunter et al., 
1984), the binding of CaM to the cytosolic juxtamembrane region of the receptor where 
Thr654 residue is located (Martín-Nieto and Villalobo, 1998), and its O-GlcNAcylation. 
Our group demonstrated that phosphorylation of Thr654 by PKC prevents CaM binding 
to this region, and conversely binding of CaM prevents Thr654 phosphorylation by PKC 
(Martín-Nieto and Villalobo, 1998). Thus, it is expected that if Thr654 were targeted by 
OGT a more complex functional picture could emerge by the presence of this O-
GlcNAcylated residue. Particularly, since phosphorylation of Thr654 appears to inhibit 
ligand-dependent EGFR activation maintaining the receptor in stand-by at the plasma 
membrane slowing its internalization (Sánchez-González et al., 2010), and CaM 
binding appears to contribute to ligand-dependent EGFR activation in living cells (Li et 
al., 2012).  
Another important issue to study is the potential impact that O-GlcNAcylation has 
on EGFR functionality. Since, the OGA inhibitor Thiamet G will block the de-O-
GlcNAcylation, and most likely will lead to the accumulation of O-GlcNAcylated proteins 
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including EGFR, we hypothesized that this could result in increased receptor activity 
upon EGF stimulation, of course in the scenario in which Thr654 were targeted by 
OGT. However, our results using the OGA inhibitor shows little, if any, changes in the 
time-dependent activation of the receptor by EGF in A431 cells, suggesting perhaps 
that the proposed cross-talk (Kaleem et al., 2009) is not correct. Both OGA and OGT 
inhibitors used in this study showed small effect on the EGF-dependent wound closing 
assay, both accelerating the ligand-driven closure (Supplementary Figure 5S). 
However, when using the OGT inhibitor (BADGP) and no stimulation present, we were 
able to observe significant delay in the artificial wound closing in A431 cells 
(Supplementary Figure 5S). Nevertheless, this observation strongly suggests that O-
glycosylation is essential for tumor migration and invasion, but since BADGP is not a 
specific inhibitor of OGT it does not mean necessarily that the delay we observed is 
due to the inhibition specifically of this transferase.  
We were able to locate in the C-terminal sequence of human ncOGT an amino 
acid sequence comprising of the amino acids 987LEYLKKVRGKVWKQRISSP1005 that 
have great potential to be a CaM-BD. The latter sequence not only exhibit the 
necessary 1-5-10 CaM canonical biding motif, but contains a sequence 991KKVRGK996  
with high potential of being a monopartite nuclear localization signal (NLS) 
K(K/R)X(K/R) (Hodel et al., 2001). The possibility this sequence being a CaM-BD and a 
NLS at the same time is not surprising. In fact, there are many example of proteins 
such as the adaptor protein Grb7 (García-Palmero and Villalobo, 2012), the 
transcriptional factors SRY and SOX9 (Hanover et al., 2009), and nuclear myosin I 
(Dzijak et al., 2012) among others, where the CaM-BD overlaps the NLS. Moreover, 
the results from the Ca2+-dependent CaM-affinity chromatography and the co-
immunoprecipitation assays, indeed, confirmed that both OGT and CaM are possible 
binding partners. Generating deletion or substitution mutants lacking the proposed 
CaM-BD in ncOGT would give the ultimate answer if this is true or not. However, it is 
noteworthy to mention that we were not able to detect any effect using the CaM 
inhibitor W-7 on the O-GlcNAcylation status of A431 cell proteins and no apparent 
differences on the O-GlcNAcylation of the ET1-55/ EGFR cells was observed when 
CaM was down-regulated. We believe that the latter observation is most likely due to 
the possibility that CaM could regulate other function such as the shuttling of the 
transferase from the nucleus to the cytoplasm, as it does with Grb7 (García-Palmero 
and Villalobo, 2012) rather than affecting its activity.  
With this Thesis we establish the foundation for three new lines of investigation 
that may reveal new regulatory mechanisms and pathways that could be of help in 
DISCUSSION  
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understanding and targeting diseases such as cancer. We demonstrated that, indeed 
tyrosine-phosphorylated CaM and the generated phospho-(Tyr) mutant CaM exert 
differential roles compared to non-phosphorylated CaM. The generated mutants 
presented the typical characteristics of the wild type CaM and appeared to be fully 
functional. The whole panel of mutants was able to activate CaM-dependent systems 
such as EGFR, c-Src, PDE1 and eNOS in vitro, and therefore these mutants could be 
useful to study as well the role of phospho-(Y)-CaM in living cells. The latter can be 
achieved by expressing the phospho-mimetic CaM mutants in conditional CaM-KO 
cells (Panina et al., 2012) and allow to study in detail the role of phospho-(Y)-CaM in 
living cells. We also demonstrate novel data on the CaM/c-Src axis, showing that CaM 
can activate c-Src in a Ca2+-dependent and more efficiently in a Ca2+-independent 
manner in vitro (Stateva et al., 2015), and we strongly believe that these findings 
should bring back CaM/c-Src   back   on   the   “track”,   as  CaM may regulates c-Src in a 
more complex manner in living cells than previously thought. Finally, we demonstrated 
for the first time that EGFR is subjected to O-GlcNAcylation in two distinct cancer cell 
lines: human carcinoma epidermoide A431 cells and human lung carcinoma A549 
cells. Elevated O-GlcNAcylation and OGT levels has been found to correlate with 
higher breast cancer malignancy (Krzeslak et al., 2012), and the same observation has 
been done for lung and colon cancers (Mi et al., 2011), and prostate cancer (Lynch et 
al., 2012, Kamigaito et al., 2014) among others (reviewed in de Queiroz et al., 2014). 
Evidently both O-GlcNAcylation and EGFR are hallmarks of these severe pathological 
processes. It is of great interest to investigate the putative action of O-GlcNAc on 
EGFR functionality including EGF-independent activation, membrane location, nuclear 
translocation, internalization, intracellular traffic and/or degradation via the lysosomal 
and/or the ubiquitin-proteasome pathways. How these events may affect important 
EGFR-mediated cellular functions, such as cell proliferation, differentiation, cell 
survival, and programmed cell death warrant also special attention. Further 
investigation on this subject as well as the elucidation of the functional role exerted by 
CaM on OGT functionality would make a valuable contribution to the field of O-
GlcNAcylation.
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1. Тhe generated Y/D and Y/E phospho-mimetic CaM mutants are functional and 
biologically active: 
 All of the CaM species bind Ca2+ as shown by circular dichroism, Tb3+ 
fluorescence and thermal stability experiments 
 All of the CaM species are able to activate specific the CaM-dependent 
enzymes PDE1 and eNOS in a Ca2+-dependent manner. 
 
2. CaM(Y99D/Y138D), but not CaM(Y99E/Y138E), has lower potential to activate 
PDE1 and exhibit effect similar to phospho-(Y)-CaM.  
 
3. CaM(Y99E/Y138E) has higher potential to activate eNOS than wild type CaM 
and shows effect similar to phospho-(Y)-CaM. 
 
4. Both double Y/D and Y/E CaM mutants do not have any differential effects on 
the activation of c-Src. 
 
5. CaM(Y99D/Y138D) has significantly higher ability to activate EGF-dependent 
activation of purified EGFR in the absence and presence of Ca2+ than Ca2+/ 
CaM. 
 
6. Apo-CaM has higher activatory effect on the auto-phosphorylation of c-Src 
suggesting that c-Src has more than one CaM-BD. 
 
7. The highly specific calmodulin inhibitor W-7 blocked the EGF and H2O2 driven 
activation of c-Src in A431 and/or SK-BR-3 cells, pointing out that CaM is 
actively involved in the regulation of Src in vivo. 
 
8. Human EGFR is subjected to O-GlcNAcylation in A431 and A549 cells but not 
in HeLa cells and mouse EGFR-T17 fibroblast. 
 
9. The highly specific OGA inhibitor Thiamet G increased significantly the O-
GlcNAcylation of the receptor, but did not have any effect on its EGF-dependent 
activation in living cells. 
 
10. OGT is a putative CaM-binding protein. 
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10.1 Supplementary material:   
 
Supplementary Figure 1S: Ca2+-induced thermal stability detected in the Far-UV CD 
spectra of the different CaM species. Far-UV CD spectra for wild type (wt) and the Y/E CaM 
mutants  (12  μM)  were  recorded  at   increasing temperatures (20-90 ºC) in 20 mM Tris-HCl (pH 
7.5), 0.1 M KCl, containing 1 mM CaCl2 (left panels) or 1 mM EGTA (right panels). Similar 
spectra were recorded for the CaM Y/D mutants. The arrows are pointing the temperature 
dependent change of the CaM spectra in the absence of Ca2+ (presence of EGTA) or presence 
of Ca2+. 
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Supplementary Figure 2S: Testing CaM down-regulation in conditional CaM-KO cells on 
the activation status of Src family kinase(s). The ET1-55/EGFR and DT40/EGFR cells were 
treated  with  1  μg/ml   tetracycline   for   the   indicated   times,   then the proteins were extracted and 
subjected to SDS-PAGE and Western blot as described under Material and Method. The 
membranes were probed with anti-phospho-Y416 Src family, anti-CaM and anti-EGFR 
antibodies. Protein staining with Fast Green is shown as a loading control. 
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Supplementary Figure 3S: EGFR fails to phosphorylate OGT in vitro. Recombinant 
EGFRcyt, that contain only the cytosolic part of the EGFR, was incubated in the absence or 
presence of ATP and OGT as indicated. The samples were then subjected to Western Blot 
using anti-phospho-Tyr antibody (clone 4G10). After striping the membrane was reprobed with 
anti-EGFR and anti-OGT antibodies to confirm the presence of the indicated proteins. 
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Supplementary Figure 4S: Lectin overlay of the immunoprecipitated EGFR. EGFR 
was   immunoprecipitated   (IP)   from   A431   cells   treated   with   100   μM   PUGNAc (OGA 
inhibitor). After the immunoprecipitation the receptor was subjected to PNGase F and O-
glycosidase plus neuraminidase (O-Gly/Neur) treatments as indicated and processed by 
SDS-PAGE and Western blots (WB) and overlaid (OL) with WGA (A) or PNA (B) as 
described in Materials and Methods. The membranes were then stripped and reprobed 
with an anti-O-GlcNAc antibody (RL2) (A) antibody and anti-EGFR antibody as a loading 
control.  
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  A                         
 
 
 
B           
            
         
 
Supplementary Figure 5S: Effect of OGA and OGT inhibitors on the healing of an 
artificial wound. (A) Artificial wounds were performed in confluent monolayers of A431 
cells in the absence (None) or in the presence of 1 mM BADGP (OGT inhibitor), and 10 nM 
EGF as indicated. Photographs were taken at different times in order to follow the closure 
of the different wounds using a Zeiss Axiovert 200M Multi-stage Automated microscope 
with 4x objectives to follow the repopulation of the wounds. The plot represents the mean ± 
SEM (n=8) for non-stimulated and (n=4) for the EGF-stimulated samples of opening of the 
wound in the different conditions as indicated. Significant differences versus controls are 
presented (ANOVA; *** p<0.0001). (B) Artificial wounds were performed in confluent 
monolayers of A431 cells in the absence (None) or in the presence of 100  μM  Thiamet-G 
(OGA inhibitor) and 10 nM EGF as indicated. Photographs were taken as described in (A). 
The plot represents the mean ± SEM (n=4) of the opening of the wound in the different 
conditions as indicated.  
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Erratum'
'
1. On'Page'51,'5.'Material'and'Methods'section,'5.1'Antibodies:'the'following'
antibody'should'be'included:'Anti?EGFR''Mouse'Anti?EGF'Receptor'antibody'
obtained'from'BD'Biosciences'(New'Jersey,'U.S.)'used'for'determining'the'total'
EGFR'in'the'experiment'presented'in'Figure'35,'Panel'B.''
'
2. On'page'87,'Result'section,'Legend'of'Figure'30:'the'concentration'of'the'EGF'used'
to'activate'the'EGFR'was'1'μM'instead'of'10'nM.'
'
3. Page'108,'Discussion'section.'“And'the'EGFR'phosphorylates'Src'(Parks'and'Ceresa,'
2014)”'should'be'substituted'by'“And'EGFR'activates'Src'(Parks'and'Ceresa,'2014)”'
